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Atherosclerotic and restenotic lesions develop as a result of an excess inflammatory 
response to vascular injury. Glucocorticoid hormones have widely-recognised 
anti-inflammatory and anti-proliferative properties which appear to make them ideal 
candidates for inhibition of vascular lesion development. Indeed, administration of 
glucocorticoids to experimental animals does inhibit the growth of vascular lesions in 
some models. In addition, glucocorticoids are currently being trialled clinically as 
anti-restenotic agents. However, glucocorticoid excess in patients, either as a result 
of Cushing’s syndrome or chronic steroid therapy, is associated with enhanced CVD 
risk. Therefore, the effects of glucocorticoids on vascular lesion development remain 
imperfectly understood.  
 
The overall objective of these studies was to explore the influence of endogenous and 
exogenous glucocorticoids on vascular lesion development using murine models of 
atherosclerosis (ApoE-/- mice fed a “western” diet) and neointimal hyperplasia (wire-
induced femoral artery injury). The work described in this thesis addresses the 
hypothesis that glucocorticoids are pro-atherogenic, yet anti-restenotic. 
 
Mice were bilaterally adrenalectomised to investigate the role of endogenous 
glucocorticoids on vascular lesion development. Removal of the adrenal glands had 
no influence on atherogenesis or neointima development. The influence of 
exogenous glucocorticoids on lesion development was assessed by orally 
administering dexamethasone (0.1 or 0.8mg/kg/day). Atherosclerotic lesion burden 
was augmented by dexamethasone administration. Conversely, fibro-proliferative 
neointimal proliferation was inhibited by dexamethasone. However, this effect was 
obscured by thrombotic lesion development. It was proposed that this thrombotic 
effect is attributable to increased plasminogen activator inhibitor-1 (PAI-1), which 
was tested using PAI-1 deficient mice. Although PAI-1 was found to mediate the 
systemic pro-thrombotic effect of dexamethasone, it is not required for the enhanced 





These results suggest that physiological levels of endogenous glucocorticoids play a 
limited role in vascular lesion development. Conversely, although exogenous 
glucocorticoids inhibit fibro-proliferative intimal hyperplasia, they appear to have 
significant detrimental influences on lesion development, augmenting atherosclerosis 
and inducing thrombotic neointimal lesion formation following vascular injury. 
Further research is therefore required to improve the cardiovascular outcome of 
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Cardiovascular disease (CVD) and its complications, such as stroke, myocardial 
infarction (MI) and peripheral vascular disease, are the single biggest cause of death 
in the developed world, accounting for almost 191,000 deaths (33.3% of all 
mortality) per annum in the UK alone. Almost half of these deaths are from coronary 
heart disease, with around one in seven women and one in five men dying from this 
condition (www.heartstats.org; accessed January 2011). The mortality rates for CVD 
have declined by ~40% in the last decade, which has been attributed mostly to the 
reduction in major risk factors, primarily smoking, and also to advances in treatment 
and secondary prevention. In contrast, morbidity rates have been increasing, in 
parallel with the current pandemic of cardiovascular risk factors such as obesity and 
diabetes (www.heartstats.org; accessed January 2011). It is, therefore, imperative to 
improve our current understanding of the factors involved in the pathogenesis of 
CVD and advance research into new therapies for this condition. 
 
Central to the pathogenesis of CVD is vascular lesion development, which can 
manifest itself in a number of clinical conditions, including atherosclerosis and 
restenosis following percutaneous coronary interventions (PCI). Both atherosclerosis 
and restenosis are reactions to vascular injury, involving inflammation and cellular 
proliferation (Kibos et al., 2007; Ross et al., 1977). Glucocorticoid hormones have 
widely-recognised anti-inflammatory and anti-proliferative properties (Barnes, 1998) 
which appear to make them ideal candidates for inhibition of vascular lesion 
development. Indeed, administration of glucocorticoids to experimental animals does 
inhibit the growth of vascular lesions in some models (Asai et al., 1993; Makheja et 
al., 1989; Naito et al., 1992). In addition, glucocorticoids are currently being trialled 
clinically as anti-restenotic agents (Ferrero et al., 2009; Ribichini et al., 2005). 
However, chronic glucocorticoid excess in patients, either as a result of Cushing’s 
syndrome (Colao et al., 1999; Etxabe et al., 1994) or of chronic administration 
(Solomon et al., 2006; Souverein et al., 2004), is associated with enhanced CVD risk 
(e.g. central obesity, insulin resistance, dyslipidemia and hypertension). Therefore, 
the net effects of glucocorticoids on vascular lesion development remain imperfectly 
understood. Elucidating these effects will improve our understanding of the role of 
glucocorticoid activity in regulating atherogenesis and restenosis and the therapeutic 
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potential of glucocorticoids as a treatment for, or as a target in, CVD. This 
introduction will consider the mechanisms that contribute to atherosclerotic and 
restenotic vascular remodelling, the physiological role of glucocorticoids and their 
influence on the cardiovascular system. 
1.1 Vascular remodelling 
In order to appreciate the processes that occur during vascular remodelling it is 
necessary to understand the structure of the healthy arterial wall and the functional 
role of the three component layers – the tunica intima, tunica media and tunica 
adventita (Figure 1.1). 
1.1.1. The structure of the normal artery wall 
1.1.1.1 Tunica intima 
The innermost layer of the artery wall consists of a confluent monolayer of 
endothelial cells, lying on a basement membrane of collagen, laminin and 
proteoglycans. In some arteries the intima can be more extensive containing focal 
accumulations of vascular smooth muscle cells (VSMCs) and additional layers of 
extracellular matrix (Stary, 1990). Underneath this lies the internal elastic lamina 
(IEL) which separates the intima from the media (Newby, 2000). The endothelium is 
crucial to the regulation of vascular tone as it produces a number of vasodilators: 
nitric oxide (NO) (Furchgott et al., 1980; Ignarro et al., 1987; Palmer et al., 1987), 
endothelial-derived hyperpolarising factor (EDHF) (Busse et al., 2002; Chen et al., 
1988) and prostacyclin (PGI2) (Weksler et al., 1977), as well as vasoconstrictors: 
endothelin-1 (Yanagisawa et al., 1988) and thromboxane A2 (TXA2) (Ingerman-
Wojenski et al., 1981; Moncada et al., 1976). Importantly, the endothelium also acts 
as an anti-thrombotic barrier between the circulation and the basement membrane 
(section 1.1.4.1). In addition, it is an important modulator of vascular inflammation 
and angiogenesis (Levick, 2003). 
1.1.1.2 Tunica media 
The tunica media is the middle layer of the vascular wall, which lies between the IEL 
and the external elastic lamina (EEL). It is made up exclusively of VSMCs 








Figure 1.1: Structure of the artery in health and disease. 
A: Transverse section of a normal mouse femoral artery stained with United States trichrome 
(UST) histological stain (collagen: green, smooth muscle: red, elastin: purple). The tunica 
adventitia lies outside the external elastic lamina (EEL, white arrowheads) and stains strongly for 
collagen. The tunica media lies between the EEL and the internal elastic lamina (IEL, black 
arrowheads) and stains strongly for smooth muscle. The tunica intima consists of a monolayer of 
endothelial cells on the luminal side of the IEL. L: lumen. B: Transverse section of a 
brachiocephalic artery from an apolipoprotein E-/- mouse, which is susceptible to atherosclerosis, 
stained with UST. A large atherosclerotic lesion has developed, incorporating lipid (*) and fibrous 
material in the intima of the vessel wall. Medial remodelling is also evident in this artery. Scale 




elastic and collagenous fibrils and layers of elastic laminae (Newby, 2000). The 
principal function of the media is to control vessel diameter through regulation of 
smooth muscle tone by circulating factors, endothelium-derived factors and 
neurotransmitters. In large elastic arteries, such as the aorta and brachiocephalic 
artery, the media is rich in elastic laminae and fibres and relatively poor in VSMCs, 
allowing the vessel to accommodate pulsatile cardiac output. In addition, the media 
in these arteries is rich in collagen, to maintain vessel shape and integrity and to 
prevent over-expansion of the vessel wall. In contrast, muscular arteries, such as the 
brachial and femoral arteries, are rich in VSMCs providing greater regulation of 
blood flow and pressure (Levick, 2003). 
1.1.1.3 Tunica adventitia 
The outermost layer of the vessel wall is separated from the tunica media by the 
EEL. It consists of a collagen-rich ECM containing VSMCs, fibroblasts, 
macrophages and adipocytes (Newby, 2000). In larger vessels, the adventitia 
contains nerves and capillaries (vasa vasorum) to supply the vessel wall with 
nutrients (Bohr et al., 1980). The main function of the adventitia is to provide 
mechanical strength and stability to the vessel and to anchor it to the surrounding 
tissue. However, the adventitia can also regulate vascular function through the 
release of NO (Muller et al., 2000; Pluta, 2006) and vasoactive adipokines (Yudkin 
et al., 2005). The adventitia may also influence vascular remodelling as it has been 
suggested that proliferation and migration of adventitial fibroblasts may contribute to 
atherosclerotic lesion development (Xu et al., 2007). 
1.1.2. Atherosclerosis 
Atherosclerosis is the most clinically relevant manifestation of vascular lesion 
development. It is defined as a slowly progressing inflammatory disease, which 
involves medium- and large-sized arteries, such as the coronary and carotid arteries 
(Leys, 2001; Ross, 1999). Atherosclerosis is characterised by the accumulation of 
lipid and fibrous material within the artery wall. The development of these fatty 
lesions usually occurs slowly over several decades, starting in childhood, and often 
does not manifest itself until middle-age or later (Stary, 1990). Atherosclerotic 
lesions are largely asymptomatic prior to a cardiovascular event giving 
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atherosclerosis the reputation of a ‘silent killer’. When symptoms do occur, their 
nature is determined by the location of the lesion and the vulnerability of the organ 
supplied by the affected artery. For example, stenosis in the coronary artery results in 
myocardial ischaemia, which can produce angina or MI (Tortora et al., 2003). 
 
There are three main mechanisms by which atherosclerosis leads to symptoms. 
Firstly, the lesion can expand sufficiently to occlude the lumen and tissue ischaemia 
will occur, as in angina pectoris. However, atherosclerotic arteries can outwardly 
remodel to accommodate expanding lesions, maintaining a near normal lumen 
diameter (Glagov et al., 1987). Secondly, spasm of the atherosclerotic artery can 
interrupt blood flow and potentially lead to the acute coronary syndromes of angina 
and MI (Zhang et al., 2005b). However, the most clinically-significant mechanism of 
symptom emergence is the rupture of an unstable plaque, leading to intravascular 
thrombosis, unstable angina and MI (Davies et al., 1984).  
 
Atherosclerotic plaques are categorised by pathologists into 8 grades of lesion (Stary 
et al., 1995; Stary et al., 1994). These are more generally described in three 
categories of lesion: the fatty streak, the fibrous plaque and the complicated lesion 
(Ross et al., 1976a; Ross et al., 1976b). The separate lesion types are distinguished 
by their characteristic morphological features. Atherosclerotic lesions are 
predominantly intimal in nature but more advanced lesions can modify the 
underlying media and adventitia (Stary et al., 1994). 
1.1.2.1  The fatty streak 
The earliest recognisable lesion of atherosclerosis is the ‘fatty streak’. It is common 
in infants and young children (Napoli et al., 1997) but can also be found in adults, 
(Stary et al., 1994).  Fatty streaks may be visible as yellow-coloured streaks or 
patches on the intimal surface of arteries, and often occur at branch points and areas 
of low shear stress. They consist primarily of lipid-filled macrophages, also known 
as foam cells, and VSMCs (Aqel et al., 1985; Vedeler et al., 1984), but T-
lymphocytes have also been identified in these lesions (Munro et al., 1987). Fatty 
streaks characteristically have little extracellular lipid (Munro et al., 1988). These 




The fibrous plaque, the fundamental lesion of atherosclerosis, often projects into the 
arterial lumen and may impede the flow of blood. These plaques consist of: a fibrous 
cap composed of smooth muscle cells, collagen fibrils and proteoglycans (Murata et 
al., 1986; Yla-Herttuala et al., 1986); a cellular area beneath the cap consisting of 
foam cells, VSMCs and T-lymphocytes, many of which are activated (Jonasson et 
al., 1986); and a deep core of lipid and necrotic tissue. There is morphological and 
chemical evidence for the presence of an ‘intermediate’ lesion, bridging the fatty 
streak and the fibrous plaque (Katz et al., 1976; Small, 1988; Stary, 1992). This 
evidence, along with the verification of the development of fibrous plaques in the 
same anatomical location as fatty streaks, supports the hypothesis that fatty streaks 
are the precursor of fibrous plaques during the pathogenesis of atherosclerosis (Stary 
et al., 1994). However, it has been suggested that fatty streaks are reversible (Birch, 
1965) and therefore may not all develop into fibrous plaques. 
1.1.2.3 The complicated lesion 
Complicated lesions are characterised by having undergone necrosis, rupture and 
repair. Consequently, they often contain thrombi or remnants of thrombi on their 
surface. Repeated rupture or ulceration of lesions can result in the development of 
multilayered fibrous atheromas, which can include new blood vessels and 
calcification (Weissberg, 2000). Lesions defined as complicated may or may not 
occlude the lumen and may or may not produce clinical manifestations. As described 
above, lesion rupture and thrombosis, are more clinically significant than stenosis 
(Davies et al., 1984). The vulnerability of a lesion to rupture or fissure is primarily 
determined by its composition. Plaques with a large lipid core and a thin fibrous cap 
are more prone to rupture than those with a thick cap. Importantly, the composition 
of the fibrous cap is a crucial determinant of plaque stability, with a prevalence of 
inflammatory cells and a relative paucity of smooth muscle cells promoting plaque 
rupture (Weissberg, 2000).  As there is a plethora of differences in size, lipid content 






In 1856, Rudolph Virchow proposed that the lesions of atherosclerosis result from an 
excessive wound-healing response to injury of the artery wall (Virchow, 1856). This 
hypothesis has subsequently been updated and revised a number of times (Ross, 
1999; Ross, 1993; Ross et al., 1977; Ross et al., 1976a; Ross et al., 1976b), evolving 
into the proposal that atherosclerosis is a response to endothelial dysfunction. 
Importantly, atherosclerotic plaque development results not only from the 
progressive inflammatory response to endothelial dysfunction, but also from the 
ongoing repair and remodelling of the vessel. 
 
Endothelial dysfunction can be caused by a number of risk factors, including 
elevated and modified low density lipoprotein (LDL) cholesterol, hypertension, 
diabetes mellitus, elevated homocysteine concentrations, some infectious organisms 
and free radicals. Endothelial damage results in a compensatory response that alters 
the normal homeostatic properties of the endothelium, increasing its adhesiveness 
and permeability (Figure 1.2A). Increased adhesiveness is mediated by an up-
regulation of leukocyte and endothelial adhesion molecules such as intercellular 
adhesion molecule-1 (ICAM-1) (Collins et al., 2000), vascular cell adhesion 
molecule-1 (VCAM-1) (Preiss et al., 2007), and the P- and E-selectins (Dong et al., 
1998). Monocytes and T-lymphocytes adhere to the endothelium and migrate into the 
sub-endothelial space under the influence of chemoattractant molecules such as 
monocyte chemotactic protein-1 (MCP-1) (Gu et al., 1998) and osteopontin 
(Giachelli et al., 1998). In addition, there is increased lipid transport across the 
endothelium resulting in an accumulation in the sub-endothelial space (Mora et al., 
1987). Within the intima of the vessel, monocytes mature into macrophages and 
proliferate under the influence of macrophage colony-stimulating factor (M-CSF). 
These tissue macrophages act as scavenger cells, taking up oxidised-LDL 
cholesterol, via the CD36 receptors present on their surface (Nicholson et al., 1995), 
and forming the characteristic foam cells of the early fatty streaks of atherosclerosis 
(Figure 1.2B). Activation of macrophages and T-lymphocytes results in expression 
of a variety of pro-inflammatory cytokines and growth factors, including tumour
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Figure 1.2: Pathogenesis of atherosclerosis. 
A: Endothelial dysfunction results in an increased permeability to monocytes, T-lymphocytes and 
low density lipoprotein (LDL) cholesterol, allowing accumulation in the intima of the vessel wall. 
Monocyte-derived macrophages and T-lymphocytes propagate the inflammatory response by 
proliferating and promoting further leukocyte infiltration, through release of cytokines and 
chemokines. B: Macrophages mobilise vascular smooth muscle cells (VSMC) from the media and 
stimulate their proliferation, and scavenge oxidised (ox)-LDL to form foam cells. C: Continuation 
of the inflammatory response, lipid accumulation and VSMC recruitment, results in the 
development of a fibrous plaque; with a lipid-rich necrotic core and fibrous ‘cap’. However, T-
lymphocytes and macrophages can promote plaque rupture by inducing VSMC apoptosis and 
extracellular matrix (ECM) degradation, and inhibiting further VSMC recruitment and 
proliferation. Exposure of the lipid-rich core of the plaque to the circulation will trigger platelet 
activation and coagulation, resulting in the formation of a thrombus of activated platelets and 
fibrin. D: Activated platelets can stimulate VSMC migration, proliferation and ECM deposition to 
form a new fibrous plaque. IEL: internal elastic lamina, VCAM-1: vascular cell adhesion 
molecule-1, ICAM-1: intercellular adhesion molecule-1, TNF-α: tumour necrosis factor-α, IL-1: 
interleukin-1, PDGF: platelet-derived growth factor, MCP-1: monocyte chemotactic protein-1, 
IGF: insulin-like growth factor, bFGF: basic fibroblast growth factor, IFN-γ: interferon-γ, TGF-β: 
transforming growth factor-β, MMPs: matrix metalloproteinases. 
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necrosis factor alpha (TNF-α), platelet-derived growth factor (PDGF) and interleukin 
(IL)-1, which recruit and activate additional inflammatory cells, and stimulate 
VSMCs and endothelial cells to produce further inflammatory mediators (Libby, 
2000).  This leads to the formation of the first stage of atherosclerotic lesions, the 
fatty streak, comprising lipid-filled macrophages and T-lymphocytes. At this stage 
lesion development is reversible but with continued exposure to atherosclerosis risk 
factors, the inflammatory response cannot overcome the chronic vessel wall injury 
and so continues indefinitely. 
1.1.2.4.2 Progression of atherosclerosis 
As injury and the inflammatory response continue, macrophages and lymphocytes 
continue to migrate from the blood into the lesion and release a cascade of 
chemotactic and proliferative growth factors and cytokines (including PDGF (Ferns 
et al., 1991), insulin-like growth factor (IGF) (Bornfeldt et al., 1992), basic fibroblast 
growth factor (bFGF) (Lindner et al., 1991), TNF-α and IL-1 (Fukumoto et al., 
1997)) that stimulate VSMCs to migrate to, and proliferate in, the intima (Figure 
1.2B). This leads to the development of a fibrous plaque with a VSMC-rich cap, 
which plays a pivotal role in maintaining plaque stability and protecting against 
plaque rupture. VSMCs in the intima change from a ‘contractile’ to a ‘synthetic’ 
phenotype and secrete ECM, including elastin and collagen (Newby et al., 2000). 
Therefore, although VSMCs play a large role in the development of the lesion by 
producing pro-inflammatory mediators, they also play a major role in the creation of 
the fibrous cap through synthesising matrix molecules. It is not clear whether these 
VSMCs originate from the media or are derived from circulating smooth muscle 
progenitor cells (Dzau et al., 2002). In addition, continuation of the inflammatory 
response, increasing numbers of macrophages and T-lymphocytes and release of pro-
inflammatory cytokines, eventually leads to further damage and focal necrosis (Ross, 
1999).  Necrosis of foam cells releases their internalised lipids along with the pro-
inflammatory contents of the foam cell, contributing to the cholesterol-rich lipid core 
(Witztum, 1994). The exact mechanism behind macrophage apoptosis, preceding 
secondary necrosis, remains incompletely understood but has been suggested to be a 
reaction to oxidised-LDL overload (Colles et al., 2001; Salvayre et al., 2002). 
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Therefore, as the pro-inflammatory environment is maintained by the activated 
macrophages, T-lymphocytes and VSMCs, the lesion develops into a characteristic 
fibrous plaque, with a fibrous cap overlying a lipid-rich necrotic core (Figure 1.2C). 
This can be compensated somewhat by dilation of the artery, maintaining the lumen 
(Glagov et al., 1987). These fibrous lesions can, however, develop to the point where 
the artery can no longer compensate by dilatation and the plaque encroaches into the 
lumen, altering blood flow.  
1.1.2.4.3 Plaque rupture 
As mentioned previously, the vulnerability of a plaque to rupture is largely 
determined by its composition, rather than size. Indeed, the majority of acute 
myocardial infarctions result from atheroma that cause < 50% stenosis, as assessed 
by angiography (Libby, 2000). Compositional factors which influence the 
susceptibility of a plaque to rupture include: size of the lipid core, thickness and 
collagen content of the fibrous cap and extent of inflammation (Falk et al., 1995). 
Aortic plaques containing a core occupying >40% of the plaque are considered 
particularly vulnerable and at a high risk of rupture and thrombosis (Davies et al., 
1993). Fibrous caps are well-recognised to be most vulnerable at the thin, “shoulder” 
regions, highlighting the importance of cap thickness in plaque stability (Richardson 
et al., 1989). In addition, the VSMC content and collagen content of fibrous caps are 
important markers of plaque vulnerability as they provide biomechanical strength to 
the cap and resistance to local mechanical stresses created by blood flow and 
pressure (Libby, 2000). Indeed, disrupted aortic caps having been shown to contain 
less VSMCs and collagen than intact caps (Burleigh et al., 1992; Davies et al., 1993). 
Inflammatory cells can reduce plaque stability in a number of ways (Figure 1.2C). 
Activated T-cells may stimulate metalloproteinase (MMP) production by 
macrophages in lesions leading to enzymatic degradation of ECM proteins in the 
fibrous cap (Libby, 1995). Pro-inflammatory cytokines, in particular interferon-γ 
(IFN-γ) and transforming growth factor (TGF)-β, released from macrophages inhibit 
VSMC proliferation, while inhibiting or promoting collagen synthesis, respectively 
(Amento et al., 1991; Newby, 2000). Activated macrophages can induce VSMC 
apoptosis by direct cell-cell contact (Boyle et al., 2001) and by releasing the 
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cytokines IFN-γ, IL-1β and TNF-α (Geng et al., 1996). This is further compounded 
by the fact that VSMCs in the fibrous cap of a mature plaque have an enhanced 
susceptibility to apoptosis and a reduced ability to proliferate (Bennett et al., 1998). 
 
Most deaths from atherosclerosis transpire as a result of occlusive thrombus 
formation following plaque rupture (Weissberg, 2000). Exposure of the lipid core to 
the circulation immediately causes platelet activation and aggregation and activation 
of the coagulation pathway, resulting in thrombosis (Figure 1.2D). The ensuing 
complications include MI, stroke and acute peripheral vascular occlusion. However, 
it is now clear that clinically silent non-occlusive plaque rupture plays a role in 
plaque growth (Burke et al., 2002; Mann et al., 1999). PDGF and thrombin can act to 
induce further VSMC recruitment, proliferation and ECM synthesis (Ferns et al., 
1991; Fingerle et al., 1989; Kanthou et al., 1995), thus stimulating the formation of a 
new fibrous cap (Figure 1.2D). The atherosclerotic plaque can, therefore, expand due 
to repeated episodes of rupture and repair, leading to the development of a 
complicated lesion.  
1.1.2.5 Current treatments of atherosclerosis 
Primary prevention (i.e. preventing or delaying the clinical disease among 
asymptomatic patients) of atherosclerosis is largely focussed on promoting lifestyle 
changes including weight loss, increased exercise, smoking cessation and dietary 
modification. Secondary prevention of atherosclerosis, in patients with established 
CVD or a high risk of developing CVD (e.g. patients with diabetes mellitus), can 
also incorporate pharmacological intervention to manage hypertension (e.g. ACE 
inhibitors, β-blockers), to reduce heart work load (nitrates), to lower circulating 
lipids (statins) and to reduce thrombotic risk (anti-platelet/anti-coagulant therapy; 
aspirin, warfarin). Anti-platelet and fibrinolytic therapy is also administered 
following MI in an attempt to re-open the blocked coronary artery. 
 
Surgical intervention is often used in patients with severe angina or after an acute 
MI. Coronary artery bypass graft (CABG) surgery uses saphenous vein or mammary 
artery grafts from the patient to bypass the blocked coronary artery. This procedure is 
often used in patients with multiple vessel disease. A less invasive approach is PCI, 
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based on the technique of percutaneous transluminal balloon angioplasty introduced 
by Andreas Gruntzig (Gruntzig et al., 1979). The procedure entails the dilation of a 
stenosed artery by inflation of an intra-luminal balloon catheter, introduced from a 
femoral arteriotomy via a guidewire. PCI has become the most commonly used 
intervention for coronary artery disease, with over 80,000 performed in the UK in 
2008 (www.heartstats.org). Although PCI has revolutionised the treatment of 
atherosclerosis, it has been limited by a high incidence (30-50%) of re-occlusion 
(restenosis) of the vessel, thereby requiring further re-vascularisation intervention. 
The introduction of vascular stents has successfully reduced the need for re-
vascularisation (from 21% to 10% at 1 year in the BENESTENT trial (Macaya et al., 
1996)). However, restenosis remains a significant problem, affecting 10-30% 
patients who receive stents (Bhargava et al., 2003). 
1.1.3. Restenosis 
Restenosis is the re-occlusion of an artery following PCI for the treatment of 
atherosclerosis. It is understood to occur via several mechanisms including elastic 
recoil, negative remodelling, early thrombosis and neointimal hyperplasia (Kibos et 
al., 2007). To address these problems, bare metal stents (BMS) were introduced to 
provide a rigid luminal scaffold for the vessel. While BMS successfully reduce 
elastic recoil and negative remodelling in nearly all patients (Fischman et al., 1994; 
Hoffmann et al., 1996), thrombosis and neointimal hyperplasia remain a significant 
burden on the success of using stents. In fact, stent implantation augments the fibro-
proliferative response by inducing a more intense and prolonged inflammatory state 
(Welt et al., 2002) due to the severity of injury and the persistence of a foreign body 
in the vessel wall (Schwartz et al., 1992b). Understanding the pathogenesis of the 
neointimal proliferation that defines in-stent restenosis is critical for the development 
of anti-restenotic therapies to improve the clinical outcome following PCI.  
1.1.3.1 Pathogenesis of neointimal proliferation 
The pathophysiology of neointimal proliferation is complex and incompletely 
understood but is thought to involve thrombosis, inflammation, cellular proliferation 
and extracellular matrix production, all of which contribute to lumen loss. In 1992, 
Schwartz et al postulated a hypothesis for the mechanism of neointimal proliferation 
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following vascular injury (Schwartz et al., 1992a). In his hypothesis there are three 
stages in neointimal lesion formation; thrombotic (stage I), cellular recruitment 
(stage II) and proliferative (stage III). It is suggested that the thrombotic stage occurs 
immediately after, and as a direct consequence of, endothelial damage. This leads to 
formation of a thrombus composed of aggregated platelets, fibrin and trapped 
erythrocytes. The second stage of healing comprises cellular recruitment into the 
thrombus itself. Firstly, re-endothelialisation occurs at the thrombus/blood boundary, 
followed by recruitment of monocytes (later macrophages) and lymphocytes. The 
macrophages are responsible for thrombolysis and phagocytosis of thrombus 
components. The cellular infiltrates, as well as the thrombus, are likely to secrete 
growth factors and chemo-attractants which facilitate further recruitment of cells 
(including smooth muscle cells). The final stage involves cellular proliferation, as the 
thin fibrous cap of smooth muscle cells thickens, and elaboration of extracellular 
matrix, eventually resulting in a mature, smooth muscle-rich neointima. 
1.1.3.1.1 Thrombosis 
Vascular injury exposes sub-endothelial collagen and tissue factor to the circulation, 
triggering the coagulation cascade and platelet adhesion and activation. This results 
in the formation of a thrombus composed of activated platelets, fibrin and trapped 
erythrocytes. More details on the pathways involved in thrombus formation are 
described below (section 1.1.4). In addition, endothelial denudation will result in the 
loss of anti-thrombotic factors (e.g. NO, PGI2 and tissue plasminogen activator 
(tPA)), further contributing to thrombus formation (Weintraub, 2007). Activated 
platelets release a variety of mitogens/chemoattractants which promote monocyte 
and smooth muscle cell migration and proliferation: PDGF is a potent VSMC 
chemoattractant and its expression in VSMCs has been shown to peak in accordance 
with peak neointimal cellular proliferation (Uchida et al., 1996); TGF, TXA2, 
thrombin and serotonin have been described to promote VSMC proliferation 
(Chandrasekar et al., 2000); P-selectin is implicated in platelet-leukocyte interactions 
and its deficiency has been shown to reduce neointimal proliferation (Kumar et al., 
1997a); and platelet-derived IL-1 plays a key role in mediating the inflammatory 
response at the site of vascular injury (Loppnow et al., 1998). Therefore, the initial 
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thrombus that develops as a result of endothelial damage clearly has the potential to 
contribute to neointimal development. In addition, Schwartz et al postulate that the 
thrombus plays a further role by acting as a “scaffold” into which VSMCs and 
leukocytes can migrate and proliferate to form the neointima (Schwartz et al., 
1992a). Certainly, several anti-coagulant/anti-platelet treatments reduce neointimal 
proliferation in animal models, including low molecular weight heparin and hirudin 
(Buchwald et al., 1996), acetylsalicylic acid (Clopath, 1980), aurintricarboxylic acid 
(Matsuno et al., 1998) and anti-platelet serum (Moore et al., 1976). However, several 
anti-coagulant/anti-platelet regimens have been investigated in clinical trials and 
shown to have no effect on restenosis (Kastrati et al., 1997; Schwartz et al., 1988). 
Only one, the platelet aggregation inhibitor cilostazol, has shown an anti-restenotic 
effect, but this has been attributed to its direct anti-proliferative influence on VSMCs 
(Take et al., 1997; Tsuchikane et al., 1999). Therefore, whether thrombus formation 
is obligatory for neointima development is open to debate. 
1.1.3.1.2 Inflammation 
The recruitment and activation of leukocytes induced by vascular injury has been 
shown to play a critical role in the pathogenesis of neointimal proliferation 
(Wainwright et al., 2001; Welt et al., 2002). Indeed, in a rmodel of stent-induced 
injury, monocyte presence in the vessel wall has been shown to parallel proliferation 
and intimal thickening (Rogers et al., 1998). In clinical studies, circulating monocyte 
counts after stenting show a positive correlation with neointima area 6 months after 
PCI (Fukuda et al., 2009). Studies using animal models show leukocytes infiltrate 
rapidly following vascular injury, with neutrophils observed within 6-24 hours (Cole 
et al., 1987; Welt et al., 2000) and T-lymphocytes (Tanaka et al., 1993) and 
monocytes (Miller et al., 1996) after 2-14 and 3-8 days, respectively. In the clinic, 
leukocytes are activated in patients 24-48 hours after angioplasty (De Servi et al., 
1990; Steg et al., 1993). Inflammatory cell recruitment and infiltration are mediated 
by a number of mechanisms (Welt et al., 2002): interaction with platelet p-selectin 
via Mac-1 adhesion molecule; release of MCP-1 and IL-8 from VSMCs, endothelial 
cells and leukocytes; and up-regulation of the endothelial adhesion molecules  
ICAM-1, VCAM-1 (Tanaka et al., 1993) and E-selectin (Wainwright et al., 2001). 
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Once recruited and activated, leukocytes produce a wide range of vasoactive 
substances, including oxygen-derived free radicals, proteolytic enzymes, growth 
factors, cytokines and chemokines, which may contribute to neointima development. 
In pathological studies, markers of inflammation in arterial tissue correlate strongly 
with restenosis after angioplasty or stenting (Farb et al., 2002; Moreno et al., 1996). 
Indeed, plasma concentrations of inflammatory markers MCP-1, IL-6, IL-1β, M-CSF 
and C-reactive protein are elevated following PCI and predict the incidence of 
restenosis (Hojo et al., 2001; Kochiadakis et al., 2007; Pietersma et al., 1995; Suzuki 
et al., 2000). Also, expression levels of TNF-α, IL-1β and IL-6 are up-regulated 
following angioplasty in humans and animal models (Wainwright et al., 2001; Wang 
et al., 2007a). A number of these cytokines, including M-CSF, TNF-α and IL-1β 
induce smooth muscle cell proliferation (Ikeda et al., 1990; Selzman et al., 1999; 
Shiba et al., 2007) and administration of these factors augments neointima 
development in animal models (Fukumoto et al., 1997; Shiba et al., 2007). In 
addition, IL-6 stimulates VSMC migration (Ikeda et al., 1991; Wang et al., 2003). 
Furthermore, a number of these inflammatory markers can stimulating further 
leukocyte recruitment: MCP-1 is a potent monocyte chemoattractant and activator 
(Gu et al., 1998); TNF-α and IL-1β increase adhesiveness of leukocytes to the 
endothelium through elevated ICAM-1 and VCAM-1 expression (Wainwright et al., 
2001); and IL-1 can promote T-lymphocyte intimal recruitment (Rao et al., 2008).  
 
The importance of inflammation in neointimal proliferation can be demonstrated in 
animal models, with dramatic reductions in lesion development following depletion 
of leukocytes (Miller et al., 2001; Wolff et al., 2004). Moreover, reduced neointimal 
lesion size has been reported after targeted disruption/inhibition of inflammatory 
mediators including p-selectin (Hayashi et al., 2000; Wang et al., 2005b), Mac-1 
(Golino et al., 1997; Rogers et al., 1998), VCAM-1 (Oguchi et al., 2000), ICAM-1 
(Yasukawa et al., 1997; Zou et al., 2000), MCP-1 (Egashira et al., 2007; Grassia et 
al., 2009) or its receptor chemokine (C-C motif) receptor 2 (CCR2) (Liehn et al., 
2010; Schepers et al., 2006), IL-1 receptor (Chamberlain et al., 2006; Morton et al., 
2005), TNF-α (Lambert et al., 2010) and M-CSF (Shiba et al., 2007). Indeed, 




VSMCs are undoubtedly involved in neointimal proliferation as they are the main 
cell type present in mature neointimal lesions in animal models (Carmeliet et al., 
1997c; Lindner et al., 1993; Sata et al., 2000) and in restenotic lesions induced by 
PCI in the clinic (Gravanis et al., 1989; Ueda et al., 1991). As previously mentioned, 
leukocytes recruited to the site of injury, as well as activated platelets of the 
thrombus, secrete growth factors and chemoattractants which facilitate the 
recruitment of VSMCs. Schwartz et al postulate that the VSMCs initially form a 
“cap” on the luminal edge of the thrombus, before migrating and proliferating 
inwards, towards the media (Schwartz et al., 2002). In addition, VSMCs actively 
contribute to neointimal development by propagating the inflammatory and 
proliferative response, through secretion of adhesion factors, cytokines and mitogens. 
These include the aforementioned IL-1β, IL-6, TNF-α, MCP-1 and M-CSF as well as 
bFGF (Libby et al., 1992; Lindner, 1995). The importance of VSMC proliferation 
can be demonstrated by the reduction in neointimal lesion size with the anti-
proliferative drugs paclitaxel (Axel et al., 1997) and rapamycin (Burke et al., 1999), 
in animal models of neointimal proliferation. Indeed these two drugs are used 
clinically in drug-eluting stents (DES) to prevent in-stent restenosis (section 1.1.3.2). 
Paclitaxel binds to and stabilises microtubules of the mitotic spindle thereby 
inhibiting cell division (Choritz et al., 2010). Rapamycin inhibits mammalian target 
of rapamycin (mTOR), thereby interfering with the transcription of genes involved in 
VSMC proliferation. By this mechanism, rapamycin also inhibits the proliferation of 
T-lymphocytes, contributing to its anti-restenotic effect (Martinet et al., 2007).  
 
As well as providing neointimal mass, VSMCs also contribute to the development of 
neointima through their deposition of ECM; collagen, elastin and proteoglycans 
(Bentzon et al., 2010b). A key chemokine mediating ECM production from VSMCs 
is TGF-β (Bobik, 2006). Its contribution to restenosis is suggested by up-regulation 
of TGF-β isoforms and their receptors following balloon injury in rats (Ward et al., 
1997). In addition, over-expression of TGF-β increases neointima development 
(Nabel et al., 1993), while TGF-β mRNA degradation (Yamamoto et al., 2000) and 
suppression of TGF-β expression (Backes et al., 2010) attenuate lesion development.  
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Somewhat paradoxically, enzymatic degradation of the ECM in the basement 
membrane and media is likely an important process in migration of VSMCs and 
subsequent intimal hyperplasia. There is evidence that several MMPs are involved in 
this process: MMP-9, MMP-2 and membrane type 1 (MT1)-MMP expression 
increase following arterial injury in rats (Shofuda et al., 1998; Zempo et al., 1994); 
inhibition or deficiency of MMP-9 or MMP-2 inhibits neointima development in 
animal models (Cho et al., 2002; Galis et al., 2002; Johnson et al., 2004; Mason et 
al., 1999); MT1-MMP+/- mice have reduced neointima development (Filippov et al., 
2005); tissue inhibitor of matrix metalloproteinase-1 (TIMP-1) administration 
attenuates neointimal proliferation (Furman et al., 2002). In addition to MMPs, 
serine proteases have been implicated in VSMC migration and neointima formation. 
The urokinase plasminogen activator (uPA) receptor (uPAR) is required for VSMC 
migration and proliferation (Kenagy et al., 2002; Okada et al., 1995) and expression 
of uPA and uPAR is increased at the site of arterial injury (Plekhanova et al., 2001). 
Indeed, uPA-/- and plasminogen-/- mice have reduced intimal hyperplasia following 
injury (Lijnen et al., 1998). In addition, uPA and plasmin can mediate VSMC 
migration by directly activating a number of MMPs (Lijnen et al., 1998). 
 
Intimal VSMCs found in neointimal lesions are generally accepted to be of a 
“synthetic” phenotype, rather then the “contractile” phenotype of medial VSMCs 
(Shanahan et al., 1998; Weintraub, 2007). Characteristically, these VSMCs resemble 
immature, dedifferentiated VSMCs and have lower levels of contractile proteins, 
contain fewer myofilaments, and produce 4 to 5 times more ECM than their 
contractile counterparts (Schwartz et al., 1986), but are defined as “smooth muscle” 
due to their immunoreactivity for α-smooth muscle actin. The source of VSMCs in 
neointimal lesions is under debate. There have been recent suggestions that they 
differentiate from the circulating bone marrow-derived inflammatory cells which 
infiltrate the vasculature during the initial response to injury (Sahara et al., 2007; 
Sata et al., 2002; Tanaka et al., 2003). However, there are critics of this proposal 
who claim to have refuted the existence of bone marrow-derived smooth muscle cells 
in vascular lesion, suggesting methodological discrepancies account for the 
confusion (reviewed in (Bentzon et al., 2010b)). Instead, many still believe intimal 
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VSMCs are derived from mature, medial smooth muscle cells, which have 
undergone phenotypic modulation, based on seminal papers from the '70s and '80s 
(Clowes et al., 1989; Clowes et al., 1986; Clowes et al., 1983; Schwartz et al., 1975). 
Support for this hypothesis comes from observations that cultured adult VSMCs 
spontaneously undergo a phenotypic change, assuming a number of the 
characteristics of intimal VSMCs in vivo (Chamley-Campbell et al., 1979). This 
change is thought to be a response to several stimuli, including endothelial 
denudation (Thyberg, 1998), arterial stretching (Birukov et al., 1995), exposure to 
mitogens, such as PDGF and bFGF, and remodelling of the ECM (Thyberg, 1998). 
1.1.3.2 Current anti‐restenotic approaches 
As mentioned previously, although BMS virtually eliminate the elastic recoil and 
negative remodelling aspects of restenosis following PCI, neointimal hyperplasia, or 
in-stent restenosis, is exacerbated by stent implantation. Subsequently, drug-eluting 
stents (DES) were developed to target the proliferative response to stent 
implantation. Briefly, DES are metal stents coated with a polymer containing a 
pharmacological agent, which is slowly released into the vessel wall. The most 
widely used DES are coated with the immunosuppressive agent, rapamycin (also 
known as sirolimus) or the anti-mitotic agent, paclitaxel (Llau et al., 2010). Indeed, 
angiographic coronary restenosis rates have fallen below 10% with the used of DES 
in several randomised trials (Newsome et al., 2008; Roy et al., 2007; Stone et al., 
2007) and a meta-analysis revealed a 70% reduction in the requirement for target 
vessel revascularisation (TVR) with DES when compared with BMS (Indolfi et al., 
2005).  
 
However, angiographic improvement in restenosis by DES has not been translated 
into a reduction in clinical cardiac events, such as MI and death. In addition, several 
concerns have been raised with regard to DES, including, inflammation, delayed 
healing and endothelialisation, endothelial dysfunction and late acquired incomplete 
stent malapposition (LASMA) (Carlsson et al., 2007; Rodriguez, 2009). Moreover, 
observational and randomised studies have demonstrated higher rates of late (>1 
month post PCI) and very late (>1 year post PCI) stent thrombosis with the use of 
DES (Thuesen et al., 2010), which can be translated into a high incidence of death 
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and MI (Rodriguez, 2009). With that, dual anti-platelet therapy (aspirin and 
thienipyridines) is required for a minimum of 6 months to 1 year after DES 
implantation. In addition, ~30-35% of PCI candidates have either restrictions or 
contraindications for DES implantation, for example diabetics and patients with long 
(>20mm) lesions or with existing in-stent restenosis (Rodriguez, 2009).  
 
To address these limitations, a new generation of DES has been developed, 
characterised by improvement in the stent platform, polymer (biodegradable) and 
drug. Examples include everolimus-eluting stents (EES) and zotarolimus-eluting 
stents (ZES) (Dangas et al., 2010). Everolimus and zoterolimus are derivatives of 
sirolimus, thus function as anti-proliferative and immunosuppressant mTOR 
inhibitors (Chen et al., 2007; Martinet et al., 2007). Indeed, recent large randomised 
studies have shown that the new generation EES is superior to the first generation 
paclitaxel-eluting stents (PES) in terms of TVR, MI and stent thrombosis (Kedhi et 
al., 2010). Importantly, it has been suggested that a moderate suppression, rather than 
a strong reduction in neointimal growth, will achieve the right balance of attenuating 
luminal loss while reducing the thrombotic risk (Rodriguez et al., 2009). 
 
Additionally, systemic anti-inflammatory and immunosuppressive therapies, which 
were originally trialled in the BMS era, are still being considered as alternatives to 
DES. The main candidates are: the aforementioned immunosuppressant, sirolimus; 
the glucocorticoid, prednisolone, and the selective phosphodiesterase 3 inhibitor, 
cilostazol. The influence of systemic sirolimus therapy on restenosis following BMS 
implantation and on recurrent in-stent restenosis has been assessed in a number of 
clinical trials, all demonstrating a significant reduction of restenosis, TLR and major 
adverse cardiac and cerebrovascular events (MACCE) (Hausleiter et al., 2004; 
Rodriguez et al., 2006; Waksman et al., 2004). Systemic prednisone therapy has 
been investigated in the two IMPRESS studies, concluding that oral prednisone 
therapy in patients undergoing coronary BMS implantation significantly reduced the 
risk of MACCE, TVR and restenosis, over those in the placebo group (Ferrero et al., 
2009; Ribichini et al., 2005; Versaci et al., 2002). In the CREST study, cilostazol-
treated patients with stent implantation experienced a 52% reduction in the risk of 
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restenosis, compared to placebo-treated patients (Douglas et al., 2005). As cilostazol 
acts by inhibiting platelet aggregation, it has also shown potential as an alternative to 
dual anti-platelet treatment in preventing thrombotic events (Jeong et al., 2009), for 
example in patients with clopidogrel resistance.  
1.1.4. Thrombosis 
Thrombus formation is the key contributor to haemostasis following vascular 
damage, alongside vasoconstriction. As has been described previously, thrombosis 
also plays a significant role in the pathogenesis of both atherosclerosis and 
restenosis. In addition, most clinical manifestations of atherosclerosis arise as a direct 
result of thrombosis following plaque rupture: for example, MI and stroke. Also, in-
stent thrombosis is a major concern associated with DES. Indeed, anti-thrombotic 
therapies such as aspirin and clopidogrel are currently used clinically for the 
management of atherosclerosis and the prevention of in-stent thrombosis. 
 
Thrombosis involves the formation of a ‘platelet plug’ at the site of injury, which is 
then stabilised by cross-linked fibrin. The pathways involved in thrombosis are 
relatively well understood and involve a complex interaction between the 
endothelium, platelets, inflammatory cells and the coagulation cascade. Resolution of 
a thrombus is mediated by the fibrinolytic pathway and inflammatory cells. 
1.1.4.1 Endothelium 
Under normal conditions the endothelium sustains a vasodilatory and local 
fibrinolytic state in which platelet activation, coagulation and inflammation are 
suppressed. A non-thrombogenic endothelial surface is maintained though a number 
of mechanisms: (1) vasodilatation by production of NO, PGI2, PDHF; (2) prevention 
of platelet adhesion and activation by adenosine, NO, PGI2; (3) prevention of 
leukocyte adhesion and transmigration by NO, IL-10; (4) attenuation of thrombin 
formation through production of tissue factor pathway inhibitor (TFPI), activation of 
protein C (to activated protein C (APC)) via thrombomodulin, activation of 
antithrombin III; (5) inhibition of fibrin deposition though local production of tPA 
and uPA; and (6) efficient scavenging of oxygen radicals by NO, urate and 
superoxide dismutase (SOD) (Becker et al., 2000).  
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In contrast, endothelial dysfunction/damage induces a pro-thrombotic state, 
characterised by: (1) vasoconstriction due to release of platelet activating factor 
(PAF) and endothelin-1; (2) platelet and leukocyte adhesion and activation by up-
regulation of PAF, von Willebrand factor (vWF), P-selectin, E-selectin, ICAM-1, IL-
8, MCP-1, TNF-α; (3) promotion of thrombin formation and fibrin deposition by 
increased expression of tissue factor (TF), plasminogen activator inhibitor-1 (PAI-1), 
vWF and Factor (F)V (Wakefield et al., 2008). In addition, endothelial damage 
exposes the pro-adhesive platelet-activating subendothelial matrix of TF, vWF, and 
collagens (Becker et al., 2000). 
1.1.4.2 Platelets 
Platelets (thrombocytes) play a critical role in thrombosis by becoming activated and 
aggregating to form a ‘platelet plug’ in response to endothelial damage. This process 
is referred to as primary haemostasis. Circulating platelets initially adhere to vWF of 
the exposed basement membrane via their glycoprotein (GP) Ib/XI/V receptors. This 
interaction promotes platelet expression of the GP IIb/IIIa receptor, which binds 
vWF and collagen, stabilising adhesion of platelets to the vessel wall (Jennings, 
2009). These adhesions activate the platelet, stimulating a conformational change 
from smooth discs into irregular spheroids that protrude filopodia rich in GP IIb/IIIa 
receptors. These enhance adhesion and mediate platelet-platelet interactions, or 
platelet ‘aggregation’ (Brisson et al., 1997). 
 
Activated platelets also release a plethora of factors which influence thrombosis 
(reviewed in (Anitua et al., 2004)), including an array of agonists (adenosine 
diphosphate (ADP), TXA2, PAF) and their receptors, which propagate a platelet 
activation chain reaction. An important additional platelet agonist is thrombin, which 
is generated by the prothrombinase complex on the surface of platelets as part of the 
coagulation cascade. Thrombin activates platelets by cleaving the protease-activated 
receptors (PAR), PAR1 and PAR4. Platelet activation also induces the expression of 
adhesive molecules (GPs, P-selectin, fibrinogen, thrombospondin, vWF), which 
enables platelets to aggregate and interact with other cell types and, importantly, 
allows fibrin to stabilise the aggregated ‘platelet plug’. In fact, thrombin and fibrin 
generation is localised to the surface of platelets by their release of clotting factors 
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FV and FXI. Platelets also regulate coagulation through inhibitors of the coagulation 
cascade (antithrombin III and TFPI) and mediators and inhibitors of the fibrinolysis 
pathway (uPA, PAI-1, α2-antiplasmin) (section 1.1.4.5).  
1.1.4.3 Coagulation cascade 
The coagulation cascade of secondary haemostasis is a series of sequential reactions 
in which zymogens of serine proteases are activated, ultimately resulting in the 
formation of cross-linked fibrin, which acts to stabilise the aforementioned ‘platelet 
plug’. It was originally proposed that coagulation occurs secondary to platelet 
activation, however it has now been suggested that these two events happen 
simultaneously (Furie et al., 2005). The coagulation cascade is classically divided 
into three pathways, the ‘contact activation (intrinsic) pathway’ and the ‘tissue factor 
(extrinsic) pathway’, both of which activate the ‘final common pathway’ of FX, 
thrombin and fibrin (Figure 1.3).  
 
The contact activation pathway is initiated when blood comes into contact with sub-
endothelial collagen. A complex of prekallikrein and high-molecular-weight 
kininogen (HMWK) also interacts with the exposed ECM, activating FXII. FXIIa 
goes on to sequentially activate FXI and FIX. FIXa, with its glycoprotein FVIII 
cofactor (activated by thrombin), then activates FX (Ahmad et al., 2003). The 
importance of the contact activation pathway in thrombosis is demonstrate by the 
bleeding disorders haemophilia A and B, which result from a deficiency in FVIII and 
FIX, respectively (Gailani et al., 2007).  
 
The tissue factor pathway is activated when plasma is exposed to extra-vascular TF, 
constitutively expressed by medial VSMC, pericytes and adventitial fibroblasts 
(Mackman et al., 2007). Plasma FVII is subsequently activated and forms a 
TF/FVIIa complex. This complex instantaneously goes on to catalytically activate 
FX. The main function of the tissue factor pathway is to augment the contact 
activation pathway. Under physiological conditions vascular cells which are in 
contact with the blood do not express TF. In contrast, under pathological conditions a 
number of vascular cells are induced to express TF, including leukocytes, endothelial 





Figure 1.3: Coagulation cascade and fibrinolysis pathway. 
The coagulation cascade mediates the formation of cross-linked fibrin through sequential 
activation of serine proteases. Coagulation is activated when plasma contacts the sub-endothelial 
surface (contact activation pathway) or extra-vascular tissue factor (tissue factor pathway). Both 
lead to the activation of factor X, which interacts with activated factor V and phospholipids to 
form the ‘prothrombinase complex’. This complex activates thrombin from its zymogen in a Ca2+-
dependent reaction. Thrombin goes on to catalyse the conversion of fibrinogen to fibrin and the 
activation of factor XIII (factor XIIIa), which cross-links the fibrin strands. Coagulation is 
regulated by the inhibitors: tissue factor pathway inhibitor (TFPI), activated protein C (APC) and 
antithrombin III (AT III). Fibrinolysis is the process by which fibrin is degraded by the serine 
protease plasmin. Plasmin is generated from inactive plasminogen by tissue plasminogen activator 
(tPA) or urokinase plasminogen activator (uPA). Fibrinolysis is regulated by the inhibitors: 




of patients with atherosclerosis. The importance of the tissue factor pathway in 
thrombus formation is demonstrated by patients with FVII deficiency experiencing 
abnormal bleeding analogous to patients with haemophilia A and B. TF deficiency 
has never been described in the clinic, but TF-/- mice die during embryonic 
development due to vascular and haemostatic defects (Carmeliet et al., 1996; 
Toomey et al., 1996). 
 
Once activated by either FIXa or TF/FVIIa, FXa forms a ‘prothrombinase complex’ 
with its cofactor Va (activated by thrombin) on the phospholipid surface of activated 
platelets, endothelial cells or monocytes (Mann et al., 1988), thus localising 
thrombus formation to the site of injury (Green, 2006). The prothrombinase complex 
then cleaves the zymogen prothrombin to generate the serine protease thrombin in a 
Ca2+-dependent reaction. Thrombin then goes on to catalyse the conversion of 
fibrinogen to fibrin. Thrombin can act to propagate the coagulation cascade by 
activating platelets (via PAR1 and PAR4), FV and FIX, as well as FXII, which 
stabilises the clot through catalysing the cross linking of fibrin (Fenton et al., 1991). 
Due to its central role in coagulation, thrombin is the main target of anti-thrombotic 
therapies (Fenton et al., 1998). 
 
Coagulation is modulated by a number of circulating protease inhibitors, including 
antithrombin III, which rapidly inactivates FXIIa, FXIa, FIXa, FXa and thrombin 
(Tortora et al., 2003), and TFPI, which inhibits the catalytic activity of TF/FVIIa 
(Baugh et al., 1998; Lu et al., 2004). In addition, the serine protease APC, activated 
by thrombin, degrades FVa and FVIIIa (Tortora et al., 2003) (Figure 1.3). As well as 
by inhibition of the coagulation cascade, thrombosis is modulated by enzymatic 
degradation of the fibrin strands in a process termed ‘fibrinolysis’. 
1.1.4.4 Inflammation 
Inflammation is a potent pro-thrombotic stimulus, which can promote coagulation, 
inhibit fibrinolytic activity and increase platelet reactivity. Inflammatory cytokines, 
TNF-α and IL-1α, induce tissue factor expression in monocytes/macrophages. 
Indeed, inflammatory cells in atherosclerotic plaques produce abundant tissue factor, 
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which becomes exposed to the blood following plaque rupture (Libby et al., 2002). 
Mononuclear leukocytes also appear to release blood-borne tissue factor in 
microparticles (Giesen et al., 1999). These microparticles also contain P-selectin 
glycoprotein ligand-1 (PSGL-1), which binds platelet P-selectin and mediates the 
accumulation of tissue factor into developing thrombi (Falati et al., 2003). In 
addition, C-reactive protein can lead to complement activation (Wolbink et al., 
1998), which is thought to play a role in the formation of the platelet prothrombinase 
complex (Sims et al., 1989). Activated monocytes are also capable of binding and 
activating FX and FV (Shantsila et al., 2009), thereby directly augmenting the 
coagulation cascade and fibrin production. Inflammatory mediators can also promote 
coagulation through down-regulation of the anti-coagulants antithrombin III, APC 
and TFPI (Esmon, 2004; Levi et al., 2008). The inflammatory cytokines TNF-α and 
IL-1β also influence fibrinolysis at the level of plasminogen activation (Biemond et 
al., 1995). They can induce tPA and uPA release from the endothelium, but also a 
sustained increase in PAI-1 (Scarpati et al., 1989; van der Poll et al., 1991). The 
overall effect on fibrinolysis is complete inhibition and, as a consequence, inadequate 
fibrin dissolution (Levi et al., 2010). Inflammatory cytokines can also directly 
influence platelets, for example: IL-6 can increase platelet production and reactivity 
to thrombin (Esmon, 2004) and PAF can directly activate platelets (Levi et al., 
2010). 
  
Importantly, communication between inflammation and coagulation is bidirectional, 
such that coagulation can also mediate inflammatory activity. Indeed, platelets store 
a host of inflammatory mediators, including growth factors (PDGF, TGF-β, bFGF, 
IGF-1), cytokines and chemokines (IL-8, IL-1), which are released upon activation 
(Anitua et al., 2004). In addition, platelet-monocyte binding, mediated by platelet P-
selectin and monocyte PSGL-1, markedly enhances the production of IL-1, IL-8, 
MCP-1 and TNF-α (van Deventer et al., 1990). Thrombin can promote leukocyte 
adhesion and activation, through elaboration of endothelial adhesion molecules 
(Esmon, 2000). Furthermore, Factor Xa, Factor VIIa and thrombin can activate 
mononuclear cells and endothelial cells, eliciting the production of IL-6 and/or IL-8 
(Sower et al., 1995; van der Poll et al., 2001). Additionally, fibrinogen and fibrin 
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directly influence the production of TNF-α, IL-1β and MCP-1 from mononuclear 
cells and endothelial cells (Szaba et al., 2002). Thrombin can release the potent 
neutrophil agonist PAF from the endothelium (Bar-Shavit et al., 1986). Thrombin-
mediated platelet activation can also induce CD40 ligand release which can in turn 
induce TF synthesis and increases the cytokines IL-6 and IL-8 (Esmon, 2003). 
Fibrinolytic factors may also have inflammatory influences: uPAR mediates 
leukocyte adhesion to the vascular wall (Levi et al., 2010), and cytokine and growth 
factor production though trans-membrane signal transduction (Blasi et al., 2002).  
 
Furthermore, endogenous anti-coagulants (antithrombin III, TFPI and APC) possess 
potent anti-inflammatory properties. Many of these properties are a direct result of 
inhibiting coagulation, and subsequent induction of inflammatory mediators. 
However, there is increasing evidence that these anti-coagulants possess anti-
inflammatory effects that are independent of their influence on the coagulation 
cascade. Firstly, antithrombin III induces PGI2 release from the endothelium, which 
inhibits platelet activation and aggregation, blocks neutrophils tethering to the vessel 
wall, and decreases endothelial production of inflammatory cytokines and 
chemokines (Esmon, 2003; Uchiba et al., 1998). Antithrombin III can also bind to 
receptors on the surface of neutrophils, monocytes and lymphocytes, thereby 
blocking their interaction with endothelial cells (Harada et al., 1999; Horie et al., 
1990), and inhibiting their expression of cytokines and adhesion molecules (Esmon, 
2003). Secondly, TFPI has been shown to reduce leukocyte activation and decrease 
TNF-α (Enkhbaatar et al., 2000). These effects appear to be independent of blood 
coagulation but the mechanisms responsible remain unknown. Thirdly, APC reduces 
endothelial expression of adhesion molecules and cytokine formation (Joyce et al., 
2001). In addition, binding of APC to monocytes inhibits (nuclear factor κB (NFκB) 
activation and TNF-α production (White et al., 2000). 
 
While inflammatory cells possess many pro-thrombotic properties, they also play an 
important role in resolution of the thrombus. Thrombus resolution involves several 
processes: (1) covering of the thrombus surface with monocytes and endothelial 
cells; (2) penetration of monocytes inside the thrombus; and (3) thrombolysis and 
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phagocytosis of thrombus components (Shantsila et al., 2009). MCP-1 is an 
important mediator of monocyte recruitment to the site of thrombosis and is known 
to contribute to the organisation and resolution of thrombi (Humphries et al., 1999). 
Once recruited, monocytes infiltrate the thrombus and promote its dissolution 
through secretion of the plasminogen activators tPA and uPA (Kung et al., 1993; Soo 
et al., 1996). It has been shown by electron microscopy that platelets and fibrin are 
then phagocytosed by the monocytes (Poole, 1966; Shirasawa et al., 1971). 
1.1.4.5 Fibrinolysis pathway 
Fibrinolysis is the process by which thrombus is dissolved once the damage has been 
repaired. Plasminogen, a circulating zymogen, is converted by the plasminogen 
activators (tPA or uPA) to the serine protease plasmin. Once formed, plasmin cleaves 
fibrin, generating soluble degradation products (Figure 1.3).  
 
tPA is synthesised and secreted primarily by endothelial cells, regulated by a variety 
of stimuli including thrombin, acetylcholine, histamine, adrenaline, exercise and 
shear stress (Cesarman-Maus et al., 2005). However, monocytes are the principle 
source of tPA during thrombus resolution (Soo et al., 1996). tPA-mediated activation 
of plasminogen occurs on the surface of fibrin and appears to be the major intra-
vascular mediator of fibrin dissolution (Cesarman-Maus et al., 2005). Conversely, 
uPA-mediated plasminogen activation is mainly involved in ECM remodelling and 
cell migration (Lijnen et al., 1998). 
 
Endothelial cells, monocytes, macrophages and neutrophils all express cell-surface 
receptors which bind plasminogen and tPA and/or uPA, localising fibrinolysis to the 
thrombus and protecting it from circulating inhibitors (Cesarman-Maus et al., 2005). 
The main inhibitors of fibrinolysis include: thrombin-activated fibrinolysis inhibitor 
(TAFI), which inhibits tPA and plasminogen binding to fibrin, thereby attenuating 
plasmin production (Dempfle, 2007); plasminogen activator inhibitor-1 (PAI-1), 
which directly inhibits both tPA and uPA (Gils et al., 2004); and α2-antiplasmin, 
which directly inhibits plasmin (Lee et al., 2004) (Figure 1.3). Fibrinolysis is also 
modulated positively by the ability of plasmin to cleave tPA and uPA, subsequently 
increasing their activity and generating more plasmin (Cesarman-Maus et al., 2005). 
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The fibrinolysis pathway is an important target for pharmacologic thrombolysis 
therapy, which involves administration of analogs of tPA to lyse clots and restore 
perfusion, following acute thrombotic event such as pulmonary embolism, stroke, 
deep vein thrombosis and ST-segment elevation myocardial infarction (STEMI). 
While PCI produces superior outcomes for the treatment of STEMI (Keeley et al., 
2003), thrombolysis remains an important first-line treatment for at least one-third of 
STEMI patients (Carver et al., 2009). In fact, thrombolysis can be as effective as PCI 
if administered within 3 hours of symptom onset (Hanna et al., 2010).  
1.2 Glucocorticoids 
Glucocorticoids are steroid hormones synthesised from cholesterol in the adrenal 
cortex and secreted into the circulation when needed. These steroids play important 
roles in metabolism and development, and mediate physiological and 
pathophysiological responses to stress. In addition, glucocorticoids have potent anti-
inflammatory and immunosuppressive properties, which are utilised therapeutically 
for the treatment of inflammatory conditions. Indeed, glucocorticoids have been 
shown to inhibit both atherosclerotic and neointimal lesion in animal models. 
However, glucocorticoid excess is also associated with an increase risk of CVD, 
throught to be attributable to the systemic metabolic influences of glucocorticoids 
(section 1.2.3). This demonstrates the complexity of glucocorticoid physiology and 
pharmacology, and the context-dependency of glucocorticoid effects. The primary 
endogenous glucocorticoid in man is cortisol, whereas in rodents, which lack the 
enzyme 17α-hydroxylase in the adrenal, corticosterone predominates.  
1.2.1. Regulation of glucocorticoid action 
Due to their wide range of physiological functions (section 1.2.2), glucocorticoid 
action is tightly regulated by a number of mechanisms influencing their synthesis, 
transport, metabolism and receptor activation. 
1.2.1.1 HPA axis 
Glucocorticoid synthesises and secretion from the adrenal cortex is under the 
influence of the hypothalamic-pituitary-adrenal (HPA) axis (Figure 1.4). 
Corticotropin-releasing hormone (CRH) is secreted from the hypothalamus and acts 
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Figure 1.4: Regulation of glucocorticoid production within the hypothalamic-pituitary-
adrenal (HPA) axis.  
Regulation of the HPA axis occurs under the influence of circadian rhythm, stress responses and 
negative feedback from circulating glucocorticoid levels. Stimulation of the hypothalamus 
prompts secretion of corticotrophin-releasing hormone (CRH). This stimulates 
adrenocorticotropic hormone (ACTH) release from the anterior pituitary, which in turn triggers 
glucocorticoid synthesis and secretion from the adrenal cortex. The 11β-hydroxysteroid 
dehydrogenase (11βHSD) isoenzymes interconvert active glucocorticoids, such as cortisol in man 
and corticosterone in rodents, and their inactive counterparts, cortisone and 11-
dehydrocorticosterone, respectively. These enzymes are considered to be important regulators of 
tissue-specific glucocorticoid action. 
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to release adrenocorticotropic hormone (ACTH) from the anterior pituitary gland 
into the circulation. Arginine vasopressin (AVP) can also stimulate ACTH release 
and acts in synergy with CRF (Antoni, 1993). ACTH then acts on the adrenal glands, 
stimulating the biosynthesis of glucocorticoids from cholesterol, catalysed by 
members of the cytochrome P450 oxidase enzyme family and 3β-hydroxysteroid 
dehydrogenase, resulting in glucocorticoid secretion into the blood. ACTH 
influences the steroidogenic pathway by a number of mechanisms: (1) stimulating 
lipoprotein uptake into cortical cells, thus increasing cholesterol bioavailability; (2) 
increasing transport of cholesterol to, and across, the mitochondrial membrane; and 
(3) increasing cholesterol binding to side-chain cleavage enzyme (P450scc), which 
catalyses the conversion of cholesterol to pregnenolone (Nussey et al., 2001). In 
addition to glucocorticoids, ACTH stimulates mineralocorticoid (mainly aldosterone) 
and androgen precursor (mainly dehydroepiandrosterone (DHEA)) synthesis and 
secretion from the adrenal cortex. CRH secretion is under the influence of the 
circadian clock, and therefore produces diurnal variations in ACTH, and 
subsequently glucocorticoid, secretion, with peak concentrations in the early morning 
and a nadir in the evening (Nussey et al., 2001). Stimulation of CRH secretion can 
also be regulated by stressors, including emotional stress, excessive heat or cold, 
injury, and infection. In addition, glucocorticoids regulate their own release to 
maintain physiological plasma levels by negative feedback suppression (de Kloet, 
1991), at both the hypothalamic and pituitary level. As this negative feedback is 
mediated through activation of glucocorticoid receptors (GR) (de Kloet et al., 1998) 
and mineralocorticoid receptors (MR) (Berardelli et al., 2010), synthetic 
glucocorticoids such as dexamethasone and prednisolone also suppress the HPA axis. 
This can result in glucocorticoid insufficiency if the exogenous glucocorticoid 
therapy is stopped abruptly. 
1.2.1.2 Corticosteroid‐binding carrier proteins 
Glucocorticoid bioavailability is also regulated by its interaction with carrier 
proteins. Approximately 95% of secreted cortisol is bound to carrier proteins; 80-
90% to corticosteroid-binding globulin (CBG) and 10-15% to albumin (Lewis et al., 
2005). The remaining 5% is free to diffuse across cell membranes and bind to 
intracellular receptors. According to the ‘free hormone hypothesis’ (Mendel, 1989), 
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steroid hormones bound to carrier proteins are biologically inactive and provide a 
reservoir of inactive circulating hormone. Therefore, corticosteroid-binding carrier 
proteins regulate the amount of free glucocorticoid available for receptor-mediated 
action. In addition, there is a slight diurnal variation in plasma levels of CBG, which 
fluctuates in the opposite direction to glucocorticoid diurnal variation, thereby 
accentuating the diurnal profile of free cortisol (Hsu et al., 1988; Lewis et al., 2006).  
1.2.1.3 Pre‐receptor glucocorticoid metabolism 
Metabolic inactivation of glucocorticoids provides an additional control of 
glucocorticoid activity. The 11β-hydroxysteroid dehydrogenase (11βHSD) 
isoenzymes interconvert active glucocorticoids, such as cortisol (corticosterone in 
rodents), and their inactive counterpart, cortisone (11-dehydrocorticosterone in 
rodents) (Figure 1.4). Both cortisol and cortisone are then metabolised in the liver, 
first by the A-ring reductases followed by several oxidation, hydroxylation and 
conjugation reactions. The resultant metabolites, 5α – and 5β-tetrahydrocortisol and 
5β-tetrahydrocortisone, are excreted in the urine and are often used as biomarkers of 
glucocorticoid metabolism (Aranoff et al., 1980). The 11βHSD isoenzymes are now 
appreciated to play important roles in the tissue-specific regulation of glucocorticoid 
action, rather than just in the clearance of glucocorticoids.  
1.2.1.3.1 11βHSD1 
11βHSD1 has the ability to interconvert glucocorticoids in both directions, but 
mainly catalyses the reductase reaction in vivo (Seckl et al., 2001), regenerating 
active hormone from inert 11-keto metabolites. These results are supported by 
studies in 11β-HSD1-/- mice, which cannot convert 11-dehydrocorticosterone to 
corticosterone in vivo (Kotelevtsev et al., 1997). 11β-HSD1 is under complex 
regulatory control. Factors that influence its expression and activity include 
inflammatory cytokines, growth factors, sex steroids, insulin and glucocorticoids 
themselves (Tomlinson et al., 2004). 11βHSD1 is widely expressed, notably in 
tissues rich in GR: liver, lung, adipose, brain, VSMCs, gonads, anterior pituitary and 
adrenal cortex (Tomlinson et al., 2004). This suggests that its physiological role is to 
amplify local glucocorticoid concentrations in glucocorticoid target tissues, thereby 
maintaining adequate ligand exposure to the relatively low-affinity GR (Seckl et al., 
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2001). Indeed, there is increasing evidence of the role that 11βHSD1 plays in 
glucocorticoid-mediated processes such as: gluconeogenesis (Kotelevtsev et al., 
1997) and insulin sensitivity (Walker et al., 1995) in the liver; adipocyte 
differentiation in the adipose tissue (Bujalska et al., 1999); cognitive function in the 
brain (Yau et al., 2001); and negative feedback regulation of the HPA axis 
(Kotelevtsev et al., 1997). Furthermore, enhanced 11βHSD1 activity has been 
implicated in some common clinical syndromes including obesity and type 2 diabetes 
mellitus (Seckl et al., 2001). 11βHSD1 is therefore an exciting potential therapeutic 
target for the treatment of the metabolic syndrome. Indeed, based on animal studies 
(Alberts et al., 2002), promising results have been reported from a phase II clinical 
trial, which has shown selective 11βHSD1 inhibition to lower glucose levels, 
improve insulin resistance, lower fasting cholesterol and LDL levels in patients with 
type II diabetes (Rosenstock et al., 2010).  
1.2.1.3.2 11βHSD2 
Conversely, 11βHSD2 mainly catalyses the dehydrogenase reaction, converting 
active glucocorticoids to their 11-keto metabolites. In addition to endogenous 
cortisol, 11βHSD2 possesses the ability to inactive the synthetic glucocorticoids 
dexamethasone and prednisolone and also reduce their 11-dehydro metabolites (Best 
et al., 1997; Diederich et al., 2002; Siebe et al., 1993). 11βHSD2 is highly expressed 
in mineralocorticoid target tissues: kidney, colon, and salivary glands (Walker et al., 
2003). Mutations in 11βHSD2 gene are seen in patients with the congenital 
syndrome of apparent mineralocorticoid excess (SAME) (Dave-Sharma et al., 1998) 
and 11βHSD2-/- mice have similar features of glucocorticoid-mediated 
mineralocorticoid excess, including sodium retention, hypokalaemia, and salt-
dependent hypertension (Kotelevtsev et al., 1999). It is, therefore, believed that the 
major role of 11βHSD2 is to protect the mineralocorticoid receptor (MR) from illicit 
occupation by glucocorticoids. Co-localisation with 11βHSD2 explains why MR, 
which has similar affinities for cortisol and aldosterone (Funder, 2007), preferentially 





It has also been noted that 11βHSD2 is expressed in tissues that are not classic 
mineralocorticoid targets. For example, high levels of 11βHSD2 are present in the 
placenta, where MR is not abundant. Its role in this tissue is believed to be to protect 
the foetus from the relatively high levels of maternal glucocorticoids (Edwards et al., 
1993; Meaney et al., 2007). Indeed, in humans and in animal models, prenatal 
inhibition of 11βHSD2 reduces birth weight and causes offspring hyperglycemia, 
hypertension, increased HPA axis reactivity, and increased anxiety-related behaviour 
(Harris et al., 2010). In addition, cardiac 11βHSD2 may prevent fibrosis caused by 
glucocorticoid-mediated MR activation (Glorioso et al., 2005; Konishi et al., 2003). 
The role of vascular 11βHSD2 in modulating the vascular effects of glucocorticoids 
is discussed below (section 1.2.2.4) 
1.2.1.4 Receptor activation 
Glucocorticoids exert their effects by interacting with intra-cellular glucocorticoid 
(low affinity type II) receptors (GR) and mineralocorticoid (high affinity type I) 
receptors (MR), both of which are members of the nuclear hormone receptor super 
family of ligand-activated transcription factors (Parker, 1993). While GRs are 
ubiquitously expressed, MRs are only expressed in select tissues and are often 
protected from activation by glucocorticoids by co-localisation of 11βHSD2. Thus, 
glucocorticoids exert most of their physiological effects through GR. In the absence 
of glucocorticoids, GR is bound to a large protein complex that includes two subunits 
of the heat shock protein Hsp90, which maintains the receptor in an inactive state. 
Upon glucocorticoid binding, Hsp90 dissociates and the active ligand/receptor 
complex dimerises and translocates rapidly to the nucleus (Figure 1.5). Within the 
nucleus the complex binds to DNA at consensus sites termed glucocorticoid response 
elements (GRE) in the 5’-upstream promoter region of glucocorticoid-sensitive 
genes. The result is either to repress or induce the transcription of the target gene. 
Co-activators and co-repressors provide additional control over the tissue-specific 
pattern of response to GR activation. There are believed to be 10-100 genes in each 
cell that are directly regulated by GR, but many genes are indirectly regulated 
through an interaction with other transcription factors, including activator protein-1 





Figure 1.5: Mechanism of action of glucocorticoids in target cells.  
Glucocorticoids (GC) enter the cell and bind to the cytoplasmic glucocorticoid receptor (GR), 
stimulating the release of the heat shock protein (Hsp) 90. The receptor/hormone complex then 
dimerises and enters the nucleus. The receptor complex then binds glucocorticoid response 




As previously mentioned, GRs are ubiquitously expressed; however, levels of both 
messenger ribonucleic acid (mRNA) and protein vary between cell and tissue types. 
This contributes significantly to tissue-specific sensitivity to glucocorticoids as 
cellular sensitivity is directly proportional to the receptor concentration (Oakley et 
al., 1993). Perinatally, GR levels are programmed by environmental manipulations, 
including neonatal stress (de Kloet et al., 1990) or in utero dexamethasone 
administration (Cleasby et al., 2003). However, in adults there is dynamic auto-
regulation of GR levels by glucocorticoids, which mediates short-term control over 
glucocorticoid sensitivity. In most cells glucocorticoids can promote GR down-
regulation, which consequently reduces the span of cellular responsiveness to 
glucocorticoids (Bellingham et al., 1992). Ligand-induced GR down-regulation is 
mediated by both a reduction in GR gene expression (Oakley et al., 1993) and an 
increase in proteasome-mediated GR degradation (Wallace et al., 2001).  
 
Although glucocorticoids are understood to exert their physiological effects through 
nuclear hormone receptors, there is increasing evidence that they have additional 
non-genomic effects.  These rapid effects do not involve interaction with genes but 
are instead mediated by the interaction of glucocorticoids with specific membrane 
receptors (Gametchu et al., 1999; Stellato, 2004; Tasker et al., 2006). For example, 
glucocorticoids have been shown to inhibit smooth muscle contraction in the trachea 
via nongenomic actions that are not blocked by the intracellular GR antagonist 
mifepristone (Sun et al., 2006). In the heart, glucocorticoids induce endothelial NO 
production from nitric oxide synthase (NOS) via activation of the Akt intracellular 
signalling pathways (Hafezi-Moghadam et al., 2002). However, the physiological 
relevance of these non-genomic responses to glucocorticoids remains uncertain 
(Tasker et al., 2006). 
1.2.1.5 Pharmacological therapy 
Clinically, glucocorticoid administration is used predominately as physiological 
replacement in glucocorticoid deficiency and, in higher doses, as an anti-
inflammatory or immunosuppressant. Replacement therapy tends to use 
glucocorticoids with both GR and MR activity, for example hydrocortisone (the 
synthetic form of cortisol). However, these steroids are limited by their high 
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bioavailability and short half-life and so require doses which produce supra-
physiological circulating concentrations in the first few hours after administration 
(Howlett, 1997). Importantly, exogenous glucocorticoids also cannot easily replicate 
the diurnal rhythm of endogenous cortisol secretion. Anti-inflammatory therapy 
usually employs the synthetic glucocorticoids prednisolone (GR and MR agonist) 
and dexamethasone (GR agonist) (Coghlan et al., 2003). While both of these 
synthetic compounds are substrates for the 11βHSD isoenzymes, dexamethasone is 
relatively protected from dehydrogenation (Best et al., 1997), which is likely to 
increase its bioavailability. The therapeutic use of glucocorticoids is limited by a 
range of systemic side effects mediated through the ubiquitously expressed GR, 
including osteoporosis, dyslipidaemia, hypertension, hyperglycaemia and peptic 
ulcers (Moghadam-Kia et al., 2010). 
1.2.2. Physiological actions 
Endogenous glucocorticoids have a wide-range of homeostatic functions in the body, 
regulating a number of important developmental and metabolic processes, 
modulating inflammation, as well as influencing the cardiovascular system. Given 
the range and complexity of glucocorticoid physiology, their effects are highly 
sensitive to context (for example, physiological vs supraphysiological levels, MR- vs 
GR-mediated action and acute vs chronic exposure) and thus can be difficult to 
predict. However, the importance of glucocorticoids, and their homeostasis, is clearly 
demonstrated in patients with adrenal disease. A deficiency in glucocorticoid 
production, Addison’s disease, is characterised by muscle weakness, depression, loss 
of weight, low blood pressure and hypoglycaemia (Ten et al., 2001) and 
susceptibility to Addisonian 'crisis' at times of intercurrent illness. Glucocorticoid 
deficiency can also occur on abrupt withdrawal of chronic glucocorticoid treatment. 
This occurs due to suppression of the HPA axis, and endogenous glucocorticoid 
production, by chronic high circulating exogenous glucocorticoid levels. Conversely, 
Cushing’s syndrome is caused by glucocorticoid excess, which can result from 
chronic steroid treatment (Souverein et al., 2004; Wei et al., 2004), Cushing’s 
disease, caused by a pituitary gland adenoma that secretes excessive levels of ACTH 
which subsequently elevates cortisol (Colao et al., 1999; Etxabe et al., 1994), or an 
adrenal adenoma that secretes excessive levels of cortisol (Stratakis et al., 2007).  
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Characteristics of Cushing’s syndrome include thinning of skin, poor wound healing, 
obesity, diabetes, hypertension, dyslipidaemia, mood disturbances and increased 
CVD event rate (Newell-Price et al., 2006). 
1.2.2.1 Developmental effects 
During development, glucocorticoids play an important role in regulating foetal 
growth and organ maturation in preparation for extra-uterine life. GR is expressed in 
most tissues from mid-gestation onwards, as well as in the placenta and foetal 
membranes (Cole et al., 1995). MR expression is more limited and is only present at 
later gestational stages (Brown et al., 1996). Correspondingly, there is a rise in 
cortisol levels during late pregnancy, which parallels increased maturity of foetal 
organs (Smith et al., 1974). Glucocorticoid treatment is often used to accelerate lung 
development in foetuses at risk of pre-term delivery (San Feliciano et al., 2011). 
However, excess foetal exposure to glucocorticoids can have a detrimental influence 
on early life programming, increasing the risk of developing diabetes and obesity in 
adulthood (Reynolds, 2010). Placental 11βHSD2 is crucial in protecting the foetus 
from excessive exposure to maternal glucocorticoids (Edwards et al., 1993). 
1.2.2.2 Metabolic effects 
The main metabolic effects of glucocorticoids occur in the liver, adipose tissue, 
pancreas and brain, in response to stressors (starvation, physical and psychological 
stress). Glucocorticoids oppose the effects of insulin and increase conversion of 
stored energy (glycogen, triglycerides and protein) to available energy (glucose and 
free fatty acids). Glucocorticoids also oppose insulin-mediated reduction of central 
appetite (Chavez et al., 1997), stimulating the intake of fat (Castonguay, 1991) and 
sugar (Epel et al., 2000). In addition, glucocorticoids inhibit the secretion of insulin 
from pancreatic β-cells (Lambillotte et al., 1997; Ling et al., 1998). Glucocorticoids 
also increase the hepatic release of fatty acids and glucose as energy by increasing 
protein catabolism and gluconeogenesis, while decreasing liver mitochondrial β-
oxidation (Morton et al., 2001). The aim of the metabolic effects of endogenous 
glucocorticoids is to increase energy availability to the skeletal muscles and brain at 
times of stress, to enhance ‘fight or flight’ (Walker, 2007). Although glucocorticoids 
are useful in adapting to short-term stress, longer term glucocorticoid excess has 
39 
 
maladaptive metabolic consequences including obesity, dyslipidaemia and diabetes 
mellitus, as characterised in Cushing’s syndrome (Newell-Price et al., 2006). The 
contrast between short-term weight loss and long-term weight gain exemplifies the 
context-sensitivity of glucocorticoid action. 
1.2.2.3 Anti‐inflammatory and immunosuppressive effects 
Glucocorticoids have potent anti-inflammatory and immunosuppressive properties, 
which make them highly effective agents in controlling inflammatory diseases, 
including asthma, rheumatoid arthritis, inflammatory bowel disease and autoimmune 
diseases, as well as in the prevention of transplant rejection.  
 
Glucocorticoids control inflammation by attenuating many aspects of the 
inflammatory process by a GR-mediated increase of the transcription of anti-
inflammatory genes and decrease of the transcription of inflammatory genes. GR are 
expressed in endothelial cells (Oishi et al., 2011) and inflammatory cells, notably 
macrophages (Liu et al., 1999), which have a key role in inflammatory processes. 
For example, glucocorticoids increase the synthesis of the anti-inflammatory 
cytokine IL-10, which inhibits the transcription of many pro-inflammatory cytokines, 
chemokines and inflammatory enzymes (Wang et al., 1995). In addition, 
glucocorticoids induce the transcription of the IL-1 receptor antagonist (Levine et al., 
1996) and IL-1 receptor 2, which binds IL-1 but has no signalling capacity (Colotta 
et al., 1993), thus reducing the activity of the pro-inflammatory cytokine IL-1. 
Although the up-regulation of these mediators will contribute to the anti-
inflammatory effects of glucocorticoids, the down-regulation of pro-inflammatory 
mediators is likely to be the most significant mechanism by which glucocorticoids 
hinder inflammatory processes. For example, glucocorticoids inhibit the transcription 
of several pro-inflammatory cytokines (IL-1β, IL-2, IL-3, IL-4, IL-5, IL-6, IL-11,  
IL-13, TNF-α and M-CSF) and chemokines (IL-8, RANTES (regulated upon 
activation, normal T cell expressed and secreted), MCP-1, MCP-3, MCP-4 and 
macrophage inflammatory protein-1α (MIP-1α)) (reviewed in (Barnes, 1998)). The 
result is the attenuation of the recruitment of immune cells, such as neutrophils, 
monocytes, T-lymphocytes and granulocytes, to the site of inflammation, and the 
inhibition of their activation and proliferation.  
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Glucocorticoids also inhibit the transcription of the inflammatory enzyme inducible 
NOS (iNOS) in macrophages (Di Rosa et al., 1990), perhaps by inhibiting the most 
important transcription factor regulating iNOS gene transcription, NFκB (Barnes, 
1998). In addition, glucocorticoids inhibit the expression of endothelial adhesion 
molecules, further contributing to the inhibition of immune cell recruitment to the 
site of inflammation. This may in part be due to their inhibitory effects on the 
cytokines that induce adhesion molecule expression (IL-1β and TNF-α), but 
glucocorticoids may also directly inhibit the transcription of the genes encoding 
ICAM-1 and E-selectin (Cronstein et al., 1992). Furthermore, these hormones 
regulate the maturation of monocytes into highly phagocytic macrophages (Giles et 
al., 2001), and enhance the phagocytosis of apoptotic leukocytes (Liu et al., 1999), 
promoting the resolution of inflammation (Heasman et al., 2003). 
 
It should be noted that physiological levels of glucocorticoids exert both pro- and 
anti-inflammatory effects. It has been proposed that at low circulating levels, 
glucocorticoids exert primarily permissive effects on inflammation. As circulating 
levels increase to the high end of the normal diurnal range, glucocorticoids become 
stimulatory. Higher circulating levels of glucocorticoids, such as in times of stress or 
following pharmacological administration, potently inhibit inflammation (Yeager et 
al., 2004). This is another example of the context-sensitivity of glucocorticoid action. 
1.2.2.4 Cardiovascular effects 
Functional GR and MR are expressed in cardiovascular tissues, including VSMCs 
(Dhawan et al., 2007; Krug et al., 2010), endothelial cells (Nguyen Dinh Cat et al., 
2010; Oishi et al., 2011) and cardiomyocytes (Latouche et al., 2010; Sun et al., 
2008), supporting the idea that glucocorticoids interact directly with the 
cardiovascular system. Indeed, glucocorticoids have diverse effects on 
cardiovascular tissues influencing tone, vascular development, inflammation and 
vascular lesion formation (section 1.2.3). In addition, both 11βHSD1 and 11βHSD2 
are expressed in VSMCs (Hatakeyama et al., 1999) and endothelial cells (Brem et al., 
1998), suggesting that pre-receptor glucocorticoid metabolism may influence steroid 




Physiological levels of endogenous glucocorticoids are required to sustain normal 
blood pressure and fluid volume, in response to stimuli such as shock. These steroids 
increase blood pressure by mechanisms that are incompletely understood, but are 
likely to involve renal, cardiac and vascular actions. For example, glucocorticoids 
play an important role in the regulation of fluid and electrolyte balance, by 
modulating renal sodium retention and thus plasma volume. This is likely to be 
mediated indirectly by glucocorticoids influencing the production of angiotensinogen 
by the liver (Brasier et al., 1996), AVP in the hypothalamus (Raff, 1987) and atrial 
natriuretic peptide (ANP) by cardiac myocytes (Shields et al., 1988). They can also 
regulate cardiac output by influencing contractility and work performance of the 
heart (Pirpiris et al., 1993).  
 
Importantly, glucocorticoids are also believed to have direct effects on vascular tone, 
enhancing contractility of the vessel wall and thus peripheral vascular resistance 
(Yang et al., 2004b). Glucocorticoids increase vasoconstriction by: (1) increasing the 
secretion of the vasoconstrictors angiotensin II (Mendelsohn et al., 1982), 
endothelin-1 (Morin et al., 1998) and erythropoietin (Kelly et al., 2000); (2) 
augmenting the sensitivity of VSMCs to vasoconstrictors such as angiotensin II and 
noradrenaline (Ullian, 1999); (3) up-regulating the angiotensin II receptor (Sato et 
al., 1994); and (4) down-regulating the expression of the Na+/Ca2+ exchanger in 
VSMCs, increasing intracellular Ca2+ and promoting contraction (Smith et al., 1994). 
Furthermore, glucocorticoid-mediated enhanced constriction may be secondary to 
impaired endothelium-dependent relaxation. Indeed, glucocorticoids can attenuate 
endothelial-dependent vasodilatation to acetylcholine (Mangos et al., 2000) and 
reduce the release of vasodilatory agents such as NO (Whitworth et al., 2002), PGI2 
(Grunfeld et al., 1986) and prostaglandin E2 (PGE2) (Handa et al., 1984) from 
endothelial cells. Although glucocorticoids play an important role in blood pressure 
homeostasis, elevated levels are associated with hypertension. The mechanisms 
behind glucocorticoid-induced hypertension are complex and not fully elucidated. 
Although not essential, renal MR agonism has been suggested to play a role (Smets 
et al., 2010). Indeed, 11βHSD2 deficiency in SAME (Ferrari, 2010) and in mice 
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(Kotelevtsev et al., 1999) results in glucocorticoid-induced MR activation and 
hypertension. There is, however, increasing evidence to suggest a non-renal 
mechanism contributes to glucocorticoid-induced hypertension, mediated by direct 
effects on endothelial cells and VSMCs (Ullian, 1999).  
1.2.2.4.2 Angiogenesis 
Angiogenesis, the growth of new blood vessels from pre-existing vasculature, is a 
complex process regulated by many activators and inhibitors. It is a crucial process 
during embryonic development, as well as during wound healing and in the female 
reproductive tract in adults. However excessive angiogenesis has been associated 
with a number of diseases including cancer, diabetic retinopathies and rheumatoid 
arthritis (Carmeliet, 2003). The ability of glucocorticoids to inhibit angiogenesis has 
been confirmed in vitro, in vivo and in tumour-bearing animals (Folkman et al., 
1983; Logie et al., 2010; Small et al., 2005). In addition, genetic deletion of 
11βHSD1 has been shown to enhance angiogenesis both in vitro and in vivo (Small 
et al., 2005). Despite considerable research, the mechanisms behind glucocorticoids’ 
anti-angiogenic properties are incompletely understood. However, there are several 
possible pathways through which glucocorticoids may inhibit angiogenesis: (1) 
modification of cytokine production; (2) inhibition of leukocyte interaction with the 
endothelium; (3) inhibition of protease activity; (4) degradation of extracellular 
matrix; (5) inhibition of growth factor activity; (6) inhibition of the arachidonic acid 
cascade; (7) impairment of vessel maturation and stability; and (8) non-
transcriptional effects (reviewed in (Hadoke et al., 2006)). It has been suggested that 
glucocorticoid-mediated inhibition of angiogenesis is independent of GR and MR 
(Crum et al., 1985). However, others have shown it to be GR-dependent (Logie et 
al., 2010; Small et al., 2005). 
1.2.2.4.3 Intra‐vascular inflammation 
As their anti-inflammatory actions proceed through GR-mediated interactions within 
blood vessels and inflammatory cells (section 1.2.2.3), glucocorticoids have the 
potential to directly attenuate intra-vascular inflammation. For example, 
glucocorticoids decrease expression of endothelial adhesion molecules, cytokines 
43 
 
and chemokines, and so directly inhibit the recruitment of immune cells such as 
neutrophils and macrophages into the vasculature (reviewed in (Barnes, 1998)). In 
addition, as well as being expressed in VSMCs (Hatakeyama et al., 1999) and 
endothelial cells (Brem et al., 1998), 11βHSD1 is expressed in inflammatory cells 
such as T-lymphocytes (Zhang et al., 2005a) and activated macrophages (Thieringer 
et al., 2001), suggesting that pre-receptor glucocorticoid metabolism may contribute 
to regulation of intra-vascular inflammation. The anti-inflammatory influence of 
glucocorticoids on the vascular inflammatory conditions associated with CVD is 
discussed in detail below. 
1.2.3. Glucocorticoids and CVD 
1.2.3.1 Glucocorticoids and CVD risk factors 
While physiological levels of endogenous glucocorticoids play an important role in 
adaptive responses to stressors, excess circulating glucocorticoid levels are 
maladaptive. The detrimental consequences of hypercortisolaemia include metabolic 
and cardiovascular complications such as obesity, hypertension, dyslipidaemia, 
hyperglycaemia and insulin resistance (Newell-Price et al., 2006). These symptoms 
parallel with features of the metabolic syndrome, a cluster of risk factors associated 
with a high risk for CVD and type 2 diabetes mellitus (Thomson et al., 2007). 
Indeed, CVD is the main cause of mortality in Cushing’s patients (Pivonello et al., 
2008; Ross et al., 1982). Non-Cushing’s hypercortisolaemia, for example in those 
predisposed to HPA hyperactivity by early life programming (Seckl, 2004) or those 
receiving exogenous glucocorticoid replacement therapy, is also associated with 
obesity, dyslipidaemia and diabetes (Filipsson et al., 2006; Reynolds, 2010). In 
addition, chronic glucocorticoid therapy for inflammatory conditions is limited by a 
number of adverse side effects including the metabolic and cardiovascular 
complications associated with an increase risk of CVD (Moghadam-Kia et al., 2010; 
van Raalte et al., 2009). 
1.2.3.2 Glucocorticoids and atherosclerosis 
The influence of glucocorticoids on atherosclerosis is complex and incompletely 
understood. In addition to their effects to induce systemic risk factors for CVD, 
glucocorticoids also have a plethora of local actions on the vascular wall, some of 
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which may contribute to the pro-atherosclerotic effects of glucocorticoids. For 
example dexamethasone enhances formation and accumulation of cholesterol esters 
in human smooth muscle cells (Petrichenko et al., 1997) and macrophages (Cheng et 
al., 1995; Yang et al., 2004a), as well as inhibit cholesterol efflux from macrophages 
(Ayaori et al., 2006). In addition, prednisolone has been shown to delay endothelial 
migration and cytoskeletal rearrangement, thus inhibiting endothelial wound repair 
(Fyfe et al., 1995). Endothelial NO availability can also be disturbed by 
dexamethasone-induced augmentation of reactive oxygen species (ROS) production 
(Iuchi et al., 2003).  
 
However, glucocorticoids can also mediate a number of anti-atherosclerotic 
processes in the vessel wall including the potent anti-inflammatory effects (section 
1.2.2.3) that glucocorticoids are primarily utilised for clinically. Furthermore, 
dexamethasone inhibits incorporation of modified LDL into macrophages (Asai et 
al., 1993; Chono et al., 2006) and foam cell formation (Tauchi et al., 2000) in vitro 
as well as reducing macrophage growth induced by ox-LDL (Sakai et al., 1999). 
Thus, glucocorticoids have the potential to prevent lipid accumulation in the intima, 
a crucial process in the pathogenesis of atherosclerosis. In addition, dexamethasone 
increases circulating high density lipoprotein (HDL), an atheroprotective lipoprotein 
(Saladin et al., 1996). Dexamethasone, hydrocortisone and prednisolone also have an 
inhibitory effect on VSMC proliferation (Voisard et al., 1994) and dexamethasone 
have been shown to inhibit VSMC migration (Goncharova et al., 2003), both of 
which contribute to the progression of atherosclerosis. Therefore, the net effect of 
glucocorticoids on atherosclerotic lesion development is likely a balance of their 
systemic influences and their local pro- and anti-atherosclerotic effects (Figure 1.6) 
and, thus, is likely sensitive to context.  
 
In pre-clinical studies, dexamethasone administration has consistently been shown to 
inhibit atherogenesis both in rabbits (Asai et al., 1993; Makheja et al., 1989; Naito et 
al., 1992) and in mice (Tauchi et al., 2001), attributed to the anti-inflammatory 
properties of the steroids. However, this beneficial influence of glucocorticoid 





Figure 1.6: Systemic vs local effects of glucocorticoids on the cardiovascular system.  
Glucocorticoids can interact locally with endothelial cells, vascular smooth muscle cells 
(VSMCs) and macrophages, thereby modulating vascular function, structure and response to 
inflammation. Glucocorticoids also have systemic effects on non-vascular organs, such as the 
liver, adipose and kidneys, which are associated with increased risk of cardiovascular disease. 







anti-inflammatory glucocorticoid therapy will augment atherogenesis in patients with 
inflammatory diseases (Maxwell et al., 1994). Indeed, glucocorticoid administration 
is associated with an increased prevalence of carotid artery atheroma, visualised by 
ultrasound, in patients with rheumatoid arthritis (del Rincon et al., 2004). 
Pharmacoepidemiological studies have also found a positive correlation between 
glucocorticoid therapy and cardiovascular events, particularly an increase in the 
incidence of heart failure and MI (Davis et al., 2007; Solomon et al., 2006; 
Souverein et al., 2004; Wei et al., 2004). Intriguingly, the effect of glucocorticoids 
was not altered by adjustment for components of the metabolic syndrome (Souverein 
et al., 2004; Wei et al., 2004), confirming that the influence of glucocorticoids on 
cardiovascular outcome is not mediated exclusively by the known systemic 
metabolic risk factors. However, it continues to be difficult to dissect the influence of 
exogenous glucocorticoids from the underlying inflammatory conditions, which may 
themselves be pro-atherogenic. 
  
As with chronic glucocorticoid therapy, endogenous glucocorticoid excess is also 
associated with an increase in CVD risk factors, in man. Although few studies have 
investigated the incidence of cardiovascular events, Cushing’s patients have been 
shown to have intimal thickening and a higher incidence of atherosclerotic plaques 
than controls, visualised by echo-Doppler ultrasonography (Faggiano et al., 2003), 
even 5 years after the removal of the tumour responsible for glucocorticoid excess 
(Colao et al., 1999). In addition, higher plasma cortisol in response to stress has been 
associated with coronary artery stenosis, quantified by angiography (Alevizaki et al., 
2007). This is supported by animal studies that have reported social stress to increase 
atherogenesis (Bernberg et al., 2008; Okwusidi et al., 1991; Shively et al., 2009).  
 
The pro-atherosclerotic effect of endogenous glucocorticoids is further supported in 
murine models of glucocorticoid deficiency, in which prevention of pre-receptor 
generation of glucocorticoids by inhibition of 11βHSD1 attenuates atherosclerotic 
lesion development (Hermanowski-Vosatka et al., 2005; Nuotio-Antar et al., 2007). 
Similarly, adrenalectomy inhibited aortic lesion development in a rat model of 




Glucocorticoids clearly have the potential to inhibit neointimal proliferation due to 
their potent anti-inflammatory properties (section 1.2.2.3). Indeed, glucocorticoids 
have been shown to attenuate the inflammatory response to vascular injury by 
inhibiting leukocyte accumulation following cuff placement (Hagihara et al., 1991) 
or balloon-injury in rabbits (Poon et al., 2001), possibly by reducing the expression 
of MCP-1 (Poon et al., 2001). Also, glucocorticoids reduce the release of cytokines, 
including IL-6, IL-13, MCP-1, RANTES, TGF-β and TNF-α, after stenting in 
rabbits, measured using a cytokine array (Ribichini et al., 2007c). In addition to their 
anti-inflammatory properties, glucocorticoids can directly inhibit VSMC processes 
which are involved in neointimal proliferation. For example, glucocorticoids inhibit 
VSMC migration (Goncharova et al., 2003; Ribichini et al., 2005) and proliferation 
(Berk et al., 1988; Voisard et al., 1994) in vitro, and inhibit release of PDGF (a 
growth factor implicated in both the induction of migration and the expression of 
inflammatory chemoattractant molecules (Marmur et al., 1992)) from VSMCs, 
following vascular injury (Nakano et al., 1993).  
 
Importantly, glucocorticoids also have a number of properties which could promote 
vascular cell proliferation. For example, they can stimulate the release of growth 
factors, such as endothelin-1, from VSMCs (Morin et al., 1998) and inhibit the 
production and action of NO, a potent inhibitor of cell proliferation (Whitworth et 
al., 2002). In addition, glucocorticoids can stimulate the expression of angiotensin-
converting enzyme (ACE) in VSMCs (Fishel et al., 1995) and in endothelial cells 
(Mendelsohn et al., 1982), thus increasing the production of angiotensin II; a 
stimulant of VSMC growth both in vitro (Berk et al., 1989) and in vivo (Griffin et al., 
1991). Furthermore, glucocorticoids have been shown to prevent endothelial healing, 
through delayed endothelial migration and cytoskeletal rearrangement (Fyfe et al., 
1995), which may contribute to continued inflammation and VSMC migration and 
proliferation. Thus, the overall influence of glucocorticoids on neointimal 
proliferation will depend on the balance between the anti-inflammatory/anti-




In pre-clinical studies, glucocorticoid administration has consistently been shown to 
inhibit neointimal development in a number of animal models, including the rat 
(Guzman et al., 1996; Nagasaki et al., 2004; Villa et al., 1994), rabbit (Hagihara et 
al., 1991; Petrik et al., 1998; Valero et al., 1998; Van Put et al., 1995) and mouse 
(Pires et al., 2005). In addition, glucocorticoid-coated stents inhibited neointimal 
proliferation in the dog femoral artery (Strecker et al., 1998) and in the pig coronary 
artery (Wang et al., 2005c). Following the success of these animal studies, 
glucocorticoids have been trialled as anti-restenotic agents in the clinic, both as 
systemic treatment alongside PCI and as local treatment in the form of DES. Oral 
therapy with high-dose prednisone for 45 days gave positive results in the IMPRESS 
trials, with a significant reduction in MACCE, TLR and angiographic restenosis, in 
patients with elevated systemic markers of inflammation following PCI (Ribichini et 
al., 2005; Versaci et al., 2002). However, while oral glucocorticoid treatment has 
advantages of being low cost and easy to administer and control, there are 
contraindications including diabetes mellitus, severe arterial hypertension and peptic 
ulcers. In addition, high-dose glucocorticoid treatment can result in adverse effects 
such as gastric pain, impaired glucose tolerance, worsened hypertension and, 
occasionally, neutropenia (Ribichini et al., 2007a). Local glucocorticoid delivery, in 
the form of dexamethasone-eluting stents (DexES), has the advantage of avoiding the 
systemic secondary effects of steroids, while releasing a high dose of steroid at the 
site of the target lesion. Unfortunately, although there have been some positive 
clinical outcomes and/or angiographic results with DexES (Han et al., 2006; 
Jimenez-Valero et al., 2007; Liu et al., 2003; Patti et al., 2005), there are a number of 
studies describing DexES as having no effective anti-proliferative actions in acute 
coronary syndromes (Hoffmann et al., 2004b; Pesarini et al., 2009), no benefit over 
BMS in patients with stable angina (Gaspardone et al., 2006; Hoffmann et al., 
2004a), and an association with relatively high restenosis rates in patients with 
diabetes mellitus (van der Hoeven et al., 2008).  
 
While there has been an assortment of investigations into the effects of exogenous 
glucocorticoids on neointimal proliferation, there do not appear to be any reports 
detailing the influence of endogenous glucocorticoids. However, two studies carried 
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out in this department, have investigated the effect of endogenous glucocorticoids on 
neointimal proliferation through manipulation of 11βHSD1. Inhibition or genetic 
deletion of 11βHSD1 was shown to reduce neointimal lesion development following 
intra-luminal wire injury in ApoE-/- mice, suggesting endogenous glucocorticoids are 
in fact pro-restenotic (Iqbal, 2010). However, a similar study using C57Bl/6 mice, 
described manipulating 11βHSD1 to have no effect on neointimal proliferation 
following wire-injury (Macdonald, 2007). The conflicting results between these two 
studies might be attributed to metabolic disturbances caused by ApoE deficiency.  
1.2.3.4 Thrombotic effects of glucocorticoids 
Although it is widely accepted that inflammation causes thrombosis and thrombosis 
stimulates inflammation (section 1.1.4.4) anti-inflammatory glucocorticoids have 
well-described pro-thrombotic properties. Indeed, a hypercoagulable state and 
increased incidence of thromboembolic complications are reported in Cushing’s 
syndrome (Boscaro et al., 2002; La Brocca et al., 1997). This hypercoagulable state 
is mainly attributed to an increase in clotting factors, including FV, FVIII, FIX, FXI, 
FXII and prothrombin (Dal Bo Zanon et al., 1983; Patrassi et al., 1985; Sjoberg et 
al., 1976), as well as an inhibition of fibrinolysis via an increase in PAI-1 and α2-
antiplasmin (Patrassi et al., 1985; Patrassi et al., 1992). Glucocorticoid treatment in 
healthy individuals (Brotman et al., 2006) and in patients following organ transplant 
surgery (Patrassi et al., 1995; Sartori et al., 1999) is also associated with increased 
coagulation and reduced fibrinolytic activity (Patrassi et al., 1997; Patrassi et al., 
1995; Sartori et al., 1999). These results are complemented by in vivo studies in rats 
which report reduced fibrinolysis following dexamethasone treatment (van Giezen et 
al., 1994; van Giezen et al., 1992), and a number of in vitro studies which describe a 
dexamethasone-induced increase in PAI-1 mRNA and protein levels in a number of 
different human and animal cell lines (Fukumoto et al., 1992; Halleux et al., 1999; 
Ma et al., 2002; Yamamoto et al., 2004). 
 
In addition to influencing the coagulation and fibrinolysis factors, glucocorticoids 
may also promote thrombosis by modulating endothelial function. Excess circulating 
glucocorticoids in Cushing’s patients or with glucocorticoid administration have 
been reported to increase circulating levels of vWF (Fatti et al., 2000; Jilma et al., 
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2005; Sartori et al., 1999) and p-selectin (Jilma et al., 2005), changes likely to 
increase platelet adhesion to the endothelium. These results are complemented by in 
vitro demonstrations that glucocorticoids increase production of vWF by cultured 
human and animal endothelial cells (Graf et al., 1990; Huang et al., 1995; Yamamoto 
et al., 2004).  
 
A number of (often contradictory) studies, report an influence of glucocorticoids on 
platelet function. van Giezen et al showed that dexamethasone inhibits platelet 
aggregation in rats, thus suggesting an anti-coagulant outcome (van Giezen et al., 
1994; van Giezen et al., 1992). Conversely, methyl prednisolone has successfully 
been used clinically to reverse clopidogrel-related inhibition of platelet aggregation 
(Qureshi et al., 2008) and dexamethasone has been shown to block inhibition of 
platelet aggregation by activated macrophages in vitro (Pinto et al., 1993). In 
addition, increased circulating concentrations of cortisol have been described to 
increase platelet aggregation in ex vivo animal vessels (Fantidis, 2010). However, 
whether glucocorticoids can exert these effects by directly modulating platelet 
function is not fully understood, considering glucocorticoids mediate many of their 
effects through GR-mediated de novo mRNA and protein synthesis and platelets are 
anuclear and so incapable of synthetic activity. However, functional GR has been 
shown to be expressed in human platelets and glucocorticoids may modulate platelet 
function through non-genomic pathways (Moraes et al., 2005). Alternatively, the 
influence of glucocorticoids on platelets may be mediated indirectly though their 













Vascular lesion development arises from an inflammatory and proliferative response 
to vascular wall injury. Glucocorticoid hormones have widely-recognised 
anti-inflammatory and anti-proliferative properties which appear to make them ideal 
candidates for inhibition of vascular lesion development. Indeed, glucocorticoids are 
currently being trialled clinically as anti-restenotic agents and administration of 
glucocorticoids to experimental animals inhibits the growth of vascular lesions in 
some models. However, a previous study in this department found that inhibition of 
neointimal lesion formation by administration of dexamethasone was obscured by 
excessive thrombosis at the site of injury. In addition, chronic glucocorticoid excess 
in patients (either as a result of Cushing’s syndrome or chronic treatment) is 
associated with increased cardiovascular disease. The influence of glucocorticoids on 
vascular lesion development, therefore, remains incompletely understood and 
appears to be highly sensitive to context. 
 
The overall objective of this PhD was to explore the influence of endogenous and 
exogenous glucocorticoids on atherosclerotic lesion development and neointimal 
proliferation. Based on clinical evidence, this thesis addresses the hypothesis that 
glucocorticoids are pro-atherosclerotic and anti-restenotic. 
 
It is therefore proposed: 
 
• removal of endogenous glucocorticoids by adrenalectomy will attenuate 
atherosclerotic lesion development yet augments neointimal proliferation. 
 
• glucocorticoid administration will augment atherosclerotic lesion 







In order to address these hypotheses, the specific aims of the work described in this 
thesis were to:  
 
1. determine the influence of physiological levels of endogenous 
glucocorticoids and the impact of a pharmacological dose of an exogenous 
glucocorticoid on atherosclerotic lesion development in ApoE-/- mice fed a 
western diet. 
 
2. determine the role of physiological levels of endogenous glucocorticoids and 
the impact of pharmacological doses of an exogenous glucocorticoid on 
neointimal lesion development following intra-luminal wire injury of the 
mouse femoral artery. 
 
3. elucidate the mechanism behind the local thrombus formation associated with 
























All animal experiments were performed in accordance with the Animals (Scientific 
Procedures) Act (UK), 1986 and with local ethical committee approval. All non-
genetically-modified mice were of the inbred C57Bl/6J strain purchased from Harlan 
Laboratories, UK. All ApoE knockout (ApoE-/-) mice (C57Bl/6J background) were 
bred in-house. All PAI-1 knockout (PAI-1-/-) mice were imported from The Jackson 
Laboratory, ME, USA. Mice were bred and housed at the University of Edinburgh 
Biomedical Research Facility at Little France in a controlled 12hr light/dark cycle 
environment, at room temperature (RT; defined as 21 ± 2°C) and 50% humidity. 
Animals were allowed free access to standard laboratory chow (Special Diet 
Services, UK) and drinking water, unless otherwise stated.  
2.2 In vivo techniques/treatments 
2.2.1. Adrenalectomy 
Mice were randomised to undergo bilateral adrenalectomy, with sham adrenalectomy 
used as a control, as described by de Jong et al (de Jong et al., 2007), to assess the 
effect of endogenous glucocorticoids on vascular lesion development 
2.2.1.1  Animal preparation  
Mice were weighed, and anaesthetised by inhalation of isoflurane (4%; Merial 
Animal Health Ltd., UK) in an exposure chamber. Upon loss of consciousness, the 
animals were transferred onto a heated pad to maintain body temperature, where 
administration of anaesthetic (2% isoflurane in oxygen) was maintained via a nose 
cone. The animals were given a subcutaneous injection of analgesic (0.05mg/kg of 
bodyweight buprenorphine; Alstoe Animal Health, UK) prior to commencing the 
surgery. All surgeries were performed under a surgical microscope using aseptic 
technique: all surgical instruments were sterilised in a bead steriliser prior to surgery. 
2.2.1.2 Adrenal gland removal, wound closure and recovery 
Mice were placed in a prone position before an area in the centre of the back was 
shaved and a 15mm longitudinal skin incision was made. The mice were then rotated 
onto their right side and a small incision was made in the muscle above the spleen. 
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The left adrenal gland was then identified, isolated and removed cleanly. The 
procedure was repeated on the right side. Following closure of the skin incision with 
metal clips, the animals were ear notched for identification and were transferred to a 
clean cage to recover from anaesthesia. After surgery, all animals were allowed free 
access to 0.9% w/v saline as their drinking water, to restore salt balance. 
2.2.2. Femoral artery injury 
Intra-luminal injury was inflicted on murine femoral arteries to induce neointimal 
hyperplasia. This was achieved by the application of the intra-luminal wire-injury 
model, described by Sata et al. (Sata et al., 2000). 
2.2.2.1  Animal preparation and femoral artery isolation 
Mice were anaesthetised and prepared for surgery as described above (section 
2.2.1.1). The inner surface of the left hind limb was shaved and a 5mm skin incision 
was made at the top of the leg. The rectus femoris and vastus medialis muscles were 
separated by blunt dissection to expose the femoral neurovascular bundle. The 
femoral artery and vein were isolated from the nerve both proximally and distally to 
the femoropopliteal bifurcation. Temporary ligatures (6-0 silk suture; Fine Science 
Tools, UK), looping the artery and vein, were positioned proximal and distal to the 
popliteal branch point to allow control of blood flow in the femoral artery and vein.  
2.2.2.2  Wire injury 
The popliteal artery was isolated from the adjacent vein and ligated distally with 6-0 
silk suture. Tension was placed upon this ligature to bring the popliteal artery up into 
the plane of the femoral artery and both arteries were cleared of peri-adventitial 
connective tissue by blunt dissection. The popliteal artery was dilated with 1% w/v 
lignocaine (1% lidocaine hydrochloride; Hamlen Pharmaceuticals Ltd., UK), as 
necessary. A 0.014” diameter straight sprung angioplasty guide wire (Cook Inc., IN, 
USA) was then inserted through a transverse arteriotomy in the isolated popliteal 
artery, approximately 2mm distal to the femoropopliteal bifurcation. The proximal 
temporary ligature was loosened to allow the wire to be advanced approximately 
1.5cm into the femoral artery towards the iliac artery. The wire was left in place for 
30 seconds before being removed. On withdrawal, the proximal temporary ligature 
was re-tensioned and a further permanent ligature was positioned immediately 
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proximal to the arteriotomy site. The two temporary ligatures were removed, 
restoring blood flow to the femoral artery and reperfusing the injured area. The skin 
incision was then closed using interrupted sutures with a 6-0 silk ligature (Mersilk; 
Ethicon, UK), before the animals were transferred to a clean cage to recover from 
anaesthesia.    
2.2.3. Administration of drugs 
2.2.3.1 Systemic glucocorticoid administration 
The synthetic glucocorticoid dexamethasone (dex) was administered to investigate 
the effects of exogenous glucocorticoids on vascular lesion development. In vivo, dex 
is a potent and relatively selective GR agonist (Kim et al., 1998). Dex (Sigma-
Aldrich, UK) was dissolved in absolute ethanol at a concentration of 1mg/mL before 
being diluted in the animals’ standard drinking water to achieve doses of 0.1 and 
0.8mg/kg/day, through monitoring the animals’ weight and water consumption. 
2.2.3.2 Western diet administration 
A high cholesterol “Western” diet was used to accelerate atherosclerotic lesion 
development in ApoE-/- mice. The diet (0.21% cholesterol, 21% fat, D12079B; 
Research Diets Inc., USA) was stored at 2-4ºC until administered to the animals ad 
libitum for 12 weeks. 
2.2.4. Tail cuff plethsmography 
Systolic blood pressure was determined using the technique of tail cuff photo-
plethysmography (Cervenka et al., 2003). This technique involves monitoring blood 
flow through a rodent’s tail by light transmittance (inversely proportional to tail 
volume) at a point distal to an inflating/deflating pressurised cuff. Systolic blood 
pressure is designated as the cuff inflation pressure at which changes in tail volume, 
and therefore blood flow, are quenched.  
 
To ensure sufficient tail blood flow, mice were placed in a 40ºC chamber for 10 
minutes immediately prior to the procedure. Mice were transferred to a restraint 
positioned above a heated pad and an integrated pressure cuff/photosensor sleeve 
(Harvard Apparatus, UK) was placed around the base of the tail. Degree of restraint 
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and position of the cuff were adjusted until a regular cyclical tail volume trace, 
representing the pulse, was reached. Pulse traces were recorded while four 
inflate/deflate pressure cycles were performed. Systolic blood pressure was 
calculated as the mean measurement of the four deflate-cycles only. Once adequate 
pressure measurements were acquired mice were returned to their cages. 
2.2.5. Tail tip bleeding time 
Tail tip bleeding time was measured as an in vivo parameter of combined plasma- 
and platelet-mediated blood coagulation. Mice were anaesthetised by inhalation of 
4% isoflurane in an exposure chamber. Upon loss of consciousness, the animals were 
transferred onto a heated pad, to maintain body temperature, where administration of 
anaesthetic (2% isoflurane in oxygen) was maintained via a nose cone. The tail was 
dipped in 37ºC water for 1 minute before 0.5cm from the tip of the tail was excised 
using a scalpel. The tail wound was immediately placed in a pre-warmed Eppendorf 
of 0.9% w/v saline at 37ºC and time until bleeding ceased was recorded. 
2.2.6. Perfusion fixation 
Chemical fixatives are used to preserve tissue from degradation, prevent growth of 
microorganisms and maintain tissue structure, allowing storage and analysis of 
biological samples. Aldehyde fixatives, such as formalin, achieve fixation by the 
formation of methylene crosslinks between tissue amino groups. Perfusion of whole 
animals not only allows rapid and even delivery of fixative to all organs but also 
provides rigidity to blood vessels to maintain their luminal dimensions once excised.  
 
Mice were terminally anaesthetised with an intra-peritoneal injection of sodium 
pentobarbital (80mg/kg of bodyweight, Ceva Animal Health Ltd, UK). Following 
onset of deep anaesthesia, as determined by loss of pedal withdrawal reflex, a 
bilateral thoracotomy and transverse sternotomy were made. At this point, blood was 
collected from the right ventricle of the heart using a 23 gauge needle and syringe. 
For delivery of perfusate, a 23 gauge needle was advanced 4mm through the left 
ventricular wall and secured.  A further incision was made in the right atrial wall to 
allow perfusate to run off. Phosphate-buffered saline (PBS; 24 mL; 1 tablet per 
200mL deionised water to give phosphate buffer (0.01 M) containing KCl (2.7 mM) 
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and NaCl (137 mM), pH 7.4; Sigma-Aldrich, UK) containing 10U/mL heparin (Leo 
Laboratories, UK), was delivered to the left ventricle at a constant rate (6mL/min) by 
a peristaltic pump (Gilson, UK). Ideally, a constant (physiological) pressure should 
have been used to prevent any vascular damage. Immediately after perfusion with 
heparinised PBS, 10% neutral buffered formalin (24mL; Sigma-Aldrich, UK) was 
delivered to the left ventricle. Adequate fixation was determined by blanching of the 
liver and muscle rigidity. Following perfusion, the animal was immersed in 10% 
neutral buffered formalin for a further 48 hours to ensure full fixation. 
2.3 Ex vivo techniques 
2.3.1.  Semi‐quantitative atherosclerosis scoring 
The high cholesterol-fed ApoE-/- mouse model of atherosclerosis has sites of the 
arterial tree that are predisposed to atherosclerotic plaque development: aortic root, 
lesser curvature, brachiocephalic artery, origin of the left carotid artery and left 
subclavian artery, origins of the renal arteries and the femoral artery branches. To 
determine the distribution of plaque within the animals, the lesion size at the 
predisposed sites was semi-quantitatively scored. 
 
Following perfusion fixation (section 2.2.6), the arterial tree was dissected out as a 
whole and cleaned of connective tissue before being stored in 70% v/v ethanol 
(Fisher Scientific, UK). The arterial tree was then pinned on a Sylgard plate 
(prepared in a petri dish with Sylgard 184 silicone elastomer kit; Dow Corning, MI, 
USA). Microscopic evaluation of the entire tree was carried out by an independent 
individual blinded to treatment groups and the areas predisposed to atherosclerotic 
plaque development were semi-quantitatively scored from 1-5 where 1: no plaque, 2: 
small plaque, 3: large plaque, 4: extensive plaque, 5: extensive plaque with outward 
remodelling. Following evaluation, the trees were returned to 70% v/v ethanol. 
2.3.2.  Optical projection tomography 
Optical projection tomography (OPT) is a 3-dimensional imaging technique with 
similarities to optical coherence tomography (OCT), but providing images of greater 
resolution and at a lower cost (Sharpe et al., 2002). The current gold standard 
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examination of blood vessels by histology offers superior resolution to OPT but 3D 
reconstructions of 2D sections is time-consuming, labour-intensive and destructive. 
OPT allows quick and reproducible 3-dimensional quantifications of blood vessels, 
with the added advantage of being non-destructive, allowing further analysis with 
standard histology (Kirkby et al., 2011). Briefly, an ultraviolet source illuminates the 
rotating specimen, suspended in a refractive index-matching solution, through a filter 
selective for a specific excitation wavelength. Photons emitted by endogenous 
fluorophores in the specimen are focussed through an emission filter to the detector. 
The multiple single projections covering 360º of sample rotation are reconstructed 
using a modified computed tomography back-projection algorithm to produce a 3D 
image. 
2.3.2.1 Tissue preparation, sample embedding and mounting 
Arteries to be analysed by OPT were excised from mice following trans-cardiac 
perfusion fixation with 10% neutral buffered formalin (section 2.2.6), cleared of 
connective tissue and stored in 70% v/v ethanol. Low melting point agarose 
(Invitrogen Ltd., UK) was dissolved in distilled water to 1.5% w/v at 90ºC and 
allowed to cool to 40-50ºC before being filtered through Whatman 113V paper (GE 
Healthcare, UK) to eliminate particulate contaminants. Each artery was suspended 
vertically in 40mL of agarose solution and rapidly cooled to <20ºC to allow the 
agarose to set. Agarose blocks were glued to magnetic OPT mounts with 
cyanoacrylate adhesive (Henkel, UK) so that the artery lay in the axis of the mount. 
The mounted blocks were trimmed to a conical shape to minimise back-reflection of 
light within the plane of scanning. Mounted samples were dehydrated in absolute 
methanol (Fisher Scientific, UK) for >24 hours before being cleared in the refractive 
index matching solution BABB (34% v/v benzyl alcohol, 66% v/v benzyl benzoate; 
both Acros Organics) for >24 hours.  
2.3.2.2 Scanning and tomographic reconstruction 
Mounts with samples attached were secured in the scanning chamber by magnetic 
attachment. Under white light the sample position was adjusted until the sample 
revolved about its own axis in the centre of the field of view. Optical magnification 
was set to 1 pixel = 5.5μm and 1 pixel = 7μm for aortic arch and femoral arteries, 
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respectively. To scan, samples were illuminated by a UV source with 425/40nm 
band-pass excitation filter and 475nm low-pass emission filter (GFP1 filter). The 
exposure time was adjusted to maximise the quality of the resulting image; typically 
~650ms. Raw data were acquired by automated capture of projection images 
(1024x1024 pixels) at rotation increments of 0.9º to give 400 images covering 360º. 
 
After scanning, mounted arteries were cleared of BABB by immersion in absolute 
methanol for >24 hours. Tissues were removed from mounts and trimmed of excess 
agarose before being processed for histology as described in section 2.4. 
 
Following manual evaluation of focus and rotational misalignment of projection 
images using Data Viewer software (Skyscan, Belgium), computed tomographic 
reconstructions were calculated using NRecon software (Skyscan, Belgium). For 
each dataset, rotational misalignment was then corrected for. 
2.3.2.3 Quantification 
Reconstructed OPT tomographs were quantified using CTan software (Skyscan, 
Belgium). For each scan, a region of interest along the length of the artery was 
defined; the full length of the brachiocephalic artery in the aortic arch and 4mm 
immediately proximal to the femoropopliteal bifurcation in the femoral artery. To 
quantify lesion size, for every 50th cross-section scan-line within the region of 
interest, the outline of the lesion was estimated and traced. This was possible due to 
the greater fluorescent signal emitted by the media than the intima and by 
observation of the luminal conformation. The lesion areas for the interleaved scan-
lines were interpolated by the software and manually checked and corrected where 
required. Lesion volume was then calculated from the stack of cross-sectional areas 
by the software. To quantify lumen, the process was repeated, tracing the outline of 
the lumen area every 50th scan-line and correcting the interpolated sections. From 
both sets of data, the total volume inside the internal elastic lamina was calculated 
and thus the proportion of this volume occupied by lesion, the volumetric “stenotic 
ratio”, was calculated. As the 3-dimensional volumetric data are calculated from a 
stack of 2-dimensional cross-section areas, the maximum cross-sectional area of 





The aim of tissue processing is to remove water from the tissue and replace it with a 
solidifying medium, most commonly paraffin wax, to enable the cutting of 
sufficiently thin sections for subsequent analysis of morphology and composition. 
Formalin-fixed samples were loaded into cassettes and processed to wax using a 
Tissue-Tek Vacuum Infiltration Processor (Sakura Finetek Europe, The 
Netherlands). Briefly, cassettes were dehydrated in graded concentrations of ethanol 
(50%, 70%, 95%, 100% v/v, each for 2 hours; Fisher Scientific, UK), cleared in 
xylene (two changes, each for 2 hours; Fisher Scientific) and immersed in molten 
paraffin wax at 60ºC (three changes, each for 2 hours, Thermo-Shandon, UK). Each 
step was performed under vacuum and with agitation to accelerate infiltration of 
solvent/wax. After processing, samples were positioned in molten paraffin wax-filled 
embedding moulds and cooled rapidly on a Tissue-Tek Cryo-console (Sakura 
Finetek Europe, The Netherlands) to form solid blocks. 
 
Paraffin blocks were cut into sequential 4μm thick sections using a Leitz 1512 
microtome (Leica Microsystems, Germany). Immediately after cutting, ribbons of 
sections were floated onto a 40ºC water bath (Sakura Finetek Europe, The 
Netherlands) to stretch and smooth the sections before being mounted on Superfrost 
Plus electrostatically-coated microscope slides (VWR International, UK). Slides 
were baked at 37ºC overnight to ensure adherence of the sections to the slides. 
Brachiocephalic arteries were entirely sectioned and retained from the 
brachiocephalic bifurcation to the right carotid/subclavian bifurcation. In contrast, 
femoral arteries were sectioned in a repeated manner, where 20 sections were 
mounted on 10 slides (2 per slide) then the following 20 sections (80μm) were 
discarded. Sectioning in this manner was continued until the remaining vessel was 
morphologically normal (i.e. uninjured) under microscopic evaluation. For vessels 
for which OPT scans had previously been acquired, sectioning was localised to the 




For routine examination and morphometric analysis tissue sections were stained 
using the “United States trichrome“ (UST) method (Hadoke et al., 1995) using an 
automated stainer (Varistain Gemini, Thermo-Shandon, UK). This technique 
combines an elastin stain (Gomori’s aldehyde fuschin) with Gomori’s Trichrome 
stain, delineating collagen (green), elastin (purple) and cells (red with black nuclei). 
 
Gomori’s aldehyde fuschin was prepared by dissolving pararosaniline (Sigma, UK) 
to 1% w/v in 60% v/v ethanol. To this, 1% v/v hydrochloric acid (HCl; VWR 
International, UK) and 2% v/v fresh paraldehyde (Sigma-Aldrich, UK) were added, 
and the mixture was allowed to blue at RT for at least two days, to allow reaction of 
pararosaniline and acetaldehyde. The solution was vacuum filtered before use. 
Gomori’s trichrome was prepared in distilled water by the addition of 0.6% w/v 
phosphotungstic acid (Sigma-Aldrich, UK), 0.6% w/v chromotrope 2R (Sigma-
Aldrich, UK), 0.3% w/v fast green FCF (Sigma-Aldrich, UK) and, after vigorous 
mixing, 1% v/v acetic acid (Fisher Scientific, UK). The solution was filtered before 
use. Weigert’s iron haematoxylin was prepared by mixing equal volumes of 
Weigert’s solution A and B (Bios Europe, UK) immediately before use. Acidified 
potassium permanganate solution (0.3% w/v potassium permanganate in 0.3% v/v 
sulphuric acid) was prepared from solutions of 1% w/v potassium permanganate 
(Sigma-Aldrich, UK) and 3% v/v sulphuric acid (Fisher Scientific, UK). 
 
Sections were de-waxed in xylene and rehydrated through graded alcohols (both 
Fisher Scientific, UK) before being treated with acidified potassium permanganate 
and decolourised in 2% oxalic acid (Sigma-Aldrich, UK). Sections were then placed 
in the Gomori’s aldehyde fuschin, to stain the elastin, and differentiated in 70% v/v 
ethanol. After being rinsed in running tap water, nuclei were counter-stained with 
Weigert’s iron haemotoxylin and blued in running tap water. Sections were then 
placed in 5% w/v phosphotungstic acid, to displace previously applied dyes from 
collagen fibres, and rinsed in distilled water. In the final staining step, sections were 
immersed in Gomori’s trichrome to stain cytoplasm and collagen and then rinsed in 
0.2% v/v acetic acid. The sections were then dehydrated through graded alcohols and 
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cleared in xylene. Coverslips were mounted with the synthetic resin mountant DPX 
(Fisher Scientific, UK) either by hand or with an automated coverslipping machine 
(Consul, Thermo-Shandon, UK). The full staining protocol is detailed in Table 2.1. 
2.4.3. Picrosirius red staining 
Lesion collagen content was evaluated with picrosirius red staining which 
specifically stains collagen fibres pink/red (Puchtler et al., 1973). Sections were de-
waxed in xylene (2 x 5 min) and rehydrated through graded alcohols (each for 2 min) 
and rinsed in running tap water (5 min) before being immersed in picrosirius red 
solution for 2 hours. The staining solution was prepared by dissolving the collagen 
stain Direct Red 80 (Sigma-Aldrich, UK) and plasma counter-stain Fast Green FCF 
(Sigma-Aldrich, UK) in saturated aqueous picric acid (Sigma-Aldrich, UK), each to 
1% w/v. Sections were then briefly rinsed in tap water before being dehydrated and 
coverslipped as described above (section 2.4.2). Photomicrographs of picrosirius red-
stained sections were quantified by colour deconvolution (section 2.4.7.5). 
2.4.4. Photomicrograph acquisition 
Colour photomicrographs of histologically-stained sections of arteries were taken to 
allow analysis of lesion size and composition. Images were captured with a 
CoolSNAP colour camera (Photometrics, AZ, USA) coupled to a Axioskop light 
microscope (Carl Zeiss, UK), under 10X objective magnification, via a MicroColour 
liquid crystal RGB filter (Cambridge Research and Instrumentation Inc., MA, USA) 
using MCID Basic 7.0 software (Imaging Research Inc., ON, Canada). 
2.4.5. Morphometric analysis 
Morphometric analysis was performed on UST-stained sections. Measurements of 
area (μm2) inside the EEL, area inside the IEL and luminal area were recorded using 
Photoshop CS3 Extended software (Adobe Systems Inc, CA, USA). Potential tissue 
distortion was not taken into account during lumen quantification. From these 
measurements the medial area (area inside EEL – area inside IEL) and intimal area 
(area inside IEL – luminal area) could be calculated. The section with the largest 
intimal area was chosen to represent each artery. Additional morphometric analysis 
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An estimation of the extracellular lipid content of the brachiocephalic arteries was 
also calculated from UST stained sections. As lipid is removed from sections during 
the staining process, extracellular lipid content was quantified from the acellular 
clefts seen in the UST stained sections. These have been show to represent areas of 
extracellular lipid pooling prior to the vessels being processed (Figure 2.1), as 
previously described by Shiomi et al (Shiomi et al., 2008). The white acellular clefts 
were identified using a semi-automated colour deconvolution process (section 
2.4.7.5) and their areas calculated with Photoshop CS3 Extended software. The lipid 
content was measured in the representative section containing the largest plaque and 
was expressed a percentage of plaque area. 
2.4.7. Immunohistochemistry 
Immunohistochemistry involves the localisation of antigens in tissue sections by the 
use of specific antibodies. The antigen-antibody interaction can be visualised by 
fluorescence or enzymatic development of a chromogenic substrate, usually 
following several amplification steps. Representative sections containing the 
maximum cross-section of lesion for each artery were immunohistochemically-
stained to assess the cellular and protein composition of the lesions. 
2.4.7.1 Slide preparation 
All immunohistochemical procedures followed the following preparation protocol. 
Slides were first baked for 30 minutes at 55ºC to ensure adherence of the mounted 
paraffin sections. Slides were then de-waxed in xylene (2 x 5 min) and rehydrated 
through graded alcohols (100%: 2 x 5 mins, 70% v/v: 1 x 5 min) before being rinsed 
in running tap water (5 min) and transferred to PBS. Slides were then installed in 
Sequenza coverplates (Thermo-Shandon, UK), trapping 80μl PBS between slide and 
coverplate. Sequenzas were flushed twice with PBS. 
2.4.7.2 Smooth muscle α‐actin staining 
Following flushing with PBS, slides were incubated with 3% v/v H2O2 solution 
(Sigma-Aldrich, UK) to block endogenous peroxidise activity. After 5 min, slides 









Figure 2.1: Comparison of Oil-red-O and United States trichrome staining to assess lipid 
distribution in the a-cellular clefts of atherosclerotic plaques. 
Male ApoE-/- mice were fed a high (0.2%) cholesterol diet for 12 weeks to induce atherosclerotic 
lesion development. The brachiocephalic artery was excised and frozen before being cut into 
10μm thick transverse sections. Serial sections were stained with Oil-red-O or United States 
trichrome (UST), the latter of which removes all lipid from the section. Comparison of these 
sections confirms the acellular clefts (black arrows) seen in the UST section approximate to intra-





solutions to reduce non-specific binding of primary antibodies: 60 min with PBS 
containing 2.5% w/v bovine serum albumin (BSA; Sigma-Aldrich, UK) and 2.5% 
w/v milk powder; followed by 30 min with PBS containing 1% w/v BSA and 20% 
v/v normal serum from the species in which the respective secondary antibody was 
raised, which in this case was goat. Without washing, mouse anti-mouse smooth 
muscle α-actin primary antibody (Sigma-Aldrich, UK), diluted 1/400 in PBS 
containing 1% w/v BSA, was applied to the Sequenza and incubated for 30 min at 
RT. Sections incubated with mouse ascities fluid (Sigma-Aldrich, UK), also diluted 
1/400, served as negative controls. Sequenzas were then flushed 3 times with PBS 
before addition of goat anti-mouse IgG biotinylated secondary antibody (Vector 
Laboratories, UK), diluted 1/400 in PBS containing 1% w/v BSA. After 30 min at 
RT, the slides were washed 3 times with PBS. ExtrAvidin-Peroxidase (Sigma-
Aldrich, UK), a conjugate of streptavidin and horseradish peroxidase, was diluted 
1/200 in PBS containing 1% w/v BSA and incubated with the slides for 30 min at RT 
before the final 3 washes with PBS. Slides were removed from the Sequenzas and 
placed in PBS. The sites of immunoreactivity were determined with the horseradish 
peroxidise substrate diaminobenzidine (DAB; prepared according to manufacturer’s 
instructions; Dako Cytomation Ltd, UK). Incubation time was determined by 
microscopic evaluation of a positive control slide. The reaction was quenched in tap 
water before the slides were counterstained with one dip in Harris’s haematoxylin 
solution (Fisher Scientific, UK) and blued in running tap water for 5 min. Slides 
were then dehydrated through graded alcohols (70% v/v: 2 x 1 min, 100%: 1 x 1 
min) to xylene (2 x 2 min) before being coverslipped with DPX. 
2.4.7.3 Macrophage staining 
Following flushing with PBS, slides were incubated with 3% v/v H2O2 solution for 5 
min and then flushed twice with PBS. Slides were then incubated for 30 min with a 
blocking solution of PBS containing 1% w/v BSA and 20% v/v normal goat serum. 
Without washing, rat anti-mouse Mac2 primary antibody (Cedarlane Laboratories, 
Canada), diluted 1/6000 in PBS containing 1% w/v BSA, was applied to the 
Sequenza and incubated overnight at 4ºC. Sections incubated with rat IgG2a,κ (BD 
Pharmingen, UK), also diluted 1/6000, served as negative controls. Sequenzas were 
then flushed 3 times with PBS before addition of goat anti-rat IgG biotinylated 
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secondary antibody (Vector Laboratories, UK), diluted 1/400 in PBS containing 1% 
w/v BSA. After 30 min at RT, the slides were washed 3 times with PBS. ExtrAvidin-
Peroxidase and DAB solution were applied before counterstaining, rehydration and 
coverslipping, as described above (section 2.4.7.2). 
2.4.7.4 Fibrinogen staining 
For fibrinogen staining, antigen-retrieval was required to break the protein cross-
links, formed by formalin-fixation, masking the antigenic sites. To achieve this, 
20μg/mL proteinase K (Roche Applied Science, UK) was applied to the sequenzas 
and incubated for 20 min at 37ºC and a further 20 min at RT. Following flushing 
with PBS, blocking solutions were applied: PBS containing 2.5% w/v BSA and 2.5% 
w/v milk powder for 60 min, followed by PBS containing 1% w/v BSA and 20% v/v 
normal goat serum for 30 min. Without washing, rat anti-human fibrinogen primary 
antibody (Dako UK Ltd, UK), diluted 1/200 in PBS containing 1% w/v BSA and 
20% v/v goat serum, was applied to the Sequenza and incubated overnight at 4ºC. 
Sections incubated with rat IgG (Dako UK Ltd, UK), also diluted 1/200, served as 
negative controls. Sequenzas were then flushed 3 times with PBS before addition of 
3% v/v H2O2 solution. After 10 min and 3 washes with PBS, goat anti-rat 
biotinylated secondary antibody (Vectastain ABC kit; Vector Laboratories, UK) was 
applied. After 30 min at RT, the slides were washed 3 times with PBS. The ABC 
solution (Avadin : biotinylated peroxidase complex; Vectastain ABC kit) was then 
added to the slides and incubated at RT for 30 min before being washed off with 
PBS. DAB solution was applied before counterstaining, rehydration and 
coverslipping, as described above (section 2.4.7.2). 
2.4.7.5 Quantification 
Quantification of immunoreactivity was carried out from photomicrographs of 
immuno-stained tissues, acquired as described in section 2.4.4. Positive DAB 
staining was identified using a semi-automated colour deconvolution process and 
their areas calculated with Photoshop CS3 Extended software. Immunoreactivity was 
expressed as a percentage of DAB stained area within lesion area, delineated as 
described in section 2.4.5. To avoid problems of inter-batch variability quantitative 





Plasma samples from mice were analysed for corticosterone by competition 
radioimmunoassay to confirm the success of the adrenalectomy surgery. Samples 
were collected by tail tip into Microvette CB 300 EDTA tubes (Sarstedt Ltd, UK), 
immediately prior to sacrifice between 10am and 12pm, when corticosterone levels 
were elevated from the diurnal nadir at 8am (Holmes et al., 1997).  
 
Plasma samples were diluted 1/10 (sham animals) or 1/5 (adrenalectomised animals) 
in borate buffer (Boric acid (133mM), NaOH (180mM), HCl (0.35% v/v), BSA 
(0.5% w/v) pH 7.4; all Sigma-Aldrich, UK) and denatured (75ºC, 1 hour) to release 
corticosterone from its binding protein, corticosterone-binding globulin. The samples 
were centrifuged (16,000 x g, 5 min, RT) to pellet the debris. Denatured samples 
(20μl) were then added in duplicate to a 96 well plate. Corticosterone (Sigma-
Aldrich, UK) standards of known concentration (0.3 - 320nM) were also added in 
duplicate to the plate. Borate buffer containing [3H4] corticosterone (1µl stock (62.2 
Ci/mmol) in 6 mL borate buffer and adjusted to 5,000 cpm; GE Healthcare, UK) and 
rabbit anti-corticosterone primary antibody (diluted 1/15000; kindly provided by C. 
Kenyon) were added to each well, mixed and incubated (2 hours, RT). Following 
primary incubation, anti-rabbit secondary antibody linked to scintillation proximity 
assay (SpA) beads (diluted according to manufacturer’s instructions; GE Healthcare, 
UK) were then added to each well. The plate was sealed with anti-crosstalk film and 
inverted to mix. The plate was incubated (16 hours, RT, dark) before the 
radioactivity in each well was counted in a beta counter. A standard curve of the 
proportion of bound [3H] corticosterone (B/B0) against the standard corticosterone 
concentrations (Figure 2.2) was plotted and the level of corticosterone in each sample 
determined by interpolation from the standard curve. Finally, the result was 
multiplied by 5 (adrenalectomised animals) or 10 (sham animals) to account for the 
















Figure 2.2: Example of a corticosterone assay standard curve. 
Proportion bound [3H4] corticosterone (B/B0; y-axis) decreases as displaced by increasing 
concentrations of competing unlabelled corticosterone (x-axis). The graph points were fitted with 
a sigmoidal concentration-response curve, constructed using AssayZap software (Biosoft, UK). 
Duplicates of standards were deemed acceptable if the coefficient of variation <10%. The 
corticosterone concentration of unknown samples was determined from their B/B0 by 
interpolation against the standard curve. 
 
 




Serum samples were analysed for total cholesterol and triglyceride levels by 
colourimetric assay. Briefly, samples were incubated with reagents containing 
specific enzymes which sequentially hydrolyse and oxidise cholesterol and 
triglycerides to produce hydrogen peroxide (H2O2). In the final reaction, catalysed by 
peroxidase, the H2O2 reacts to form a chromophore (quinoneimine dye). 
 
Blood was collected by cardiac puncture into clean tubes and allowed to clot on ice 
before being centrifuged (8,000 x g, 10 min, 4ºC). The supernatant (serum) was 
removed into a fresh tube. Serum samples (neat) were added in triplicate to a 96-well 
microtitre plate. Cholesterol or triglyceride standards of known concentration (0.97 - 
27.16mM and 0.57 - 7.91mM, respectively; Thermo Scientific, UK) were also added 
in triplicate to the plate. Cholesterol or Triglyceride reagent (Thermo Scientific, UK) 
was then added to their respective plates and incubated (37ºC, 5 min). Following 
incubation, the absorbance was read at 500 and 600nm. The absorbance (A) at 
500nm is proportional to the concentration of cholesterol or triglyceride in the 
original sample. Absorbance at 600nm was subtracted as plate background. A 
standard curve of A500 – A600 against the standard concentrations was plotted (Figure 
2.3) and the concentration of cholesterol or triglyceride in each sample was 
interpolated from the standard curve. 
2.5.3. Plasma fibrinolytic factors 
Platelet-poor plasma samples (PPP) were analysed for the fibrinolytic factors PAI-1 
and tPA using enzyme-linked immunosorbent assay kits (ELISA; Innovative 
Research, MI, USA). Briefly, ELISAs involve the target antigen being immobilised, 
usually by a capture antibody coated and dried on a microtiter plate, followed by 
detection using specific antibodies. The antigen-antibody interaction can be 
visualised by enzymatic development of a chromogenic substrate, often following an 
amplification step. Platelet-poor plasma was used as platelets are a source of PAI-1 






Figure 2.3: Example of total cholesterol assay standard curve. 
The relative absorbance of cholesterol standards at 500nm-600nm increases with increasing 
concentration of cholesterol. The graph points were fitted by linear regression analysis using 
Prism 5.01 software (GraphPad software, CA, USA). Triplicates of standards were deemed 
acceptable if coefficient of variance < 10%. Standard curves were deemed acceptable if R2 > 0.98. 
The cholesterol concentration of unknown samples was determined from their A500-A600 by 




PPP samples were prepared as described in the relevant chapters (section 4.3.5, 5.3.4 
and 6.3.5). Samples diluted 1:4 with blocking buffer (3% w/v BSA in TBS buffer; 
Tris base (100mM), NaCl (150mM), pH 7.4; both Sigma-Aldrich, UK) and added 
(100μl) to the 96-well plate provided with each kit, prepared for specific antigen 
capture (Table 2.2). PAI-1 or tPA standards of known concentration (0.05 - 
50ng/mL; 100μl) were also added in duplicate to the plate. The plate was shaken 
(300rpm, 30 min) and washed (300μl wash buffer provided, three times). Following 
antigen capture, the appropriate primary antibody (Table 2.2) was added (100μl) to 
each well and the plate was shaken and washed, as before. The appropriate secondary 
antibody, conjugated to horseradish peroxidise (HRP), was then added (100μl) to 
each well, shaken and washed, as before. Following secondary incubation, 
tetramethylbenzidine (TMB) HRP substrate was then added (100μl) to each well and 
the plate was agitated for 2-10 min. 0.5M H2SO4 (Fisher Scientific, UK) was added 
(50μl) to each well to quench the reaction before the plate was mixed thoroughly and 
the absorbance was read immediately at 450nm. A standard curve of A450 against the 
standard concentrations (Figure 2.4) was plotted and the levels of PAI-1 or tPA in 
each sample were determined by interpolation from the standard curve. The result 
was multiplied by 4 to account for the initial dilution of each sample. 
2.5.4. Flow Cytometry 
Platelet activation status was determined using flow cytometry. Briefly, a beam of 
light is directed onto a hydrodynamically-focussed stream of platelet-rich plasma 
(PRP). Detectors positioned in line with and perpendicular to the light beam pick up 
forward scatter (FSC) and side scatter (SSC), respectively. FSC correlates with the 
cell volume and SSC depends on the inner complexity of the cell. Platelets have a 
unique FSC and SSC, which allows their identification (Sintnicolaas et al., 1991). In 
addition, a fluorescently-labelled antibody against CD41 (glycoprotein IIb), a 
constitutively-expressed surface protein, can be used to further isolate the platelet 
population. Activated platelets can be identified by their expression of p-selectin, 
distinguished using a fluorescently-labelled antibody against CD62P (Braun et al., 
2008). On passing the light beam, the fluorescent labels are excited into emitting a 






PAI-1: plasminogen activator inhibitor-1, tPA: tissue plasminogen activator. All ELISA kits 





























Figure 2.4: Example of active mouse tPA ELISA standard curve. 
The relative absorbance of tPA standards at 450nm increases with increasing concentration of 
tPA. The graph points were fitted by linear regression analysis using Prism 5.01 software 
(GraphPad software, CA, USA). Duplicates of standards were deemed acceptable if the 
coefficient of variation was <10%. Standard curves were deemed acceptable if R2 > 0.98. The tPA 
concentration of unknown samples was determined from their A450 by interpolation from the 




Fresh PRP was prepared from citrated blood, collected from the vena cava, by 
centrifugation (120 x g, 5 min, RT) (section 4.3.5). PRP was diluted 1:20 with 
Hanks’ basic saline (Sigma-Aldrich, UK). Appropriate antibodies were prepared in 
Hanks’ basic saline as described (Table 2.3). 10μl of each antibody preparation was 
incubated with 10μl diluted PRP at RT for 20 min. A positive control for platelet 
activation was also prepared by pre-incubating the PRP with 10μM ADP and 2mM 
Ca2+. The cells were then fixed with 1% v/v formaldehyde in Hanks’ buffered saline 
(300μl) in preparation for flow cytometry.  
2.5.4.2 Flow cytometric analysis 
Flow cytometry was performed on a FACSCalibur (Becton Dickinson, UK) and 
analysed using FlowJo software version 7.5 (Tree Star Inc., OR, USA). FSC/SSC 
characteristics were used to gate the platelets population (Figure 2.5A). A total of 
10,000 gated events were collected. To further isolate the platelets, only CD41 
positive cells were included in the analysis (Figure 2.5B). The geometric mean 
fluorescence intensity (GMFI) was quantified for CD62P-expressing platelets 
(Figure 2.5C), representing their activation status. 
2.6 Molecular Biology 
2.6.1. Genotyping ApoE‐/‐ mice 
ApoE-deficient mice were originally created by homologous recombination (Plump 
et al., 1992; Zhang et al., 1992), producing a disrupted “knockout” allele. The 
genotype of ApoE-/- mice, bred to use in these studies, was confirmed by polymerase 
chain reactions (PCR) using specific primers and the enzyme Taq DNA polymerase. 
The PCR products were then separated by size using gel electrophoresis, from which 
wild-type and knockout alleles can be identified. 
2.6.1.1 DNA extraction from tail tips 
DNA was extracted from tail tip samples from ApoE-/- mice using the Qiagen 
DNeasy Tissue Kit (Qiagen, UK). Tail tips (~5mm) were lysed in Buffer ATL 
(180μl) with proteinase K (20μl) overnight in a rotating incubator at 56ºC. The 
samples were then vortexed (15s) before Buffer AL (200μl) was added and mixed
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Figure 2.5: Assessment of platelet activation status by flow cytometry. 
Platelet activation status was assessed by flow cytometric analysis of p-selectin expression. 
Platelets were gated by FSC/SSC characteristics. In this example, 97.97% of original events were 
within the platelet gate (A). 10,000 gated events were then analysed. Platelets were further 
identified by their expression of the platelet specific antigen CD41 (B). Platelet activation was 
identified by their expression of p-selectin (CD62P), tested with a positive (+ADP) and negative 
(-ADP) control (C). An isotype control for the anti-CD62P antibody was used to identify non-
specific binding. Platelet activation status was expressed as the geometric mean fluorescence 







by vortexing (15s). Ethanol (absolute; 200μl) was then added for optimal column 
binding, and mixed by vortexing (15s). Each sample was then loaded into the 
DNeasy Mini spin column, subjected to centrifugation (6,000 x g, 1 min, RT) and the 
eluate was discarded. The column was then washed with Buffer AW1 (500μl) and 
the eluate was discarded following centrifugation (6,000 x g, 1 min, RT). The 
column was further washed with Buffer AW2 (500μl) and the eluate discarded 
following centrifugation (20,000 x g, 3 min, RT). The spin column was then placed 
in a fresh 2mL collecting tube and subjected to centrifugation (20,000 x g, 1 min, 
RT) to dry the spin column membrane and ensure no ethanol is carried over during 
DNA elution. The spin column was then placed in a fresh 1.5mL Eppendorf before 
Buffer AE (200μl) was added and incubated at RT for 1 min. DNA was eluted by 
centrifugation (6,000 x g, 1 min, RT). Eluted DNA was then stored at 4ºC. 
2.6.1.2 Polymerase chain reaction (PCR) 
PCR was carried out using the Invitrogen Taq DNA polymerase system (Invitrogen 
Ltd., UK). DNA samples (1.5μl) and primer mix (0.3mM each; Apo E Forward: 
AAC TTA CTC TAC ACA GGA TGC C, Apo E Reverse: CGT CAT AGT GTC 
CTC CAT CAG TGC; Invitrogen Ltd., UK) were pre-heated to 94ºC before 22μl 
“mastermix” was added, with a reaction composition of: 
 
MgCl2 (4.5mM) 
1x PCR Buffer  
dNTP mixture (0.5mM each) 
Taq DNA polymerase (1 unit) 
Nuclease-free water  
 
Two controls were prepared as above; one with water instead of DNA to identify any 
contaminating DNA, and one with ApoE+/- DNA to represent both the wild-type and 
transgene alleles. Samples were heated for initial denaturation (94ºC, 3 min), then 
underwent 32 cycles of PCR amplification, which consisted of denaturation (94ºC, 
35 s), annealing (58ºC, 1 min) and elongation (72ºC, 2 min). Samples were then 
incubated for an additional 3 min at 72ºC to ensure optimal elongation of products to 




PCR products were separated by electrophoresis on an agarose (Lonza, UK) gel (1% 
w/v in 1x TAE buffer; Tris-base (40mM), Acetic acid (0.01% v/v), EDTA (1mM), 
pH 8.0; all Sigma-Aldrich, UK) containing SYBR safe DNA dye (1:10,000; 
Invitrogen Ltd., UK). DNA samples (25μl) were prepared by adding loading dye 
(1μl; Promega, WI, USA). Prepared samples (26μl) were electrophoresed on the gel 
(140V, 1hr) alongside a 1Kb DNA ladder (Invitrogen Ltd., UK). The gel was then 
photographed under UV light at λ260nm to allow visualization of PCR product 
bands. The wild-type Apoe allele product was 584bp and the transgene Apoe allele 
product was 1500bp. Animals were confirmed as ApoE knockout mice if there was a 
clear transgene band and no wild-type band (Figure 2.6). 
2.6.2. mRNA quantification 
The transcript (mRNA) abundance of specific genes of interest was quantified using 
quantitative real time PCR (qPCR). Briefly, following extraction from the tissue of 
interest, total RNA was reverse transcribed to cDNA by the enzyme reverse 
transcriptase. Total cDNA then underwent qPCR using specific primers, allowing 
exponential amplification of the cDNA sequence of interest by the enzyme Taq DNA 
polymerase. The specialised 5’ to 3’ exonuclease activity of Taq DNA polymerase 
allows the use of fluorescent probes to quantify the amplification. The mRNA levels 
of the genes of interest were assessed relative to the mRNA levels of reference genes, 
to control for reverse transcription efficiency (Zhu et al., 2005). 
2.6.2.1 RNA extraction from lung 
RNA was extracted from lung using the Qiagen RNeasy Mini Kit (Qiagen Ltd, UK). 
Tissue (~30mg) was homogenised in 600μl Buffer RLT (lysis buffer) with 10µl β-
mercaptoethanol per mL, in order to denature ribonucleases released during cell 
lysis. The samples were subjected to centrifugation (16,000 x g, 3 min, RT). The 
supernatant was removed into an equal volume of 70% v/v ethanol and mixed for 
optimal column binding. This solution was then loaded into the RNeasy spin column, 
subjected to centrifugation (8,000 x g, 15 s, RT) and the eluate was discarded. The 
column was then washed with Buffer RW1 (700μl) and the eluate was discarded 










Figure 2.6: Example of ApoE-/- genotyping PCR product assessment by gel electrophoresis. 
PCR products were separated on a 1% gel at 100V for 1 hour, alongside a 1Kb DNA ladder. The 
wild-type Apoe allele product was 584bp and the transgene Apoe allele product was 1500bp. 
Animals were confirmed as ApoE knockout mice if there was a clear transgene band and no wild-





performed using Buffer RPE (500μl) followed by centrifugation (8,000 x g, 15s and 
2 min, respectively, RT) and eluate discarding, to ensure no ethanol was carried over 
during RNA elution. The spin column was then placed in a fresh 2mL collecting tube 
and subjected to centrifugation (16,000 x g, 1 min, RT) to eliminate any Buffer RPE 
carryover. The spin column was then placed in a fresh 1.5mL Eppendorf before 
RNase-free water (30μl) was added and RNA eluted by centrifugation (8,000 x g, 1 
min, RT). The eluate was added back to the column and for a further centrifugation 
(8,000 x g, 1 min, RT) to enhance the final RNA concentration. Eluted RNA was 
stored at -80°C. The RNA quality check (section 2.6.2.5) revealed there was no 
genomic DNA contamination. 
2.6.2.2 RNA extraction from liver 
RNA was extracted from liver as described above (section 2.6.2.1). The RNA quality 
check (section 2.6.2.5) revealed DNA contamination and so RNA samples underwent 
additional DNA-free (Applied Biosystems, CA, USA) treatment to eliminate 
genomic DNA. DNase 1 buffer (10x; 5μl) and rDNase 1 (1μl) were added to 50μl of 
extracted RNA and mixed gently. The samples were incubated at 37ºC for 20-30 min 
before DNase Inactivation Reagent (5μl) was added. The samples then underwent 
centrifugation (8,000 x g, 1.5 min, RT) and the supernatant, containing the RNA was 
transferred to a fresh tube. RNA was stored at -80ºC. 
2.6.2.3 RNA extraction from heart 
RNA was extracted from heart as described above (section 2.6.2.1) with the 
following modifications. Tissue (~30mg) was homogenised in 1mL Qiazol (Qiagen 
Let, UK), followed by incubation (5 min, RT) with chloroform (300μl; Rathburn 
Chemicals Ltd, UK). This alternative lysis protocol is deemed more appropriate for 
fibrous tissue, such as the heart, allowing better penetration of RNase inhibitors. The 
samples were then subjected to centrifugation (16,000 x g, 3 min, 4ºC). The top 
aqueous phase containing the RNA was removed into an equal volume of 70% v/v 
ethanol before being loaded onto the RNeasy spin column. An additional on-column 
DNase digestion step, carried out to eliminate genomic DNA: DNase 1 incubation 
mix (80μl; prepared as 10μl DNase 1 stock in 70μl Buffer RDD) was added directly 
onto the spin column membrane and incubated at RT for 15 mins. The column was 
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then washed again with Buffer RW1 (350μl) and the eluate was discarded following 
centrifugation (8,000 x g, 15s, RT). The protocol then continued as described above 
(section 2.6.2.1). Eluted RNA was stored at -80°C. 
2.6.2.4 RNA quantification 
RNA was quantified using a NanoDrop Spectrophotometer (Thermo Fisher, UK). 
The concentration of RNA was determined by the absorbance at 260nm wavelength 
(A260) using Beer’s law. The purity was assessed by the ratio A260:A280 which was 
deemed acceptable if between 1.9 and 2.1, as suggested in the NanoDrop Manual 
(Thermo Fisher, UK). 
2.6.2.5 RNA quality 
Quality of RNA was assessed by electrophoresis on an agarose (Lonza, UK) gel 
(1.5% w/v in 0.5x TBE buffer; Tris-borate (89mM), EDTA (2mM) pH 8.0; all 
Sigma-Aldrich, UK) containing SYBR safe DNA dye (1:10,000; Invitrogen Ltd., 
UK). RNA samples (2μl) were prepared by adding loading dye (10μl; Promega, WI, 
USA; diluted 1:4 in RNase-free water). Prepared samples (12μl) were 
electrophorosed on the gel (100V, 1hr) before the gel was photographed under UV 
light (λ260nm) to allow visualization of RNA bands. RNA integrity was deemed 
satisfactory if sharp, clear 28S and 18S ribosomal RNA (rRNA) bands were present 
without smearing (Figure 2.7). 
2.6.2.6 Reverse transcription polymerase chain reaction (RT‐PCR) 
Total RNA (500ng) was reverse transcribed using a Reverse Transcription System 
(Promega, UK). Each RNA sample was diluted to 57ng/μl in RNase-free water. RNA 
samples (8.7μl; 500ng) were denatured by incubation at 72ºC for 10 min, centrifuged 
for 10s to return sample to bottom of tube and returned to ice. To each denatured 
RNA sample, 11.3μl “mastermix” was added, with a reaction composition of: 
 
MgCl2 (5mM) 
1x RT buffer (2μl) 
dNTP mixture (1mM each) 
Recombinant RNasin® Ribonuclease Inhibitor (1u/μl) 
AMV (avian myeloblastosis virus) RT polymerase (15u/μg) 








Figure 2.7: Example of RNA quality assessment by gel electrophoresis. 
Eluted RNA was separated on a 1.5% gel at 100V for 1 hour. RNA integrity was assessed on the 
basis of 18S and 28S ribosomal RNA (rRNA) bands. RNA integrity was deemed satisfactory if 
sharp, clear 28S and 18S rRNA bands were present without smearing, and if 28S rRNA band was 
approximately twice as intense as 18S rRNA band, as with these 7 samples. 
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Two negative controls were prepared, as above, one with water instead of RNA (to 
identify any RNA contamination in reagents) and one without the reverse 
transcriptase enzyme (in order to detect the presence of contamination by genomic 
DNA (-veRT)). Samples were incubated at RT for 10 min, to allow annealing and 
extension of primers, followed by 15 min at 42ºC, to allow the reverse transcriptase 
to transcribe single-stranded RNA into double-stranded cDNA, and 5 min at 95ºC, to 
inactivate the enzymes. The resultant cDNA was stored at -20ºC. 
2.6.2.7 Quantitative real time PCR (qPCR) 
Abundance of mRNA was assessed using a LightCycler® 480 platform (Roche 
Applied Science, UK). Primers (Table 2.4; Invitrogen Ltd., UK) were designed to 
match intron-spanning probes within the Roche Universal Probe Library (UPL). It 
was not possible to design primers within the UPL system for some genes so 
commercially designed assays were used (Table 2.4; TaqMan® Gene Expression 
Assays; Applied Biosystems (ABI), UK). cDNA samples, including the –veRT 
sample, were diluted (1 in 20) in LightCycler H2O (Roche Applied Science, UK) and 
2μl were added to each well in triplicate. Standards were generated by serial dilution 
(1/4 – 1/512) of pooled cDNA from each sample and also added (2μl) in triplicate to 
the plate. A negative control containing water instead of cDNA was prepared to 
identify any cDNA contamination. To each standard and sample, 8μl “mastermix” 
was added.  
 
UPL primers “mastermix” reaction composition:  
 
Roche Probes Master (5μl) 
Forward primer (0.2μM) 




ABI TaqMan® Gene Expression Assays “mastermix” reaction composition: 
 
Roche Probes Master (5μl) 
1x primer/probe assay mix 






For: forward, Rev: reverse, PAI-1: plasminogen activator inhibitor-1, tPA: tissue plasminogen 
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Table 2.4: Details of qPCR primers for use with Roche Universal Probe Library (UPL) and 




The plate was spun (800 x g, 2 min, 4ºC) to ensure contents were at the bottom of the 
wells. Samples were heated for initial denaturation and activation (95ºC, 5 min), then 
underwent 50 cycles of PCR amplification, which consisted of denaturation (95ºC, 
10s), annealing and elongation (60ºC, 30s). Upon completion of the PCR 
programme, samples were cooled (40ºC, 30s). Amplification curves of cycle number 
against fluorescence were plotted. The crossing point (Cp) was calculated as the 
maximum point of the second derivative of the amplification curve. Triplicates of 
standards were deemed acceptable if the standard deviation of the Cp was < 0.5 
cycles. Negative controls were deemed acceptable if >10 Cp higher than the lowest 
standard. Standard curves were deemed acceptable if reaction efficiency was 
between 1.7 and 2.1. A standard curve of Cp against log “concentration” (serial 
dilutions of pooled samples) for each gene was generated (Figure 2.8) and the 
mRNA “concentrations” of unknown samples were determined by interpolation from 
the standard curve. The mRNA abundance of the gene of interest was presented as 
ratio to reference gene(s). Reference genes did not vary between treatments. 
2.7 Statistics 
All statistical analysis was performed using Prism 5.01 software (GraphPad software, 
CA, USA). Comparisons between OPT and histological methods were performed by 
linear regression, and subsequent F-testing to determine if the slope deviates from a 
hypothetical value of 1.0 (Chapter 3). For comparison of physiological levels of 
endogenous glucocorticoid or exogenous glucocorticoid treatment with control, 
adrenalectomised mice (Chapter 3 and 4) or comparison of exogenous glucocorticoid 
treatment with vehicle treatment (Chapter 5), statistical analysis was performed by 
one-way analysis of variance (ANOVA) with Dunnett’s post-hoc test. For 
comparison of the effects of exogenous glucocorticoids in C57Bl/6 mice and PAI-1-/- 
mice (Chapter 6), statistical analysis was performed by two-way ANOVA with 
Bonferroni’s post hoc test. In all studies, n refers to the number of individual animals 










Figure 2.8: Example of qPCR standard curve. 
The crossing point (Cp) decreases as log concentration of mRNA increases. Graph points were 
fitted with a straight line using Lightcycler 480 Software, Version 1.5 (Roche Applied Science, 
UK). Triplicates of standards were deemed acceptable if the standard deviation of the Cp was < 
0.5 cycles. Standard curves were deemed acceptable if reaction efficiency was between 1.7 and 
2.1. The mRNA concentration of unknown samples was determined from their Cp by 
interpolation from the standard curve. The mRNA levels of the target genes were quantified 






















The influence of glucocorticoids on atherosclerosis is imperfectly understood and 
unpredictable. On one hand, glucocorticoids are associated with adverse systemic 
effects on the cardiovascular system, such as dyslipidaemia (Becker et al., 1988; 
Curtis et al., 1982; Tauchmanova et al., 2002), hypertension (Whitworth et al., 2001) 
and hyperglycaemia (Delaunay et al., 1997; Tounian et al., 1997). In contrast, they 
also have potentially beneficial direct effects on the vascular wall, attenuating 
inflammation (Liu et al., 1999; Yamada et al., 1993) and smooth muscle cell 
migration and proliferation (Goncharova et al., 2003; Voisard et al., 1994), both of 
which are necessary for progression of atherosclerosis. Clinically, glucocorticoid 
excess, whether as a result of chronic glucocorticoid treatment or in patients with 
spontaneous Cushing’s syndrome, is associated with enhanced cardiovascular disease 
(Colao et al., 1999; Etxabe et al., 1994; Souverein et al., 2004; Wei et al., 2004). This 
premise is further supported by the finding that inhibition of 11βHSD1, thereby 
reducing availability of active corticosterone in glucocorticoid target tissues, is anti-
atherogenic in mice (Hermanowski-Vosatka et al., 2005; Nuotio-Antar et al., 2007) 
and adrenalectomy inhibits aortic lesion development in a rat model of 
atherosclerosis (Iams et al., 1977). There has also been one study describing a pro-
atherosclerotic effect of glucocorticoids in ApoE-/- mice fed a standard chow diet 
(Tous et al., 2006). Despite this evidence that glucocorticoids are pro-atherogenic, 
other animal studies have suggested that systemic glucocorticoid treatment protects 
against atherosclerosis, at least in rabbits (Asai et al., 1993; Makheja et al., 1989; 
Naito et al., 1992). Therefore, the influence of glucocorticoids on lesion development 
remains unclear. Elucidating these effects will improve our understanding of the role 
of glucocorticoid activity in regulating atherogenesis and the therapeutic potential of 
glucocorticoids as a treatment for, or as a target in, cardiovascular disease. 
 
The majority of in vivo atherosclerosis research has used rabbits as their primary 
animal model. The use of mice has, however, become more popular following the 
development of the ApoE-/- mouse (Plump et al., 1992; Zhang et al., 1992). 
Currently, the most commonly used murine model of atherosclerosis, both within our 
laboratory and elsewhere, combines the ApoE-/- mouse with high cholesterol, 
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“Western” diet to further accelerate plaque development. For example, 
Hermanowski-Vosatka et al used this model to show that pharmacological inhibition 
of 11βHSD1 (reducing pre-receptor generation of active glucocorticoid) ameliorates 
metabolic syndrome and prevents development of atherosclerotic lesions 
(Hermanowski-Vosatka et al., 2005). Therefore, the Western-diet fed ApoE-/- mouse 
was chosen for the investigation described in this chapter. 
 
Histological examination of atherosclerotic plaques dates back to the 1950s 
(Wanscher et al., 1951) and remains the gold standard for lesion quantification as it 
allows detailed analysis of lesion cross sectional size and composition. Nevertheless, 
histology is labour intensive and is restricted to 2-dimensional analysis, thereby 
limiting information of plaque volume. The alternative, en face measure of 
atherosclerosis, which involves staining and quantifying lipid deposition within the 
aorta (Ko et al., 2009; Mulvihill et al., 2010), are limited by the inability to inspect 
lesion thickness or cellular composition. Visualising arteries in 3-dimensions, and 
from that considering volumetric parameters of lesion development, would allow a 
more robust and sensitive measure than the traditionally used 2-dimensional 
techniques (McAteer et al., 2004). Ex vivo magnetic resonance imaging (MRI) and 
micro computed tomography (CT) have been applied to the study of murine 
atherosclerosis (Langheinrich et al., 2004; McAteer et al., 2004), but offer limited 
resolution and require long acquisition times. Optical coherence tomography (OCT) 
has been used successfully to visualise and quantify atherosclerosis in mice 
(Cilingiroglu et al., 2006), but it is yet to be reported to enable 3-dimensional 
quantification of atherosclerotic plaques. Optical projection tomography (OPT) was 
originally described for the imaging of mouse embryos (Alanentalo et al., 2007; 
Sharpe et al., 2002) and has since been utilised to allow 3-dimensional visualisation 
and quantification of murine neointimal lesions (Kirkby et al., 2011). OPT has, for 
the first time, successfully been implemented here in the visualisation of 
atherosclerotic plaques in the murine brachiocephalic artery. This technique allows 
3-dimensional quantification of the aortic arch and plaques within, a feat almost 




The work described in this chapter addresses the hypothesis that glucocorticoids are 
pro-atherogenic. It is therefore proposed that removal of endogenous glucocorticoids 
(adrenalectomy) inhibits, whilst glucocorticoid administration augments, lesion 
development in atherosclerosis-prone mice. In order to address this hypothesis, the 
specific aims of the work described in this chapter were to: 
 
• optimise the use of optical projection tomography for improved quantification 
of murine atherosclerotic plaques. 
• determine whether surgical removal of the adrenal glands reduced lesion 
development in ApoE-/- mice fed a western diet. 
• determine whether chronic administration of the synthetic glucocorticoid 
dexamethasone increased lesion development in adrenalectomised ApoE-/- 






Male ApoE-/- mice (bred in-house at the Biomedical Research Facility, Little France, 
Edinburgh, UK) aged 5 weeks and weighing 17-23 grams were used in this study. A 
tissue sample from each mouse was analysed to confirm genotype (section 2.6.1).   
3.3.2. Adrenalectomy  
In order to investigate endogenous glucocorticoids mice were randomised to undergo 
either bilateral adrenalectomy or sham adrenalectomy (section 2.2.1). 
3.3.3. Administration of drugs 
Adrenalectomised mice were provided with 0.9% w/v NaCl in their drinking water. 
Vehicle (absolute ethanol) or the synthetic glucocorticoid dexamethasone (dex; 
0.1mg/kg/day; section 2.2.3.1) were administered by addition to the drinking water. 
Animals that had undergone sham adrenalectomy were provided with vehicle in their 
standard drinking water. Drug administration commenced immediately after 
adrenalectomy/sham surgery and continued for 13 weeks (Figure 3.1). One week 
after surgery all animals were started on a high cholesterol (0.2%) Western Diet. 
Body weight and water intake were monitored throughout and used to titre the dex 
required to ensure the appropriate dose was administered.  
3.3.4. Tissue collection 
At the end of the 13-week treatment period the animals were fasted overnight, before 
blood was collected by tail tip and by cardiac puncture onto wet ice. The blood 
collected by tail tip was centrifuged (8,000 x g, 10min, 4ºC) and the plasma 
(supernatant) was removed into a fresh Eppendorf tube. The blood collected by 
cardiac puncture was allowed to clot on wet ice before being centrifuged (8,000 x g, 
10min, 4ºC) and the serum (supernatant) was removed into a fresh tube. Plasma and 
serum samples were snap frozen on dry ice and stored at -80ºC. The mice were then 
perfusion fixed under terminal anaesthesia (section 2.2.6). The whole animal was 







































































































































































































































































































































































































































The arterial tree (consisting of aorta, carotid, subclavian, iliac and femoral arteries) 
was dissected free and cleaned of connective tissue before being stored in 70% 
ethanol. Organs (liver, kidneys, spleen, heart, adrenals and thymus) were removed 
and cleaned of connective tissue and weighed. They were then stored in 10% neutral 
buffered formalin for a further 24 hours before being transferred to 70% ethanol. 
3.3.5. Measurement of blood components 
3.3.5.1 Plasma corticosterone levels 
Plasma spun from blood collected by tail tip immediately prior to sacrifice was used 
to assess corticosterone levels using a radioimmunoassay (section 2.5.1), to confirm 
successful removal of the adrenal glands.  
3.3.5.2 Serum cholesterol and triglyceride levels 
Serum spun from blood collected by cardiac puncture was used to assess cholesterol 
and triglyceride levels using respective colourimetric assays (section 2.5.2). Sera 
collected from chow-fed C57Bl/6 mice were used as controls for diet and genotype.  
3.3.6. Atherosclerotic plaque analysis 
3.3.6.1 Semi‐quantitative scoring 
To gain an insight into the extent of lesion development in ApoE-/- mice a semi-
quantitative method was used to gauge lesion development and severity. The 
dissected arterial trees were semi-quantitatively scored (1-5) for lesion size at the 
predisposed sites (aortic root, lesser curvature, brachiocephalic artery, origin of the 
left carotid artery and left subclavian artery, origins of the renal arteries and the 
femoral artery branches) for atherosclerotic plaque development in high cholesterol 
fed ApoE-/- mice, where 1: no plaque, 2: small plaque 3: large plaque, 4: extensive 
plaque, 5: extensive plaque with outward remodelling (section 2.3.1).  
3.3.6.2 Optical Projection Tomography (OPT) 
Once scored, the aortic arch (and its major branches) was isolated from the vascular 
tree and embedded in agarose for analysis by OPT (section 2.3.2). Briefly, after 
dehydration in methanol (24 hours) and clearing in a refractive index-matching 
solution of BABB (24 hours), the arch was scanned under UV light using a 
Bioptonics OPT tomograph. Computed tomography reconstructions were calculated 
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by filtered back-projection of raw data using NRecon software. This imaging 
technique provides a 3-dimensional image of the arch and the atherosclerotic plaques 
within. Volumetric measurements of the brachiocephalic artery were acquired by 
manual tracing of the estimated outline of the plaque and lumen, respectively, using 
CTan software. 
3.3.6.3 Histology 
Following acquisition of OPT scans, the aortic arch was prepared for histological 
analysis by washing in methanol before standard processing and embedding in 
paraffin wax (section 2.4.1). The specimen was then cut into 4μm thick transverse 
sections through the entire brachiocephalic artery from the carotid-subclavian 
bifurcation to the ascending aorta. Transverse sections at 80μm intervals along the 
brachiocephalic artery were stained with United States trichrome stain (section 
2.4.2). Photographs of the sections were taken using a light microscope coupled to a 
colour camera and image analysis system (MCID Basic 7.0 software; section 2.4.4). 
The plaque area and lumen area in each section were measured using Photoshop CS3 
software (section 2.4.5). The section with the largest area of plaque was chosen to 
represent each arterial sample. 
3.3.6.4 Composition 
The cellular composition of the atherosclerotic plaques was investigated using 
histological staining and immunohistochemistry on sections of the artery adjacent to 
the section identified as having the largest plaque. Smooth muscle cell content was 
assessed using an alkaline-phosphatase conjugated monoclonal primary antibody 
against smooth muscle cell α-actin (section 2.4.7.2). A monoclonal rat anti-mouse 
primary antibody against Mac-2 (clone M3/38) was used to determine the 
macrophage content of plaques (section 2.4.7.3). The collagen content of the plaques 
was assessed using Picrosirius Red staining (section 2.4.3). In addition, the 
extracellular lipid content of the plaques was estimated by quantification of the 
acellular clefts seen in the UST stained sections. These have been shown to represent 




All statistical analysis was performed by one-way ANOVA with Dunnett’s post-hoc 
test for comparison of physiological levels of endogenous glucocorticoid or 
exogenous glucocorticoid treatment with control, adrenalectomised mice. 
Comparisons between OPT and histological methods were performed by linear 
regression, and subsequent F-testing to determine if the slope deviates from a 
hypothetical value of 1.0. Statistical analysis of all data was performed using 








There were no differences in the weights of the animals at the start of the experiment. 
All animals gained weight steadily throughout the 13 week experimental period 
(Figure 3.2A), following early weight loss after adrenalectomy surgery. All animals 
lost weight at the final reading as they were fasted overnight prior to sacrifice. 
Adrenalectomy had no significant effect on body weight, whilst dex treatment 
inhibited the animals’ weight gain (p<0.05) in comparison to the adx group (Figure 
3.2B). By the end of the protocol, the surgical incisions had healed fully and the fur 
had re-grown in all animals. Food intake was consistent between the three groups 
averaging at approx. 23g per mouse per week. The average dex intake was 
0.10±0.004mg/kg/day. 
3.4.2. Organ weights 
Adrenalectomy had no effect on organ weights, whereas dex treatment reduced 
thymus weight (p<0.01; Figure 3.3A), and increased left kidney weight (p<0.05; 
Figure 3.3B). Although a similar pattern was seen in the right kidney, the difference 
was not significant (Figure 3.3C). There were no significant changes seen in the 
other organs collected (liver, heart and spleen; Figure 3.4). 
3.4.3. Plasma corticosterone levels 
Both adrenalectomised groups had significantly reduced corticosterone levels 
compared with sham adrenalectomised mice (Figure 3.5). It is important to note that 
adrenalectomy did not completely abolish circulating corticosterone level. 
3.4.4. Serum cholesterol and triglyceride levels 
Serum cholesterol and triglyceride levels were measured in blood collected post 
mortem by cardiac puncture. When compared with chow-fed C57Bl/6 mice, sham 
ApoE-/- mice on a Western diet had a 20-fold increase in cholesterol (Figure 3.6A) 
and 2-fold increase in triglycerides (Figure 3.6B). Neither adrenalectomy nor dex 













Figure 3.2: Weight changes induced by adrenalectomy and dexamethasone treatment.  
Mice were randomised to undergo sham or adrenalectomy (adx) surgery. Adx animals were 
supplied with 0.9% saline with either vehicle or dexamethasone (dex; 0.1mg/kg/day) as their 
drinking water. Atherosclerotic lesion development was accelerated by provision of a high 
cholesterol (0.2%) western diet. (A) Body weight was measured regularly throughout the 13 week 
experimental period. Mice in the three different groups had similar body weights at the start of the 
experiment and all animals gained weight steadily throughout the 13 week experimental period 
following an early weight loss after adx surgery and a final weight loss due to fasting overnight 
prior to sacrifice. (B) Change in body weight from the start to the end of the experimental period 
was also calculated. Adx had no significant effect on weight gain, whereas weight gain was 
reduced in dex-treated animals. All data expressed as mean±SEM, n=8. Data were analysed by 













































Figure 3.3: treatment. 
Mice were r omised to undergo sham or adrenalectomy (adx) surgery. Adx a imals were 
supplied with 0.9% saline supplemented with either vehicle or dexamethasone (dex; 
0.1mg/kg/day) as their drinking water. Atherosclerotic lesion development was accelerated by 
provision of a high cholesterol (0.2%) western diet. Organs were weighed upon sacrifice. Adx had 
no effect on any organ weight. In contrast, dex treatment caused a reduction in thymus weight (A) 
and an increase in left kidney weight (B). This effect was mirrored in the right kidney but did not 
reach significance (C). Data expressed as mean±SEM, n=8. Data were analysed by one-way 
ANOVA with Dunnett’s post hoc test vs adx. * p<0.05, **p<0.01. 


















domised to undergo sham or adrenalectomy (adx) surgery. Adx animals were 
supplied with 0.9% saline supplemented with either vehicle or dexamethasone (dex; 
0.1mg/kg/day) as their drinking water. Atherosclerotic lesion development was accelerated by 
provision of a high cholesterol (0.2%) western diet. Organs were weighed upon sacrifice. Neither 
adx nor dex influenced liver, heart or spleen weight. Data expressed as mean±SEM, n=8. Data 



















Figure 3.5: Plasma corticosterone levels in sham and adrenalectomised animals.  
 
 
Mice were randomised to undergo sham or adrenalectomy (adx) surgery. Adx animals were 
supplied with 0.9% saline with either vehicle or dexamethasone (dex; 0.1mg/kg/day) as their 
drinking water. Atherosclerotic lesions development was accelerated by provision of a high 
cholesterol (0.2%) western diet. Plasma corticosterone levels were measured in tail-tip plasma by 
radioimmunoassay. Both groups that underwent adrenalectomy had significantly lower plasma 
corticosterone levels when compared with sham animals. Data expressed as mean±SEM, n=8. 























Figure 3.6: Impact of adrenalectomy and dexamethasone treatment on serum cholesterol 
and triglyceride levels.  
Mice were randomised to undergo sham or adrenalectomy (adx) surgery. Adx animals were 
supplied with 0.9% saline with either vehicle or dexamethasone (dex; 0.1mg/kg/day) as their 
drinking water. Atherosclerotic lesion development was accelerated by provision of a high 
cholesterol (0.2%) western diet. Neither adx nor dex treatment had any significant effect on serum 
cholesterol (A) or triglyceride (B) levels. However, compared with chow-fed control C57Bl6 
mice (striped bars), the combination of genotype and western diet increase both cholesterol (A) 
and triglyceride (B) levels. All data expressed as mean±SEM, n=8 (controls n=6). Data were 






All animals exhibited visible atherosclerotic plaques in the lesser curvature of the 
aorta, the brachiocephalic artery and the origins of the left common carotid artery 
and the left subclavian artery (Figure 3.7). The brachiocephalic artery consistently 
exhibited the most extensive plaque burden. Neither adrenalectomy nor dex 
treatment significantly altered the lesion burden at any of the 8 areas (Table 3.1). 




Optical projection tomography imaging of atherosclerotic plaques proved very 
successful. Atherosclerotic plaques were clearly visible in both the raw images and in 
back-projected reconstructions in the expected anatomical distribution, comprising 
lesions in the lesser curvature of the arch, the brachiocephalic artery and at the 
origins of the left common carotid and left subclavian arteries (Figure 3.8A). In cross 
section, these plaques were typically eccentric in morphology and could easily be 
distinguished from the media due to its greater fluorescent signal. Similarly, the 
lumen could be distinguished from the vessel by its absence of signal (Figure 3.8B). 
 
To validate the interpretation of OPT reconstructions, cross-sectional areas of 
atherosclerotic plaque within the brachiocephalic artery were quantified from serial 
histological sections and corresponding 2D tomographic planes within the OPT 
reconstructions of the same vessels. Not only were there striking similarities between 
the histological sections and OPT virtual sections (Figure 3.8C), but also clear, 
significant correlation between the two measurement modalities (R2=0.85; Figure 
3.9A). More importantly, the slope of these relationships between histological and 
OPT measurements did not significantly deviate from 1 (p=0.88). Bland-Altman 
analysis revealed a small but positive bias in OPT-derived measurements (Figure 






Figure 3.7: Example of arterial tree used to assess atherosclerotic plaque distribution.  
Perfusion-fixed, arterial trees from ApoE-/- mice, fed a western diet for 12 weeks, were excised 
and used to assess atherosclerotic plaque distribution. Plaque size was semi-quantitatively scored 
(1-5) at sites predisposed to atherosclerotic plaque development (A); right subclavian artery 
(RSA), right carotid artery (RCA), left carotid artery (LCA), left subclavian artery (LSA), 
brachiocephalic artery (BCA), ascending aorta (AAo), descending aorta (DAo), right renal artery 
(RRA), left renal artery (LRA), right femoral artery (RFA), left femoral artery (LFA). A higher 
power image of the arch region (B) allows clear identification of the atherosclerotic plaques 






Table 3.1: Semi-quantitative scoring of lesion size at sites within the arterial tree. 
           
Site  Sham  Adx  Adx + Dex 
n   8  8  8 
       
Aortic Root  0.3 ± 0.2  1.1 ± 0.2  1.3 ± 0.3 
Inner curvature  0.9 ± 0.2  1.4 ± 0.2  1.8 ± 0.3 
Brachiocephalic artery  2.8 ± 0.3  2.4 ± 0.3  2.8 ± 0.3 
1.7 ± 0.3  2.3 ± 0.3 Root of left carotid artery  1.9 ± 0.3 
Root of left subclavian artery  1.7 ± 0.3  1.4 ± 0.3  2.3 ± 0.3 
Root of renal branches  0.5 ± 0.2  0.8 ± 0.2  1.1 ± 0.3 
Right femoral artery  1.0 ± 0.3  0.7 ± 0.2  1.3 ± 0.5 
Left femoral artery  0.9 ± 0.3  0.6 ± 0.4  0.5 ± 0.4 
TOTAL  9.5 ± 0.5  9.0 ± 1.2  11.8 ± 1.6 
           
       
  
Mice were randomised to undergo sham or adrenalectomy (adx) surgery. Adx animals were 
supplied with 0.9% saline, supplemented with either vehicle or dexamethasone (dex; 
0.1mg/kg/day), as their drinking water. Atherosclerotic lesion development was accelerated by 
provision of a high cholesterol (0.2%) western diet before isolation of the arterial tree. Areas of 
the arterial tree predisposed to atherosclerotic plaque development were semi-quantitatively 
scored 1-5 where 1: no plaque, 2: small plaque 3: large plaque, 4: extensive plaque, 5: extensive 
plaque with outward remodelling. Neither adx nor dex treatment significantly altered the score at 
any of the 8 areas, although the dexamethasone-treated animals consistently averaged the highest 
score, with the exception of the left femoral artery. All data expressed as mean±SEM, n=8. Data 














Figure 3.8: Optical projection tomographic (OPT) imaging of atherosclerotic plaques in the 
mouse aortic arch.  
Perfusion-fixed, aortic arches from ApoE-/- mice, fed a western diet for 12 weeks, were subjected 
to optical projection tomographic scanning. In non-tomographic images of the aortic arch, 
atherosclerotic plaques were clearly visible (highlighted in red) in the expected anatomical 
distribution comprising lesions in the lesser curvature of the arch, the brachiocephalic artery and 
at the origins of the left common carotid and left subclavian arteries (A). In reconstructed virtual 
cross-sections, plaques were visible with the same distribution and can easily be distinguished 
from the media due to its greater fluorescent signal (B). Regions within the plaque devoid of 
fluorescence are thought to represent intra-plaque lipid pools, which would be removed during 
histology preparation. These virtual cross sections possess striking similarity to histological, 
United States trichrome (UST)-stained sections from the same region of the same artery (C). 
Successful analysis of the brachiocephalic artery by standard histology and immunochemistry 
confirmed the non-destructive nature of this technique (C). RSA: right subclavian artery; RCA: 
right carotid artery; LCA: left carotid artery; LSA: left subclavian artery; BCA: brachiocephalic 



































Figure 3.9: Comparison of optical projection tomography (OPT) and histological methods 
for 2D analysis of brachiocephalic plaque size. 
Perfusion-fixed, aortic arches from ApoE-/- mice, fed a western diet for 12 weeks, were subjected 
to optical projection tomographic scanning before histological analysis of the same vessels. 
Comparison of 2D measures of brachiocephalic artery atherosclerotic plaque area derived from 
OPT scans and histological sections of the same area by linear regression showed a strong 
correlation and that the slope of relationship did not differ from 1 (A). Bland-Altman analysis 







processing. Crucially, however, this bias was independent of plaque size indicating 
that measurements made in this way are comparable within and between vessels. It 
was also confirmed that the OPT imaging procedure did not compromise subsequent 
analysis of lesion composition. In vessels previously subjected to OPT scanning, 
immunohistochemical staining for markers of smooth muscle (smooth muscle α-
actin) and macrophages (Mac2), and histological staining for collagen (picro-sirius 
red) all occurred with an intensity and distribution (Figure 3.8C) consistent with 
previous work with this model (Van Herck et al., 2009). 
 
While 2D comparisons of OPT and histology provide crucial validation, the novel 
potential of OPT is to allow 3D, volumetric analysis. After optimising the protocol 
for volumetric quantification for use in atherosclerotic arteries, plaque volumes were 
successfully recorded (0.18 ± 0.018 mm3; n=8). The coefficient of variation (4.79%, 
n=4) indicated that these measurements were highly reproducible. 
3.4.5.2.2 Plaque quantification by OPT 
The brachiocephalic trunk in all three groups contained extensive atherosclerotic 
plaques. Adrenalectomy had no effect on the plaque volume or maximum cross-
sectional area. In contrast, dex increased the volume of plaque (p<0.05; Figure 
3.10A), subsequently increasing the volumetric stenotic ratio (p<0.05; Figure 3.10B) 
and reducing the volumetric luminal ratio (p<0.05; Table(a)). However, the 
maximum cross-sectional area of the plaque, and corresponding lumen area, was 
unaffected by dex (Figure 3.11A and B). Analysis of the cross-sectional profile of the 
plaque revealed that dex augmented the cross-sectional area of the plaque over the 
majority of the artery, thereby accounting for the increase in plaque volume despite 





























Figure 3.10: Impact of adrenalectomy and dexamethasone treatment on brachiocephalic 
plaque volume, as assessed by optical projection tomography (OPT). 
Mice were randomised to undergo sham or adrenalectomy (adx) surgery. Adx animals were 
supplied with 0.9% saline with either vehicle or dexamethasone (dex; 0.1mg/kg/day) as their 
drinking water. Atherosclerotic lesion development was accelerated by provision of a high 
cholesterol (0.2%) western diet before isolation and OPT scanning. Plaque volumes were 
quantified from reconstructed tomograms and expressed as absolute volume (A) and as the 
volumetric stenotic ratio; plaque volume as proportion of volume inside internal elastic lamina 
(IEL; B). Adx had no influence on plaque volume. Dex treatment significantly increased absolute 
plaque volume (A) and volumetric stenosis (B). All data expressed as mean±SEM, n=6-8. Data 




Table 3.2: Impact of adrenalectomy and dexamethasone treatment on the size and 
composition of brachiocephalic atherosclerotic plaques. 
     
Measurement   Sham  Adx  Adx + Dex 
n   8  6  7 
       
(a) 3D Morphometry (OPT)       
Plaque volume (x107μm3)   18.6 ± 1.7  16.5 ± 2.5  24.3 ± 1.9* 
Luminal volume (x107μm3)   13.3 ± 1.4  14.8 ± 2.1  10.7 ± 0.7 
Volume inside IEL (x107μm3)  31.9 ± 2.1  31.3 ± 2.6  35.0 ± 2.2 
Volumetric stenotic ratio   0.58 ± 0.04  0.53 ± 0.06  0.69 ± 0.02* 
       
(b) 2D Morphometry (OPT)       
Plaque max area (x104μm2)   21.2 ± 1.2  21.3 ± 1.8  24.3 ± 1.6 
Luminal area (x104μm2)   6.9 ± 1.6  7.7 ± 1.2  6.3 ± 1.3 
Area inside IEL (x104μm2)   28.1 ± 1.5  29.1 ± 1.7  30.7 ± 1.1 
Stenotic ratio   0.76 ± 0.05  0.73 ± 0.04  0.79 ± 0.04 
       
(c) 2D Morphometry (Histology)       
Plaque max area (x104μm2)   13.6 ± 0.9  14.9 ± 2.1  16.2 ± 1.6 
Medial area (x104μm2)   10.2 ± 0.9  11.7 ± 1.4  8.6 ± 0.4 
Intima/Media ratio   1.4 ± 0.1  1.3 ± 0.1  1.9 ± 0.1** 
Luminal area (x104μm2)   10.0 ± 0.8  10.3 ± 1.2  7.4 ± 0.8 
Area inside IEL (x104μm2)   23.6 ± 1.0  25.2 ± 2.6  23.6 ± 1.7 
Stenotic ratio   0.57 ± 0.03  0.58 ± 0.05  0.68 ± 0.04 
       
 
(d) Composition (Histology/IHC)     
Smooth Muscle α‐actin (%)   2.9 ± 0.3  3.0 ± 0.2  2.9 ± 0.4 
Collagen (%)  29.4 ± 2.7  25.6 ± 3.0  30.9 ± 3.9 
Lipid (%)  27.8 ± 2.0  25.7 ± 2.8  26.0 ± 1.0 
Mac‐2 (%)   10.6 ± 2.0  11.7 ± 3.0  3.8 ± 0.9* 
           
 
  
Mice were randomised to undergo sham or adrenalectomy (adx) surgery. Adx animals were 
supplied with 0.9% saline supplemented with either vehicle or dexamethasone (dex; 
0.1mg/kg/day) as their drinking water. Atherosclerotic lesion development was accelerated by 
provision of a high cholesterol (0.2%) western diet before isolation and examination of the 
brachiocephalic artery by optical projection tomography (a and b), histology (c and d) and 
immunohistochemistry (d).  Adx had no influence on any parameter measured. Dex treatment 
augmented plaque volume, increasing the volumetric stenotic ratio and thereby reducing the 
volumetric luminal ratio (a).  Dex treatment did not influence the cross-sectional area of the 
plaque as measured by OPT (b) or histology (c), but did reduce macrophage content of the plaque 
as measured by immunohistochemistry (d). All data expressed as mean±SEM, n=6-8. Data were 


























Figure 3.11: Impact of adrenalectomy and dexamethasone treatment on brachiocephalic 
plaque and lumen cross-sectional area, as assessed by optical projection tomography (OPT). 
Mice were randomised to undergo sham or adrenalectomy (adx) surgery. Adx animals were 
supplied with 0.9% saline with either vehicle or dexamethasone (dex; 0.1mg/kg/day) as their 
drinking water. Atherosclerotic lesions development was accelerated by provision of a high 
cholesterol (0.2%) western diet before isolation and OPT scanning. Plaque and lumen cross-
sectional areas were quantified from reconstructed tomograms. Neither adx nor dex treatment 
influenced the max cross-sectional area of the plaque (A) or corresponding lumen cross-sectional 
area (B). However, analysis of the cross-sectional profiles of the plaque (C) revealed that dex 
treatment, but not adx, increased the cross-sectional area of the plaque along most of the artery. 
All data expressed as mean±SEM, n=6-8. A and B were analysed by one-way ANOVA with 




Histological analysis of the brachiocephalic artery allowed quantification of the 
maximum cross-sectional area of the plaque. Consistent with 2-D OPT 
measurements, neither adrenalectomy nor dex treatment had any significant 
influence on the maximum cross-sectional area of the plaque (Figure 3.12A) or 
corresponding lumen area (Figure 3.12B). It is worth noting that, although neither the 
plaque nor medial areas were significantly altered by dex treatment, the intima/media 
ratio was significantly increased (p<0.01; Table 3.2(c)). 
3.4.5.4 Plaque composition 
3.4.5.4.1 Smooth muscle 
Neither adrenalectomy nor dex treatment had any effect on the smooth muscle 
content of the atherosclerotic plaques, as assessed by immunohistochemical staining 
against smooth muscle α-actin. The plaques from all three groups contained 
approximately 3% smooth muscle (Figure 3.13A). 
3.4.5.4.2 Collagen 
Similarly, neither adrenalectomy nor dex had any influence on the collagen content 
of the atherosclerotic plaques, as assessed by picrosirius red staining. The collagen 
content within the plaques was approximately 30% (Figure 3.13B). 
3.4.5.4.3 Macrophages 
Macrophage content was assessed using immunohistochemical staining against Mac-
2 protein. Adrenalectomy had no influence, while dex significantly reduced the 
number of macrophages within the atherosclerotic plaques (p<0.05; Figure 3.13C). 
3.4.5.4.4 Lipid 
The lipid content of the lesion was represented by the acellular clefts that remain in 
the plaque post-histological processing. Neither adrenalectomy nor dex altered the 































Figure 3.12: Impact of adrenalectomy and dexamethasone treatment on brachiocephalic 
plaque and lumen cross-sectional area, as assessed by histology. 
Mice were randomised to undergo sham or adrenalectomy (adx) surgery. Adx animals were 
supplied with 0.9% saline supplemented with either vehicle or dexamethasone (dex; 
0.1mg/kg/day) as their drinking water. Atherosclerotic lesion development was accelerated by 
provision of a high cholesterol (0.2%) western diet before isolation and optical projection 
tomography scanning. Plaque and lumen cross-sectional areas were quantified by histological 
analysis. Neither adx nor dex treatment influenced the max cross-sectional area of the plaque (A) 
or corresponding lumen cross-sectional area (B). All data expressed as mean±SEM, n=6-8. Data 

























Figure 3.13: Impact of adrenalectomy and dexamethasone treatment on brachiocephalic 
plaque composition, as assessed by histology and immunohistochemistry. 
Mice were randomised to undergo sham or adrenalectomy (adx) surgery. Adx animals were 
supplied with 0.9% saline supplemented with either vehicle or dexamethasone (dex; 
0.1mg/kg/day) as their drinking water. Atherosclerotic lesion development was accelerated by 
provision of a high cholesterol (0.2%) western diet before isolation and analysis. Composition 
was quantified at the point of largest lesion as determined by histological analysis. Smooth 
muscle and macrophage content were assessed using immunohistochemistry, collagen content 
was assessed by picrosirius red staining and lipid content was quantified from United States 
trichrome stained sections. Neither adx nor dex treatment influenced the smooth muscle (A), 
collagen (B) or lipid (D) content of the plaque. Dex treatment, but not adx, reduced the 
macrophage content of the plaque (C). All data expressed as percentage of total area of plaque; 





The work described in this chapter addresses the hypothesis that glucocorticoids are 
pro-atherogenic. The results obtained suggest that physiological levels of 
endogenous glucocorticoids do not influence atherogenesis in this murine model. In 




A number of different methods can be utilised to determine the influence of 
endogenous glucocorticoids on physiological or pathophysiological processes in 
animals. As the aim of this investigation was to determine the effects of 
physiological levels of endogenous glucocorticoids on atherosclerotic plaque 
development, the approach adopted was global removal of glucocorticoids by 
adrenalectomy, which has not been described previously in the mouse. 
 
In order to confirm the success of the adrenalectomy surgery and to monitor the 
animals’ welfare, physiological parameters including plasma corticosterone levels, 
body weight and organ weights were measured. All animals that underwent 
adrenalectomy had significantly reduced plasma corticosterone levels. It is 
acknowledged that bilateral adrenalectomy fails to completely eliminate circulating 
corticosterone, usually retaining around 30-50% (Dubuc et al., 1986; Jacobson, 
1999; Makimura et al., 2000; Vrang et al., 2002), comparable with the levels found 
in this investigation. One possible explanation as to the source of the remaining 
corticosterone includes adrenal remains post-adrenalectomy. Upon sacrifice, all 
animals were scrutinised for the presence of adrenal remains or regenerated adrenal 
material and found to have none. An alternative source of corticosterone could be 
adrenal rest cells; cortical tissue separate from the adrenal glands. Although 
relatively well-defined in humans (Claahsen-van der Grinten et al., 2009; Linder et 
al., 2009), adrenal rest cells have only once been described in mice. Val et al 
identified a novel population of adrenal-like cells in the testis of male mice, which 
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respond to ACTH and secrete corticosterone (Val et al., 2006). Perhaps these 
adrenal-like testicular cells are the source of corticosterone in the adrenalectomised 
mice in the current study. However, detailed analysis of the testes would be required 
to confirm such a speculation. In addition, it is well known that dex administration is 
a potent inhibitor of ACTH release through negative-feedback on the HPA axis (Cole 
et al., 2000) and would therefore prevent corticosterone release from these potential 
adrenal rests. However, in the current study, dex-treated mice retained around 25% 
of their circulating corticosterone levels following bilateral adrenalectomy. 
Therefore, adrenal rests cannot account for all of the remaining circulating 
corticosterone. 
 
As has been previously shown (de Jong et al., 2007; Ingram et al., 2005; Makimura 
et al., 2003), adrenalectomy had no effect on the animals’ body weight over the 
experimental period. Conversely, the thymus weight was expected to increase 
following removal of the adrenals as has been described in a number of murine 
studies (Jacobson, 1999; Pruett et al., 2004; Reber et al., 2007). However, in this 
study there was no significant change in the weight of the organ in comparison to the 
sham animals. Another group has reported a similar lack of effect on thymus weight 
following adrenalectomy in mice (Kawiak et al., 1996). Thus, the adrenalectomy 
surgery was considered a success, with no evidence of remaining adrenal tissue, 
significantly reduced circulating corticosterone levels and healthy mice.  
 
Although bilateral adrenalectomy is a frequently-used technique to determine the 
role of glucocorticoids on physiological and pathophysiological processes (Haluzik 
et al., 2002; Lim et al., 2007; Vrang et al., 2002), it has some important limitations. 
Firstly, removal of the adrenal glands from mice eliminates not only the release of 
glucocorticoids but also the release of the other adrenal-derived hormones including 
mineralocorticoids and catecholamines. Therefore, care must be taken, when 
analysing the effects of adrenalectomy, not to assume they are solely due to the loss 
of glucocorticoids. Secondly, abolition of mineralocorticoid release requires the 
animals to be maintained on 0.9% saline in their drinking water for the remainder of 





Despite the majority of previous work concluding that endogenous glucocorticoids 
are pro-atherogenic, the results from this investigation suggest that a reduction of 
endogenous glucocorticoids to approx. 25% of normal levels has no effect on 
atherogenesis, influencing neither plaque burden nor composition. One explanation 
for this observation is that the additional removal of mineralocorticoids and 
catecholamines by adrenalectomy could themselves be influencing atherogenesis 
and, thereby, obscuring the effect of removing glucocorticoids. However, there is 
substantial evidence that mineralocorticoids themselves are also pro-atherogenic. 
Administration of aldosterone (Keidar et al., 2004) or deoxycorticosterone acetate 
(Weiss et al., 2008) to ApoE-/- mice exacerbates atherosclerotic lesion development. 
This effect is confirmed by the finding that MR blockade (Suzuki et al., 2006; Takai 
et al., 2005), inhibition of ACE (Weiss et al., 2008) or antagonism of angiotensin-
receptor 1 (Keidar et al., 2004) reduces the pro-atherosclerotic effects of 
mineralocorticoids. In addition, as described above, excessive activation of MR by 
glucocorticoids in 11βHSD2/ApoE double knock out (DKO) mice, has been shown 
to severely augment atherogenesis (Deuchar et al., 2011). Therefore, removal of 
mineralocorticoids alongside glucocorticoids by adrenalectomy would be anticipated 
to reduce MR-mediated augmentation of atherosclerosis. During an acute stress 
response, catecholamines are released from the adrenal medulla in addition to 
glucocorticoids being released from the adrenal cortex. Therefore, stress-induced 
atherosclerosis also implicates catecholamines as pro-atherosclerotic (Black et al., 
2002). Although, little has been reported on the specific effects of catecholamines on 
atherosclerosis, one study has described an increase in plaque development in   
ApoE-/- mice by norepinephrine administration (Weiss et al., 2001). In addition, 
doxazocin (an alpha-1 adrenoceptor antagonist) has been reported to reduce 
atherosclerotic lesion development in high cholesterol-fed rabbits (Swindell et al., 
1993) and reduce intima-media thickness in males with peripheral atherosclerotic 
disease (Hoogerbrugge et al., 2002). Therefore, removal of catecholamines alongside 
glucocorticoids and mineralocorticoids by adrenalectomy would be anticipated to 
further attenuate the development of atherosclerosis.  
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It is widely accepted that elevated circulating lipid levels correlate with increased 
cardiovascular disease in the clinic. A similar correlation is acknowledged in mice 
(Temel et al., 2007). Indeed, the reduction in atherosclerosis by inhibition of 
11βHSD1 described by Hermanowski et al and Nuotio-Antar et al was accompanied 
by reduced circulating lipid levels in both cases (Hermanowski-Vosatka et al., 2005; 
Nuotio-Antar et al., 2007). In the current study, adrenalectomy had no influence on 
circulating cholesterol or triglyceride levels, which may in part account for 
adrenalectomy having no effect on atherogenesis. Unfortunately, there is very little 
published on the effect of adrenalectomy on circulating lipids in mice to help indicate 
further if this finding is comparable with other studies. A single study demonstrated 
that adrenalectomy had no effect on plasma triglyceride levels in mice (Haluzik et 
al., 2002) but cholesterol levels were not reported. 
 
As well as not influencing the lipid profile in mice, adrenalectomy also had no 
influence on the composition of the plaque. It is surprising that removing endogenous 
glucocorticoids had a negligible influence on the macrophage content, considering 
these steroids are important modulators of immune cell function (Rickard et al., 
2009). However, as monocyte-derived macrophages play a crucial role in the 
development of atherosclerosis (Libby, 2002), this may also contribute to the lack of 
effect on atherogenesis by adrenalectomy. It has previously been reported that 
macrophage-specific GR inactivation has no effect of atherogenesis in mice (Preusch 
et al., 2008), supporting the conclusion that endogenous glucocorticoids have little 
influence on atherosclerosis through their macrophage-specific effects. 
 
Therefore, despite considerable evidence suggesting that endogenous glucocorticoids 
are pro-atherosclerotic, adrenalectomy had no effect on atherosclerotic plaque 
development in ApoE-/- mice. This suggests that physiological levels of endogenous 
glucocorticoids have a limited role in the regulation of atherogenesis in the mouse.  
 
As adrenalectomy did not influence any glucocorticoids-sensitive systemic 
parameters; body weight, thymus weight, serum lipid levels, or local effects; lipid 
accumulation, inflammatory content of the plaque, the lack of effect on atherogenesis 
120 
 
is not completely inexplicable. However, the mechanism behind which atherogenesis 
is unaffected by adrenalectomy remains to be elucidated. Certainly, it is required that 
the role of mineralocorticoids and catecholamines in atherosclerosis be accounted 
for. This could be elucidated by replacing physiological levels of mineralocorticoids 
and/or catecholamines to adrenalectomised animals. However, it would be 
challenging to pharmacologically mimic adrenal physiology, in particular the diurnal 
patterns of adrenal hormone secretion. Perhaps, to further determine the influence of 
endogenous glucocorticoids on atherosclerosis development, a different approach is 
necessary. The use of endothelial- and VSMC-specific GR-/- mice could provide 
crucial information on the influence of endogenous glucocorticoids in atherosclerosis 
and indicate the potential role of the endothelium and smooth muscle cells in the 
mechanism. Also, additional investigation into the role of pre-receptor metabolism of 
glucocorticoids by the 11βHSD1 enzyme would certainly help elucidate the role of 
endogenous glucocorticoids in atherogenesis. However, a more constructive 
approach may be to model endogenous glucocorticoid excess. One currently used 
method of investigating glucocorticoid excess is ACTH administration, modelling 
Cushing’s Disease (Bailey et al., 2009; Dunbar et al., 2010). ACTH stimulates 
corticosterone release from the adrenal glands, resulting in hypercorticosteronism. 
This model has been used previously to investigate the influence of glucocorticoids 
on atherosclerosis in the 1960s using dogs and rats (Rosenfeld et al., 1960; Wexler et 
al., 1960). Both studies concluded an augmentation of atherosclerosis by ACTH 
administration. It would be of interest to further investigate the effect of ACTH 
administration on atherosclerosis using our more modern models of the disease and 
analytical techniques to help further elucidate the role of endogenous glucocorticoids 
on atherosclerosis development. 
3.5.2. Exogenous glucocorticoids and atherosclerosis 
3.5.2.1 Systemic glucocorticoid treatment 
Several different glucocorticoids could have been used for administration to mice. 
Hydrocortisone (Moraes-Fontes et al., 2009), prednisone (Wissing et al., 2010) and 
prednisolone (Frijters et al., 2010) have been used previously to assess the influence 
of glucocorticoids on physiological and pathophysiological processes in mice. Dex 
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was chosen for the investigation described in this chapter as it is the glucocorticoid 
most commonly used for medium- and long-term systemic administration in mice 
(Brack et al., 1997; Gunin et al., 2003). Use of dex, therefore, allows direct 
comparisons with these studies. Dex has also been used in a number of studies 
investigating the effects of glucocorticoid administration on atherosclerosis in rabbits 
(Asai et al., 1993; Naito et al., 1992) and mice (Tous et al., 2006). In addition, dex is 
used clinically for its anti-inflammatory and immunosuppressant properties, for 
example in rheumatoid arthritis (Cole, 2006). As dex is a GR-selective 
glucocorticoid, its use also allows distinction of GR-mediated effects of 
glucocorticoids on atherosclerosis. Dex was administered in drinking water to reduce 
any stress to the animals and allow a consistent dose throughout the day (Gunin et 
al., 2003). The dose of 0.1mg/kg/day was selected as it is similar to the doses of dex 
used in previous rabbit studies (Asai et al., 1993; Naito et al., 1992) and consistent 
with the low dose used in the neointimal proliferation study, described in Chapter 4. 
Ideally, circulating dex levels would have been assayed to confirm the dose received. 
Unfortunately, this was not practical with the length of the study, number of animals 
and the cost of running the assay. However, dex intake was calculated regularly and 
the dose provided in the water bottles was adjusted to account for changes in 
drinking habbits and body weight to maintain an average of 0.1mg/kg/day.  
 
Dex was administered to adrenalectomised mice to allow distinction of the effects of 
exogenous glucocorticoids on atherosclerosis, without the added complication of 
endogenous glucocorticoids and mineralocorticoids in the circulation. It is important 
to note that 0.1mg/kg/day is a pharmacological dose of dex and thus was not used as 
a replacement for physiological levels of corticosterone that were removed by 
adrenalectomy. Future investigations could consider assessing the effect of 
glucocorticoid administration on atherogenesis in mice with intact adrenal glands. 
 
Dex treatment caused a significant inhibition of weight gain and reduced the weight 
of the glucocorticoid-sensitive thymus, confirming that this dose of dex was 
pharmacologically active in the animals. These systemic side effects are well 
documented in the mouse (Pires et al., 2005). The animals recovered fully from 
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surgery and remained outwardly healthy, with appropriate food and water intake. 
These observations suggest that the dose and method of administration of dex were 
appropriate to induce the expected pharmacological effects, whilst maintaining 
healthy animals. 
3.5.2.2 Impact of exogenous glucocorticoids on atherogenesis 
Clinically, glucocorticoid excess may induce or exacerbate several known 
cardiovascular risk factors, including: hypertension (Mangos et al., 2003), 
hypercholesterolaemia (Curtis et al., 1982) and glucose intolerance (Tounian et al., 
1997). Moreover, there is clinical evidence that prolonged corticosteroid therapy is 
associated with enhanced cardiovascular disease (Souverein et al., 2004; Wei et al., 
2004). However, it is difficult to distinguish between the effects of the exogenous 
glucocorticoid and the underlying disease for which the therapy is required, on 
atherogenesis in these patients. Thus, we turn to animal studies to help further 
elucidate the influence of exogenous glucocorticoids on atherosclerosis. The majority 
of experimental data have been generated in the cholesterol-fed rabbit model (Bailey 
et al., 1973; Friedman et al., 1964). These largely contradict clinical observations, 
reporting that steroid-treated rabbits exhibit less atherosclerosis, probably as a result 
of the potent anti-inflammatory effects of glucocorticoids (Asai et al., 1993; Naito et 
al., 1992). However, it is important to note that the lesions that develop in the 
cholesterol-fed rabbit model tend to be fatty streaks rather than complex advanced 
lesions, as described by Asai et al and Naito et al. Conversely, one animal study 
describes an increase in aortic atherosclerosis in dex-treated ApoE-/- mice on a 
normal chow diet (Tous et al., 2006), suggesting that the ApoE-/- mouse is a better 
model of human atherosclerosis than the cholesterol-fed rabbits. 
 
Based on clinical observations, it was hypothesised that exogenous glucocorticoid 
treatment would increase the development of atherosclerosis in cholesterol-fed 
ApoE-/- mice. Data acquired from OPT analysis demonstrated that systemic dex 
treatment did indeed increase atherosclerotic plaque volume in the brachiocephalic 
artery. Further analysis, including histological methods, revealed that the increase in 
plaque volume was not represented in the max cross-sectional area of plaque. 
Therefore, changes in plaque burden by dex administration would have been missed 
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if standard histological analysis alone had been used. These results support the value 
of the 3-dimensional visualisation provided by OPT in allowing a more detailed 
analysis of lesion size. 
 
The effect of glucocorticoids on atherosclerotic lesion development is likely to be a 
balance between the predominantly pro-atherosclerotic systemic effects of steroid 
treatment (Curtis et al., 1982; Delaunay et al., 1997; Whitworth et al., 2001) and the 
primarily anti-atherosclerotic local actions of steroids on the vasculature 
(Goncharova et al., 2003; Jilma et al., 2000; Liu et al., 1999). Indeed, the anti-
atherosclerotic effects of glucocorticoids in rabbits were attributed to their potent 
anti-inflammatory actions. This would inhibit recruitment and proliferation of 
macrophages (Asai et al., 1993; Naito et al., 1992) in the arterial wall and, thereby, 
reduce the formation of foam cells. Somewhat counter-intuitively, in the current 
investigation, dex significantly reduced the macrophage content of the plaque, 
despite the increase in plaque volume. Interestingly, in the study by Tous et al, which 
also describes an increase in atherosclerosis by dex, the treatment did not reduce 
macrophage content of the lesions (Tous et al., 2006). This conflict may be explained 
by Tous et al using a 3-fold lower dose of dex than in this study. Nevertheless, the 
current result does suggest that dex-mediated augmentation of atherogenesis is 
independent of macrophage numbers.  
 
It could be postulated that, whilst dex is having the expected local “anti-
atherosclerotic” effect, the detrimental systemic effects of steroid treatment are 
prevailing, tipping the balance to favour atherosclerosis development.  These 
systemic effects could include hypertension, dyslipidaemia and disturbances in 
glucose homeostasis. Although blood pressure was not measured in this 
investigation, it is well-established that glucocorticoids induce hypertension (Mangos 
et al., 2003) and, specifically, that dex induces hypertension in the mouse (Goodwin 
et al., 2010). In addition, the study described in chapter 5 demonstrates that the dose 
of dex used in this investigation (0.1mg/kg/day) induces hypertension after 3 weeks 
of treatment in male, adult C57Bl/6 mice (section 5.4.3). Therefore, it is highly likely 
that the dex-treated mice in the current investigation have elevated blood pressure. 
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Exogenous glucocorticoids have long been known to increase circulating lipid levels 
in the clinic (Becker et al., 1988; Brotman et al., 2005; Curtis et al., 1982) and in 
animal studies (Cole et al., 1982; Makheja et al., 1989; Pinheiro et al., 2009). Indeed, 
Tous et al found that dex-treated mice had increased hyperlipidaemia over controls, 
with a significant increase in plasma cholesterol concentration (Tous et al., 2006). 
However, in the current study, dex treatment barely (and not significantly) increased 
circulating cholesterol or triglyceride levels. This result was complimented by dex 
having no effect on the lipid content of the plaques, suggesting the steroid treatment 
had no influence on lipid accumulation or clearance from the arterial wall. Therefore, 
these findings suggest that hyperlipidaemia cannot account for the pro-
atherosclerotic effect of dex. However, before completely discounting the effects on 
lipids, it would be of interest to break down the total circulating cholesterol levels 
into pro-atherosclerotic LDL and anti-atherosclerotic HDL fractions (Rader et al., 
2005). If the LDL levels are significantly increased over HDL levels, this would 
indicate an atherogenic lipid profile, despite the total cholesterol levels remaining 
unaltered by dex treatment. Unfortunately, there were insufficient volumes of blood 
samples remaining to carry out this more detailed assay in this investigation.  
 
Finally, metabolic disturbances in glucose homeostasis could play a role in the 
atherogenic effects of dex. Glucocorticoids are known to play a substantial role in the 
development of the metabolic syndrome (Anagnostis et al., 2009), which is 
associated with an increased risk of type 2 diabetes mellitus and vascular disease. 
More specifically, dex administration has been shown to cause glucose intolerance in 
mice (Gounarides et al., 2008). Metabolic parameters were not assessed in this 
investigation but it would be of interest to determine whether this course of dex is 
sufficient to induce glucose intolerance and insulin resistance significant enough to 
exacerbate atherosclerotic lesion development. It is notable that Tous et al found 
normal glucose tolerance in their dex-treated ApoE-/- mice. However, as previously 
mentioned, they did use a 3-fold lower dose of dex so their result may not predict the 
metabolic status of the mice in the current study. Nevertheless, they found an 
increase in atherosclerosis despite no glucose intolerance, suggesting that metabolic 
disturbances cannot fully account for dex-mediated augmentation of atherosclerosis. 
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In conclusion, exogenous glucocorticoid treatment significantly augmented 
atherosclerotic plaque development in brachiocephalic arteries of western diet fed 
ApoE-/- mice. The mechanism behind this effect remains to be elucidated but appears 
to be independent of circulating lipid levels and macrophage numbers. This study 
supports the conclusion of Tous et al. that the ApoE-/- mouse model is a more 
clinically-relevant model of atherosclerosis than the cholesterol-fed rabbit. 
Therefore, it would be of great interest to utilise this model to expand our 
understanding of the mechanism behind the pro-atherosclerotic effects of 
glucocorticoid treatment. 
3.5.3. Optical projection tomography 
Optical projection tomography (OPT) has successfully been utilised in this 
investigation to allow reproducible quantification of atherosclerotic plaque and 
lumen volumes as well as corresponding cross-sectional areas. In addition, as OPT is 
non-destructive, standard histological and immunohistochemical analysis of the 
arteries can be carried out to allow both comparison with OPT and generation of 
further information regarding plaque composition. Qualitative similarities between 
images produced by OPT and those subsequently produced by histological analysis 
of the same vessel were striking and were confirmed by strong correlations between 
cross-sectional measurements. It should be noted that there was a small but positive 
bias, meaning that the OPT-derived measurements were consistently larger than 
those derived by histology. This inconsistency likely reflects shrinkage of these large 
vessels during histological processing, supporting the advantage of OPT over 
histology alone. Crucially, this bias was independent of plaque size, indicating that 
measurements made in this way are comparable within and between vessels. 
 
OPT offers a number of benefits over the conventional histological analysis used by 
so many. Not only is histology time-consuming and labour intensive, it also typically 
limits quantification to one snap-shot of the vessel where the largest cross-sectional 
area of the plaque is present, although some investigators do laboriously quantify 
serial section to gain a more representative measure of lesion size. Conversely, OPT 
is a more rapid technique that requires less preparation time. In addition, OPT allows 
a full 3-dimensional description of plaque volume and distribution which adds 
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greater power to determine the effects of intervention and may allow detection of 
more subtle changes in plaque development, as exemplified in this investigation. 
Given the unproven nature of this technique, full histological analysis was carried out 
following OPT scan acquisition. In future, OPT can be used to quantify plaque 
volume and distribution and therefore reduce the histological requirement to 
complimentary selective analysis of only the regions containing the largest lesion. 
 
As with any technique, OPT has some disadvantages. As the traditional refractive 
index matching solution used for OPT imaging is a lipid solvent, the extracellular 
lipid pools within the plaques were removed prior to scanning. A potential alternative 
solution could be glycerol, which, as a polar solution, may allow preservation of the 
lipid pools. However, as has been suggested for ex vivo MRI of atherosclerotic 
arteries (McAteer et al., 2004), the removal of lipid may provide a means of 
quantifying the extracellular lipid pools within the plaques by measurement of the 
holes that remain after solvent treatment. Certainly, the volume of these empty 
regions can be measured by OPT, but further optimisation will be required to 
standardise the quantification parameters, specifically the grey-level thresholding, to 
delineate the lipid from the plaque. 
 
As mentioned previously, this is the first time OPT has been described for the 
analysis of murine atherosclerotic lesions. Additionally, in this department, OPT has 
been successfully applied to the visualisation and quantification of neointimal lesions 
in the femoral artery of mice (Kirkby et al., 2011). These successes support OPT’s 
prospect as a novel technique, which can transform the way in which vascular lesions 
are analysed in animal models.  
3.5.4. Summary 
In summary, optical projection tomography has been successfully used to allow 3-
dimensional visualisation and quantification of atherosclerotic plaques in the mouse, 
providing a much needed improvement on the standard histological techniques used 
currently. Using this technique, it has been shown that exogenous glucocorticoids are 
indeed pro-atherosclerotic, whereas physiological levels of endogenous 



















Despite the conflicting evidence on the effects of glucocorticoids on atherogenesis, 
the effects of these steroids on neointimal proliferation following vascular injury is 
somewhat clearer. Certainly, there have been many investigations into the effects of 
exogenous glucocorticoids on neointimal proliferation. However, there do not appear 
to be any reports detailing the influence of endogenous glucocorticoids. 
 
Glucocorticoids clearly have the potential to inhibit neointimal proliferation due to 
their potent anti-inflammatory properties (Liu et al., 1999; Yamada et al., 1993) and 
ability to directly inhibit smooth muscle cell migration and proliferation 
(Goncharova et al., 2003; Voisard et al., 1994). Indeed, glucocorticoid 
administration has been shown to inhibit neointimal development in a number of 
animal models, including the rat (Guzman et al., 1996; Nagasaki et al., 2004; Villa et 
al., 1994) and rabbit (Hagihara et al., 1991; Petrik et al., 1998; Valero et al., 1998; 
Van Put et al., 1995). In addition, glucocorticoid-coated stents inhibited neointimal 
proliferation in the dog femoral artery (Strecker et al., 1998) and in the pig coronary 
artery (Wang et al., 2005c). There are a limited number of studies in the mouse, with 
one study describing both local and systemic dex treatment reducing neointima 
formation after cuff placement around the femoral artery (Pires et al., 2005). A 
recent study from this department concluded that both systemic dex and local cortisol 
treatment reduced neointimal proliferation following femoral artery wire-injury in 
mice (Macdonald, 2007). Therefore, there is a plethora of evidence from animal 
studies to support the contention that exogenous glucocorticoids attenuate neointimal 
proliferation. 
 
Glucocorticoids have since been trialled as anti-restenotic agents in the clinic, with 
systemic treatment alongside PCI showing positive results (Ribichini et al., 2007b; 
Ribichini et al., 2005; Versaci et al., 2002). However, there are contraindications to 
oral glucocorticoid therapy, including diabetes mellitus, severe arterial hypertension 
and peptic ulcers, as well as adverse effects such as gastric pain, impaired glucose 
tolerance and worsened hypertension (Ribichini et al., 2007a). In addition, 
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glucocorticoid administration augments atherogenesis in mice, as reported in Chapter 
3 (section 3.5.3.2). Another important complication of glucocorticoid therapy is an 
increased risk of thrombosis, thought to be partly attributable to increased activity of 
the coagulation cascade and reduced fibrinolytic activity (Brotman et al., 2006; Jilma 
et al., 2005; Patrassi et al., 1995; Sartori et al., 1999). Indeed, MacDonald et al 
describe increased local thrombus following systemic dex treatment in their murine 
femoral artery wire-injury model (Macdonald, 2007). Local glucocorticoid delivery, 
in the form of DexES, has the advantage of avoiding the systemic secondary effects 
of steroids, while releasing a high dose of steroid at the site of the target lesion. 
Unfortunately, although there have been some positive clinical outcomes and/or 
angiographic results with DexES (Han et al., 2006; Jimenez-Valero et al., 2007; Liu 
et al., 2003; Patti et al., 2005), there are a number of studies describing DexES as 
having no effective anti-proliferative actions in acute coronary syndromes (ACS) 
(Hoffmann et al., 2004b; Pesarini et al., 2009), no benefit over bare metal stents 
(BMS) in patients with stable angina (Gaspardone et al., 2006; Hoffmann et al., 
2004a), and an association with relatively high restenosis rates in patients with 
diabetes mellitus (van der Hoeven et al., 2008). 
 
Therefore, evidence from pre-clinical and human studies using systemic treatment 
suggests that exogenous glucocorticoids do have anti-restenotic effects, albeit with a 
number of contraindications and adverse effects. Unfortunately, DexES have not 
provided the advancement in the prevention of restenosis that was hoped for in the 
clinic. Therefore, elucidating the mechanisms of the anti-restenotic effects and 
adverse effects of systemic glucocorticoid therapy may help improve the therapeutic 
potential of these steroids as a treatment for the prevention of restenosis. 
 
While there has been an assortment of investigations into the effects of exogenous 
glucocorticoids on neointimal proliferation, there do not appear to be any reports 
detailing the influence of endogenous glucocorticoids. However, two studies 
(unpublished), carried out in this department, have investigated the effect of 
endogenous glucocorticoids on neointimal proliferation through manipulation of the 
enzyme 11β-hydroxysteroid dehydrogenase type 1 (11βHSD1), the enzyme 
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responsible for the conversion of inactive 11-dehydrocorticosterone to active 
corticosterone. Inhibition or genetic deletion of 11βHSD1 was shown to reduce 
neointimal development following intra-luminal wire injury in ApoE-/- mice, 
suggesting endogenous glucocorticoids are in fact pro-restenotic. However, a similar 
study using C57Bl/6 mice, described manipulating 11βHSD1 to have no effect on 
neointimal proliferation following wire-injury. The conflicting results between these 
two studies are attributed to metabolic disturbances caused by ApoE deficiency. 
There are a number of alternative methods available for manipulating endogenous 
glucocorticoids, which could add clarity to the role of these steroids in neointimal 
proliferation. Bilateral adrenalectomy is one such method, commonly used to 
globally remove endogenous glucocorticoids thereby allowing investigation into 
their role in physiological and pathophysiological processes (de Jong et al., 2007; 
Haluzik et al., 2002). Improving our understanding of the complex role of 
endogenous glucocorticoids in neointimal proliferation, using adrenalectomy, may 
enable further advancement in the treatment of restenosis.  
 
There are many well-described murine models of neointimal proliferation, including: 
intra-luminal wire injury (Lindner et al., 1993; Sata et al., 2000), carotid artery 
ligation (Kumar et al., 1997b), electrical injury (Carmeliet et al., 1997c) and 
perivascular ferric chloride injury (Schafer et al., 2002). Previous studies in this 
laboratory investigating the role of glucocorticoids in neointimal proliferation 
utilised the wire injury model of acute vascular injury. This is a well-characterised 
model of neointimal proliferation, first described by Sata et al. (Sata et al., 2000). It 
involves the insertion of an angioplasty guidewire into the femoral artery via a small 
muscular side-branch. The wire stretches the vessel, causing endothelial denudation 
and extensive medial damage. The resulting healing process produces a smooth 
muscle-rich neointimal lesion. This model was used in this investigation to maintain 




The work described in this chapter addresses the hypothesis that glucocorticoids 
attenuate neointimal proliferation. It is, therefore, proposed that removal of 
endogenous glucocorticoids (adrenalectomy) augments, whilst glucocorticoid 
administration reduces, neointimal proliferation following arterial injury in mice. In 
order to address this hypothesis, the specific aims of the work described in this 
chapter were to: 
 
• determine whether surgical removal of the adrenal glands increased lesion 
development following intra-luminal wire injury in mice. 
• determine whether chronic administration of the synthetic glucocorticoid 
dexamethasone reduced lesion development following intra-luminal wire 






Male C57Bl/6 mice (Harlan Olac, UK) aged 10-14 weeks and weighing 26-34 grams 
were used in this study.  
4.3.2. Adrenalectomy  
In order to investigate endogenous glucocorticoids mice were randomised to undergo 
either bilateral adrenalectomy or sham adrenalectomy (section 2.2.1). 
4.3.3. Administration of drugs 
Adrenalectomised (adx) mice were provided with 0.9% NaCl in their drinking water. 
Vehicle (absolute ethanol) or the synthetic glucocorticoid dexamethasone (dex; 0.1 
or 0.8 mg/kg/day; section 2.2.3.1) were administered by addition to the drinking 
water or saline, as appropriate. Drug administration commenced immediately after 
adrenalectomy/sham surgery and continued for 4 weeks (Figure 4.1).  
4.3.4. Femoral artery injury 
One week following adrenalectomy/sham and the start of drug administration, the 
mice were subjected to femoral artery injury (section 2.2.2). Briefly, an angioplasty 
wire was inserted into the artery to induce neointimal hyperplasia (Sata et al., 2000). 
4.3.5. Tissue collection 
At the end of the 4-week experimental period a tail tip blood sample was collected, 
spun to plasma and stored as described previously (section 3.3.4). The mice were 
then killed by asphyxiation in CO2 and arteries (aorta and femorals) and organs were 
collected and weighed.The aorta, femoral arteries, a lobe of the liver, the left kidney 
and adrenals were fixed in 10% neutral buffered formalin for 24 hours before being 
transferred into 70% ethanol.  The remainder of the liver, the heart, right kidney, 































































































































































































































































































































































































































Plasma spun from blood collected by tail tip immediately prior to sacrifice was used 
to assess corticosterone levels using a radioimmunoassay (section 2.5.1), to confirm 
successful removal of the adrenal glands. 
4.3.7. Neointimal lesion analysis 
4.3.7.1 Quantification 
The injured femoral arteries were processed, embedded in paraffin and cut into 4µm 
thick transverse sections (section 2.4.1). Sets of twenty serial sections (80μm) were 
collected every 160μm along the entire artery. One section every 160μm along the 
artery was stained with the United States trichrome (section 2.4.2). 
Photomicrographs were taken using a light microscope coupled to a colour camera 
and image analysis system (section 2.4.4). The area (μm2) of lesion in each section 
was measured using Photoshop CS3 software (section 2.4.5). The section with the 
largest area of lesion was chosen to represent each arterial sample 
4.3.7.2  Composition 
The cellular composition of the neointimal lesions was investigated using 
histological staining and immunohistochemistry on serial sections at the point of 
maximum lesion area. Smooth muscle cell content was assessed using an 
alkaline-phosphatase conjugated monoclonal primary antibody against smooth 
muscle cell α-actin (section 2.4.7.2). A polyclonal rabbit anti-human primary 
antibody was used to determine the fibrinogen content of the lesions (section 
2.4.7.4). A monoclonal rat anti-mouse primary antibody against Mac-2 was used to 
determine the macrophage content of the lesions (section 2.4.7.3). 
4.3.8. Statistics 
All statistical analysis was performed by one-way ANOVA with Dunnett’s post-hoc 
test for comparison of physiological levels of endogenous glucocorticoid or 
exogenous glucocorticoid treatment with control, adrenalectomised mice. Statistical 





There was no significant difference in body weight at the start of the study. In the 4-
week study, animals in all four groups showed an early weight loss after both the 
adrenalectomy and femoral artery injury surgeries (Figure 4.2A). Adrenalectomy had 
no significant effect on body weight, whereas dex caused a dose-dependent reduction 
in body weight (low dose dex: p<0.05, high dose dex: p<0.01; Figure 4.2B). The 
average dose of dex received was 0.09±0.002mg/kg/day (low dose) and 
0.80±0.04mg/kg/day (high dose). 
4.4.2. Organ weights 
Adrenalectomy slightly reduced thymus weight (p<0.05) and dex treatment 
significantly decreased thymus weight in a dose-dependent manner (low and high 
dose dex: p<0.01; Figure 4.3A). Dex treatment also resulted in a dose-dependent 
decrease in spleen weight (low and high dex: p<0.001; Figure 4.3B). High dex 
treatment also induced a significant increase in heart weight (p<0.05; Figure 4.3C). 
There were no significant changes in the weight of other organs collected (kidneys 
and liver; Figure 4.4).  
4.4.3. Plasma corticosterone levels 
Unfortunately, there were insufficient plasma volumes available from some animals, 
including the entire sham group. Plasma samples were therefore collected from intact 
control C57Bl/6 mice at the same time of day (between 10am and 12pm) and under 
the same conditions to illustrate corticosterone levels in intact mice. All samples 
from adrenalectomised animals that were analysed, which included 6/8 animals in 
the adx group, 3/6 in the high dex group and 4/7 in the low dex group, had 
corticosterone levels 10-fold lower than controls, equivalent to diurnal nadir levels 
(Figure 4.5). It is important to note that adrenalectomy did not completely abolish 


























           
  
 
Figure 4.2: Weight changes induced by adrenalectomy and dexamethasone treatment.  
Mice were randomised to undergo sham or adrenalectomy (adx) surgery. Adx animals were 
supplied with 0.9% saline with either vehicle or dexamethasone (dex; 0.1 or 0.8mg/kg/day) in 
their drinking water. Neointimal hyperplasia was induced by femoral artery wire- or ligation-
injury (FAI). Body weight was measured regularly throughout the 4-week experimental period.  
There were no differences in the weights of the animals at the start of the experiment. All animals 
showed an early weight loss after both the adrenalectomy and femoral artery injury surgeries. Adx 
appeared to have no influence on body weight, whereas dex appeared to reduce body weight (A). 
Analysis of change in body weight from start to end of the experimental period confirmed that 
adx had no significant effect on weight, whilst dex treatment caused a dose-dependent reduction 
in body weight in comparison to the adx group (B). All data expressed as mean±SEM, n=6-8. 




































                 
 
 
Figure 4.3: Organ weight changes induced by adrenalectomy and dexamethasone treatment. 
Mice were randomised to undergo sham or adrenalectomy (adx) surgery. Adx animals were 




their drinking water. Neointimal hyperplasia was induced by femoral artery wire- or ligation-
injury. Organs were weighed upon sacrifice. Adx reduced thymus weight but had no effect on any 
other organ (A). Dex treatment caused a dose-dependent reduction in both thymus (A) and spleen 
(B) weight. The high dose dex also increased heart weight (C). All data expressed as mean±SEM, 







Mice were randomised to undergo sham or adrenalectomy (adx) surgery. Adx animals were 
supplied with 0.9% saline with either vehicle or dexamethasone (dex; 0.1 or 0.8mg/kg/day) in 
their drinking water. Neointimal hyperplasia was induced by femoral artery wire- or ligation-
injury. Organs were weighed upon sacrifice. Neither adx nor dex influenced kidney and liver 
weight. All data expressed as mean±SEM, n=6-8. Data were analysed by one way ANOVA with 
Dunnett’s post hoc test vs adx. 
 






Figure 4.5: Plasma corticosterone levels in animals that underwent adrenalectomy.  
Mice were randomised to undergo sham or adrenalectomy (adx) surgery. Adx animals were 
supplied with 0.9% saline with either vehicle or dexamethasone (dex; 0.1 or 0.8mg/kg/day) as 
their drinking water. Neointimal hyperplasia was induced by femoral artery wire- or ligation-
injury. Plasma corticosterone levels were measured in tail-tip plasma by radioimmunoassay. 
Plasma samples from control C57Bl6 mice (striped bar) represent peak corticosterone levels in 
mice with intact adrenals. All adx mice measured had corticosterone levels 10-fold lower than 
control mice, equivalent to diurnal nadir levels. All data expressed as mean±SEM; Control: n=6, 
adx: n=6, adx + low dex, adx + high dex: n=3: n=4. Adx + low dex and adx + high dex were 





Adrenalectomy and low dex had no effect on lesion size. High dex treatment 
appeared to reduce lesion size, but this did not reach significance (Figure 4.6A; Table 
4.1). In addition, while the majority of neointimal lesions that developed in the sham, 
adx and low dex groups were fibro-proliferative in nature, most of the lesions that 
developed in the high dex group were acellular and appeared to be thrombotic in 
nature.  
 
The sections were re-analysed, quantifying only the fibrous (cellular) part of the 
lesions. With this approach, adrenalectomy still had no effect on the size of fibrous 
lesions. The high dex resulted in a significant decrease in fibrous lesion size but this 
effect was not seen at the low dose (Figure 4.6B).   
4.4.4.2 Neointima composition 
4.4.4.2.1 Smooth muscle and fibrinogen 
Immunohistochemical staining against smooth muscle α-actin revealed that lesions 
which developed in the sham, adx and low dex groups were relatively rich in smooth 
muscle, containing 45-65% smooth muscle. In the high dex group, staining was 
limited to the fibrous regions and made up only 17% of the lesions, although this 
reduction did not reach statistical significance (Figure 4.7). Immunohistochemical 
staining against fibrinogen further suggested that the non-fibrous components are 
thrombotic in nature (Figure 4.8). 
4.4.4.2.2 Macrophages 
The macrophage content of the lesions was assessed using immunohistochemical 
staining against Mac-2 protein. Neither adrenalectomy nor low dex treatment had 
any effect on macrophage content within the neointima, making up 11-15% of the 
lesion. Although the high dex treatment indicated a reduction in macrophage staining 




























Figure 4.6: Impact of adrenalectomy and dexamethasone treatment on neointimal lesion 
development, as assessed by histology. 
Mice were randomised to undergo sham or adrenalectomy (adx) surgery. Adx animals were 
supplied with 0.9% saline with either vehicle or dexamethasone (dex; 0.1 or 0.8mg/kg/day) as 
their drinking water. Neointimal hyperplasia was induced by femoral artery wire-injury. 
Neointima cross-sectional areas were measured at the point of largest lesion by histological 
analysis. Both total lesion (A) and fibrous lesion only (B) areas were quantified. Adx had no 
effect on lesion size. High dose dex appeared to reduce total lesion size (A), a tend that was not 
seen with the low dose, but this did not reach significance. The high dose dex did, however, 
reduce fibrous lesion size (B). Again this effect was not seen at the lower dose. All data expressed 







Table 4.1: Impact of adrenalectomy and dexamethasone treatment on the size and 








n   8  7  6  6 
         
(a) 2D Morphometry (Histology)         
Neointimal area (x104μm2)   4.0 ± 0.8  5.3 ± 0.7  5.1 ± 0.5  3.2 ± 0.3 
Medial area (x104μm2)   1.5 ± 0.2  1.2 ± 0.1  1.8 ± 0.2  1.3 ± 0.2 
Intima/Media ratio   3.2 ± 0.9  4.7 ± 0.7  3.0 ± 0.7  3.0 ± 0.4 




Smooth Muscle α‐actin (%)   52.7 ± 9.3  45.6 ± 11.1  64.1 ± 6.7  16.7 ± 5.2 
14.4 ± 3.0  11.5 ± 3.4  16.4 ± 3.8  2.2 ± 0.4 Macrophages (%) 
             
 
Mice were randomised to undergo sham or adrenalectomy (adx) surgery. Adx animals were 
supplied with 0.9% saline with either vehicle or dexamethasone (dex; 0.1 or 0.8mg/kg/day) as 
their drinking water. Neointimal hyperplasia was induced by femoral artery wire-injury, before 
isolation and examination of the left femoral artery by histology (a) and immunohistochemistry 
(b). Adx had no influence on any parameter measured. Neither dose of dex significantly altered 
total lesion area (a). The high dose of dex appeared to reduce both smooth muscle content and 
macrophage content of the plaque, as measured by immunohistochemistry (b), but these trends 
did not reach significance. All data expressed as mean±SEM, n=6-8. Data were analysed by one 


























Figure 4.7: Impact of adrenalectomy and dexamethasone treatment on neointimal lesion 
smooth muscle content. 
Mice were randomised to undergo sham or adrenalectomy (adx) surgery. Adx animals were 
supplied with 0.9% saline with either vehicle or dexamethasone (dex; 0.1 or 0.8mg/kg/day) as 
their drinking water. Neointimal hyperplasia was induced by femoral artery wire-injury. 
Composition was quantified at the point of largest lesion as determined by histological analysis. 
Smooth muscle content was assessed using immunohistochemistry. Lesions that developed in the 
sham, adx and low dex groups all strongly stained for smooth muscle α-actin. In the high dose dex 
group staining was limited to the fibrous regions and there was a trend towards a reduction in 
smooth muscle content, but this did not reach significance. Data expressed as mean±SEM, n=6-8. 
























Figure 4.8: Composition of lesions formed after femoral artery wire-injury.  
Mice were randomised to undergo sham or adrenalectomy (adx) surgery. Adx animals were 
supplied with 0.9% saline with either vehicle or dexamethasone (dex; 0.1 or 0.8mg/kg/day) as 
their drinking water. Neointimal hyperplasia was induced by femoral artery wire-injury. 
Composition was quantified at the point of largest lesion as determined by histological analysis. 
Smooth muscle (SMα-actin) and fibrinogen content was assessed using immunohistochemistry. 
Sham, adx and low dex-treated mice developed typical lesions, staining strongly for elastin (a, d, 
g) and smooth muscle (b, e, h). Whereas, high dex-treated animals developed lesions that were 
acellular, elastin-deficient and appeared to be thrombotic (j). In addition, these lesions did not 
stain for smooth muscle cells (k) and did stain for fibrinogen (l), confirming that these lesions are 


























Figure 4.9: Impact of adrenalectomy and dexamethasone treatment on neointimal lesion 
macrophage content. 
Mice were randomised to undergo sham or adrenalectomy (adx) surgery. Adx animals were 
supplied with 0.9% saline with either vehicle or dexamethasone (dex; 0.1 or 0.8mg/kg/day) as 
their drinking water. Neointimal hyperplasia was induced by femoral artery wire-injury. 
Composition was quantified at the point of largest lesion as determined by histological analysis. 
Macrophage was assessed using immunohistochemistry. Adx had no influence on the 
macrophage content of the lesions. High dose dex appeared to dramatically reduce the 
macrophage content, however this did not reach significance. This was not seen at the lower dose. 
Data expressed as mean±SEM, n=6-8. Data were analysed by one-way ANOVA with Dunnett’s 






The work described in this chapter addresses the hypothesis that glucocorticoids 
attenuate neointimal proliferation. The results obtained suggest that physiological 
levels of endogenous glucocorticoids do not influence neointima development 
following intra-vascular injury. Conversely, high dose dex administration does 
indeed reduce fibrous neointima size but this effect is not seen at a lower dose. 
Although the high dex dose reduced fibrous lesion size, its ability to decrease the size 
of the overall lesion (and thus to reduce arterial narrowing) appears compromised by 
the stimulation of thrombosis at the site of injury.  
4.5.1.  Endogenous glucocorticoids and neointimal proliferation 
4.5.1.1 Manipulating endogenous glucocorticoids 
In order to confirm the success of the adrenalectomy surgery and to monitor the 
animals’ welfare, physiological parameters (including plasma corticosterone levels, 
body and organ weights) were measured. All animals that underwent adrenalectomy 
had significantly reduced, but not abolished, plasma corticosterone levels. It is 
acknowledged that bilateral adrenalectomy fails to completely eliminate circulating 
corticosterone (Dubuc et al., 1986; Jacobson, 1999; Makimura et al., 2000; Vrang et 
al., 2002). Potential explanations for this have been discussed previously (section 
3.5.1.1), but the source of the remaining corticosterone remains to be elucidated.  
 
As has been previously shown (de Jong et al., 2007; Ingram et al., 2005; Makimura 
et al., 2003), and described in the previous chapter (section 3.4.1) adrenalectomy had 
no effect on the animals’ body weight over the experimental period. Conversely, the 
thymus weight was expected to increase following removal of the adrenals as has 
been described in a number of murine studies (Jacobson, 1999; Pruett et al., 2004; 
Reber et al., 2007). However, in this study thymus weight was actually decreased 
slightly by adrenalectomy, in comparison to the sham animals. There have been no 
previous reports of such an effect and the mechanism behind it remains to be 
elucidated. Upon sacrifice, all animals were scrutinised for the presence of adrenal 
remains or regenerated adrenal material and found to have none. In addition, dex 
treatment did not reduce circulating corticosterone levels, as would be expected in 
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intact mice due to negative feedback regulation of the hypothalamic-pituitary-adrenal 
(HPA) axis (Kageyama et al., 2009). This, therefore, supports the conclusion that the 
adrenalectomy surgery was a success, with no evidence of remaining adrenal tissue, 
significantly reduced circulating corticosterone levels and healthy mice.  
4.5.1.2 Impact of manipulating endogenous glucocorticoids on 
neointimal proliferation 
Despite evidence that glucocorticoids have the potential to inhibit neointimal 
proliferation (section 4.1), reducing endogenous glucocorticoids to approx. 25% of 
normal levels failed to influence lesion development in this investigation. Two 
previous studies (unpublished), carried out in this department, have investigated the 
effect of manipulating 11βHSD1 on neointimal proliferation in mice. Both inhibition 
and genetic deletion of 11βHSD1 has been shown to reduce neointimal development 
following intra-luminal wire injury in ApoE-/- mice, suggesting endogenous 
glucocorticoids are potentially pro-restenotic. However, a similar study using 
C57Bl/6 mice, described the same manipulations of 11βHSD1 to have no effect on 
neointimal proliferation following wire-injury. The conflicting results between these 
two studies are attributed to metabolic disturbances caused by ApoE deficiency. The 
results from the current investigation therefore complement the latter study, and as 
both of these studies were carried out in the same strain of mice and used the same 
model of vascular injury, confidence can be drawn in the mutual conclusion that 
physiological levels of endogenous glucocorticoids play a limited role in neointimal 
proliferation. It must be noted that an important difference between these studies is 
that inhibition or genetic deletion of 11βHSD1 will only influence endogenous 
glucocorticoids action in specific tissues, unlike adrenalectomy which will reduce 
endogenous glucocorticoid action globally. 
 
As described in the previous chapter, the lack of effect of adrenalectomy on 
neointimal proliferation may be due to additional removal of mineralocorticoids and 
catecholamines, along with glucocorticoids, by adrenalectomy. A number of pre-
clinical studies report that ACE inhibition and angiotensin II receptor (AT1R) 
blockade prevent neointimal proliferation following balloon injury in the carotid 
artery of rats (Clozel et al., 1993; Osterrieder et al., 1991; Powell et al., 1989). This 
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may indicate a role for mineralocorticoids in promoting neointimal proliferation but 
direct effects of angiotensin II and AT1R (Strawn et al., 2002) cannot be excluded. 
Consistent with these data, administration of aldosterone, the primary endogenous 
mineralocorticoid, increased neointimal proliferation following coronary artery 
angioplasty in pigs (Ward et al., 2001). The clinical relevance of these findings is 
supported by the demonstration that high plasma aldosterone levels in patients 
correlate with restenosis 6 months after coronary stent implantation (Amano et al., 
2006). Similarly, norepinephrine has been shown to augment neointimal proliferation 
following vascular balloon injury (Erami et al., 2002; Zhang et al., 2001). This effect 
has not only been attributed to haemodynamic changes, but also to direct alpha-1-
adrenoceptor (α1AR) activation of VSMC growth, with evidence that antagonists of 
α1AR inhibit neointimal proliferation in similar models (Fingerle et al., 1991; 
O'Malley et al., 1989; Vashisht et al., 1992; Zhang et al., 2001). Therefore, removal 
of mineralocorticoids and catecholamines by adrenalectomy would be expected to 
reduce neointimal proliferation in the current investigation. Perhaps the beneficial 
effect of removing mineralocorticoids and catecholamines is counteracting the 
potential detrimental effects of removing the anti-inflammatory glucocorticoids. 
 
As well as having no influence on the size of neointimal lesions, adrenalectomy 
appeared to have no influence on lesion composition, with similar macrophage and 
smooth muscle content to the lesions in the sham-operated animals. It had been 
anticipated that macrophage numbers may have increased in lesions from 
adrenalectomised mice as glucocorticoids can play a key anti-inflammatory role in 
the vasculature (Liu et al., 1999; Ruetten et al., 1997). However, as macrophages 
play a crucial role in the development of neointimal proliferation (Hui, 2008), the 
lack of effect of adrenalectomy on macrophage content may explain the lack of effect 
on overall neointima size. Macrophage infiltration has been shown to peak at day 7 
following wire injury and then decline steadily as the inflammation resolves 
(Macdonald, 2007). As the lesions in this study were assessed at day 21, perhaps any 
influence of adrenalectomy on macrophage infiltration was missed. To further 
investigate this hypothesis, ideally day 7 lesions would be analysed. 
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In summary, to further determine the influence of endogenous glucocorticoids on 
neointimal proliferation, perhaps a different approach is necessary. The use of 
vascular-specific GR-/- mice could provide crucial information on the influence of 
endogenous glucocorticoids and indicate the potential role of the endothelium and 
smooth muscle cells in the mechanism. Also, additional investigation into the role of 
pre-receptor metabolism of glucocorticoids by the 11βHSD1 enzyme would help 
clarify the conflicting results currently described and help elucidate the role of 
endogenous glucocorticoids in restenosis. However, a more constructive approach 
may be to model endogenous glucocorticoid excess. One currently used method of 
investigating glucocorticoid excess is ACTH administration, modelling Cushing’s 
Disease (Bailey et al., 2009; Dunbar et al., 2010). It would be of interest to utilise 
this technique in our model of intimal hyperplasia to investigate more specifically the 
role of endogenous glucocorticoids on neointimal proliferation. 
4.5.2. Exogenous glucocorticoids and neointimal proliferation 
4.5.2.1 Systemic glucocorticoid treatment 
As described previously, dex was chosen for the investigation described in this 
chapter as it is the glucocorticoid most commonly used for medium- and long-term 
systemic administration in mice (Brack et al., 1997; Gunin et al., 2003). In addition, 
dex is the most commonly used glucocorticoid in previous studies describing the 
effect of glucocorticoid treatment on neointimal lesion formation in animals 
(Hagihara et al., 1991; Karim et al., 1997; Van Put et al., 1995; Villa et al., 1994). 
Use of dex, therefore, allows direct comparison with this previous work. Dex has 
also been trialled clinically for its anti-restenotic effects in DexES. For the 
experiments described in this chapter, dex was administered in drinking water to 
reduce any stress to the animals and allow a consistent dose throughout the day 
(Gunin et al., 2003), of either 0.1 or 0.8mg/kg/day.  
 
Dex administration commenced immediately following adrenalectomy to allow the 
dose to equilibrate before arterial injury. The treatment was continued for the full 
three weeks following injury so as to maintain the influence of the steroid throughout 
the development of the lesion. Limiting the treatment to before the injury may well 
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alter the outcome on lesion development, as well as limit the systemic side effects. 
With this in mind, modifying the time-course of treatment may bring some additional 
insight into the mechanisms behind the influence of dex on neointimal proliferation. 
In addition, mice receiving dex were also adrenalectomised to allow distinction of 
the effects of exogenous glucocorticoids on neointimal proliferation, without the 
added complication of endogenous glucocorticoids and mineralocorticoids in the 
circulation. A previous study in this department had assessed the effects of 
glucocorticoid administration on neointimal proliferation in mice with intact adrenal 
glands, the results of which are discussed below. 
 
The dose-dependent weight loss and reduction in size of glucocorticoid-sensitive 
organs confirms that both doses of dex were pharmacologically active in the animals. 
These systemic side effects of dex are well documented in the mouse (Pires et al., 
2005). In addition, the high dose of dex increased heart weight. This could be an 
indication of hypertrophy of the heart as a consequence of hypertension. Blood 
pressure was not measured in these mice but glucocorticoids are known to induce 
hypertension in rodents (Goodwin et al., 2008; Whitworth et al., 2001; Zhang et al., 
2004). Indeed, the investigation described in Chapter 5 confirms that the same doses 
of dex (0.1 and 0.8mg/kg/day) show an increase in systolic blood pressure after two 
weeks treatment, in intact C57Bl/6 mice (section 5.4.3).  
4.5.2.2 Impact of exogenous glucocorticoids on neointimal proliferation 
It was hypothesised that the high dose of dex (0.8mg/kg/day; chosen as it is 
comparable to doses used in other long-term dex studies in mice (Blyth et al., 1998; 
Gunin et al., 2003)) would reduce fibrous neointimal lesion formation. There was the 
additional expectation of possible development of alternative thrombotic lesion 
instead, as shown by Macdonald et al. in a similar previous study carried out in this 
department. The lower concentration of dex (0.1mg/kg/day) was therefore included, 
with the hypothesis that it would retain the inhibition of fibrous lesion development, 
whilst avoiding some of the adverse side effects seen in animals on a higher dose of 





Interestingly, the low dex dose had no significant influence on lesion size. Despite 
changes in body weight and glucocorticoid-sensitive organs, the low dose appeared 
to be too low to influence neointimal lesion development. Conversely, the high dose 
of dex did indeed cause a dramatic reduction in fibrous neointima size. Pre-clinical in 
vivo studies have consistently described glucocorticoid treatment to reduce 
neointimal proliferation in a number of animal models, including the rat (Guzman et 
al., 1996; Nagasaki et al., 2004; Villa et al., 1994) and rabbit (Hagihara et al., 1991; 
Petrik et al., 1998; Valero et al., 1998; Van Put et al., 1995). This effect is attributed 
to the potent anti-inflammatory properties of glucocorticoids (Liu et al., 1999; 
Yamada et al., 1993) and their potential to inhibit smooth muscle cell migration and 
proliferation (Goncharova et al., 2003; Voisard et al., 1994). Indeed, the lack of 
effect of the low dose of dex on neointimal size was accompanied by no change in 
the inflammatory component of the lesions, as measured by macrophage content, nor 
the smooth muscle content of the lesions.  
 
A reduction in inflammatory cells within the neointima was expected as 
glucocorticoids are known to repress macrophage infiltration (Jilma et al., 2000; 
Yamada et al., 1993) and accumulation (Hagihara et al., 1991). It should be noted, as 
described above, that macrophage infiltration peaks at day 7 in this model of 
neointimal proliferation. As this study is investigating lesion development at day 21, 
the conditions are not optimal for studying macrophage numbers and behaviour. To 
further address the effect of dex treatment on macrophage infiltration, assessment of 
lesions at an early time point, day 2, as well as at the expected peak infiltration, day 
7, would be useful. In addition, at these time points a more comprehensive 
assessment of inflammation could be carried out using additional markers for 
macrophages (F4/80) (D'Elia et al., 2009; Naghavi et al., 2003), neutrophils (Ly6G) 
(Fridlender et al., 2009; Gahring et al., 2010) and T-lymphocytes (CD3) (Naghavi et 
al., 2003) in flow cytometry for whole blood analysis and immunohistochemistry for 




Considering the anti-migratory and anti-proliferative effects of glucocorticoids are 
relatively well established, it is surprising that the VSMC content of the lesions was 
not significantly reduced. However, in order to fully understand the influence of dex 
on the VSMCs in this model of intimal hyperplasia, the somewhat controversial issue 
of the source of the VSMCs must be addressed. Medial apoptosis following injury 
questions the suggestion that VSMCs migrate from the media. There have been 
alternative indications that they differentiate from the circulating bone marrow-
derived inflammatory cells which infiltrate the vasculature during the initial response 
to injury (Sahara et al., 2007; Sata et al., 2002; Tanaka et al., 2003). However, there 
are critics of this proposal who claim to have refuted the existence of bone marrow-
derived smooth muscle cells in vascular lesion, suggesting methodological 
discrepancies account for the confusion  (reviewed in (Bentzon et al., 2010b)). If 
indeed the VSMCs are sourced from circulating progenitors, the anti-inflammatory 
properties of dex may be directly altering the smooth muscle cell content. This is all 
speculation and would require investigation before any conclusions could be drawn.  
 
Notably, it was identified that many of the lesions in the high dex group had areas 
within the lesion that were acellular, devoid of elastin and appeared to be thrombotic, 
confirming the previous observation of MacDonald et al. Further compositional 
analysis of the lesions confirmed that the smooth muscle cells in the high dex lesions 
were limited to the fibrous part of the lesion, whilst the thrombotic areas of lesion 
stained strongly for fibrinogen, further confirming that these regions are of 
alternative, thrombotic composition. This thrombotic side effect was sufficient to 
mask the reduction in size of fibro-proliferative lesions. Consequently, vessel 
occlusion in high dex-treated animals was similar to controls. But, importantly, the 
thrombotic nature of the lesion will render it less stable than a smooth muscle-rich 
neointima, with the potential to instigate acute thrombotic events. With dex being 
used clinically as an anti-restenotic agent, it is crucial to elucidate the mechanism 
behind which dex is inducing this type of lesion. It is important to note that the 
thrombotic areas of lesion were not exclusive to the high dex group. This suggests 
that dex is not inducing atypical thrombotic lesion development as such, but instead 
may be modulating normal lesion progression. 
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In 1992, Schwartz et al postulated a hypothesis for the mechanism of neointimal 
proliferation following vascular injury, based on observations in the porcine coronary 
injury model (Schwartz et al., 1992a). In his hypothesis there are three stages in 
neointimal lesion formation; thrombotic (stage I), cellular recruitment (stage II) and 
proliferative (stage III). It is suggested that the thrombotic stage occurs immediately 
after, and as a direct consequence of, endothelial damage. This leads to formation of 
a thrombus composed of aggregated platelets, fibrin and trapped erythrocytes. The 
second stage of healing comprises cellular recruitment into the thrombus itself. 
Firstly, re-endothelialisation occurs at the thrombus/blood boundary, followed by 
recruitment of monocytes (later macrophages) and lymphocytes. The macrophages 
are responsible for thrombolysis (by secreting fibrinolytic enzymes) and 
phagocytosis of thrombus components. The cellular infiltrates, as well as the 
thrombus, are likely to secrete growth factors and chemo-attractants which facilitate 
further recruitment of cells (including VSMCs). The final stage involves cellular 
proliferation as the thin fibrous cap of VSMCs thickens and elaboration of 
extracellular matrix, eventually resulting in a mature, smooth muscle-rich neointima. 
This hypothesised model has been adapted for the specifics of the injury used in this 
study (Figure 4.10) and implemented as a potential explanation of the effects dex 
may have on neointimal proliferation. A more detailed explanation of the proposed 
pathogenesis of neointimal hyperplasia is described in Chapter 1 (section 1.1.3.1). 
 
The results described in this chapter suggest that administration of dex is impeding 
the progression of arterial healing past stage I. Therefore, the lesions observed in the 
high dex group are immature lesions with a significant thrombotic component. A 
number of mechanisms could be suggested to explain such a dex-mediated 
augmentation of the thrombotic stage and impediment of the progression to stages II 
and III. Firstly, it is well-described that glucocorticoid excess induces a 
hypercoagulable state in both the clinic and in animal studies. More specifically, 
glucocorticoid excess has been shown to increase coagulation, with augmented 
clotting factor levels (Brotman et al., 2006; Patrassi et al., 1985; Sartori et al., 1999), 
while additionally attenuating fibrinolysis with increased levels of PAI-1(Patrassi et 






Figure 4.10: Schematic hypothesis of the mechanism of neointima formation.  
A: pre-injured vessel. B: following intra-luminal wire injury the vessel has been stretched and 
denuded resulting in acute thrombosis within minutes of injury. C: Neutrophils infiltrate the 
thrombus within 24 hours of injury, followed by monocytes and leukocytes within 4 days. D: 
Smooth muscle cells begin to infiltrate roughly 6 days post-injury. The source of these smooth 
muscle cells is under debate, but there is a suggestion that they differentiate from the 
inflammatory cells (Tanaka et al., 2003). E: The neointima is completely formed within 21 days. 
EEL: external elastic lamina.;IEL: Internal elastic lamina; VSMCs: vascular smooth muscle cells.
155 
 
Therefore, there is evidence that dex treatment is likely to stabilise the thrombus 
formed by the wire-injury in the current investigation. Secondly, the potent anti-
inflammatory properties of glucocorticoids can not only inhibit infiltration (Poon et 
al., 2001) and proliferation (Asai et al., 1993) of monocyte/macrophages at the site 
of injury, reducing further inflammatory cell recruitment (Prescott et al., 1989; 
Yamada et al., 1993), but also prevent monocyte/macrophage-mediated lysis, 
through release of tPA (Kung et al., 1993), and clearance, by phagocytosis (Shantsila 
et al., 2009), of the thrombus. In addition, if inflammatory cells are a source of 
smooth muscle cells in vascular lesions, as had been suggested (Sahara et al., 2007; 
Tanaka et al., 2003), the anti-inflammatory properties of dex may also directly 
contribute to reduced VSMC content of lesions. Thirdly, the anti-migratory effects of 
glucocorticoids are also well reported. They have been shown to inhibit VSMC 
migration (Goncharova et al., 2003; Pross et al., 2002) and also to prevent trans-
migration of neutrophils through the blood vessel wall (Cronstein et al., 1992; 
Pitzalis et al., 2002). Finally, glucocorticoids have the potential to inhibit the cellular 
proliferative stage III as they have been shown to prevent proliferation of VSMCs in 
vitro (Bitzer et al., 2004; Voisard et al., 1994). 
 
Ideally, all aspects described above would be investigated to fully elucidate the 
mechanism behind glucocorticoid-mediated thrombus formation following intra-
luminal wire injury. In the interest of time, it was decided to focus on the influence 
of dex on the potential stabilisation of the thrombotic stage I, as this was deemed the 
most likely candidate to provide elucidation of the mechanism behind dex-mediated 
local thrombosis.  
4.5.3. Summary 
In summary, physiological levels of endogenous glucocorticoids appear to play a 
limited role in neointimal proliferation. Conversely, a high dose of exogenous 
glucocorticoid inhibited fibro-proliferative neointimal lesion development, but was 
associated with local thrombosis at the site of injury. In order to elucidate the 
mechanism behind this thrombotic effect, the influence of dex on thrombogenicity 




















The work described in the previous chapter suggests that high dose glucocorticoid 
treatment reduces neointimal proliferation following arterial injury in mice, but is 
associated with increased local thrombosis. It is postulated that this may be in part 
due to stabilisation of the initial thrombotic stage during neointimal lesion 
development, thus preventing lesion progression. There is a great deal of clinical 
evidence to suggest glucocorticoids are pro-thrombotic. For example, a 
hypercoagulable state and increased incidence of thromboembolic complications are 
reported in Cushing’s patients (Boscaro et al., 2002; La Brocca et al., 1997), 
attributable to increased circulating clotting factors and reduced fibrinolytic activity. 
Similarly, transplant patients receiving chronic immunomodulatory steroid therapy 
have an increased coagulation and decreased fibrinolytic potential (Patrassi et al., 
1995; Sartori et al., 1999). Although the pro-coagulant effects of glucocorticoids in 
man are well-described, less is understood with regard to the influence of 
glucocorticoids on platelet function, with very little having been reported.  
 
Importantly, there are also limited reports on the in vivo influence of glucocorticoids 
on thrombogenicity in rodents, with only evidence in rats (van Giezen et al., 1994; 
van Giezen et al., 1992). In these studies, the authors describe a dose-dependent 
effect of dex, suggesting that low doses attenuate thrombosis (primarily by inhibition 
of platelet aggregation), but this effect is lost at higher doses as a result of decreased 
fibrinolytic activity. Consequently, as with many glucocorticoid effects, the influence 
of dex on thrombogenicity appears to be sensitive to dose. Therefore, clarifying the 
influence of both doses of dex used in the previous chapter on thrombogenicity in 
mice may explain why the benefits of lesion prevention were lost as a result of 






The work described in this chapter addresses the hypothesis that high dose dex is 
pro-thrombotic, which may account for the thrombotic lesion development observed 
following arterial injury. In order to address this hypothesis, the work described in 
this chapter aims to determine the influence of high dose (0.8mg/kg/day) and low 
dose (0.1mg/kg/day) dex on thrombogenicity. Thus, the specific aims of this work 
were to determine whether administration of dex to mice in vivo influenced: 
 
• bleeding time 
• the activation status of platelets 
• the activity of the coagulation cascade 







Male C57Bl/6 mice (Harlan Olac, UK) aged 10-14 weeks and weighing 26-34 grams 
were used in this study.  
5.3.2. Administration of drug 
Mice were randomised to receive either dex (0.1 or 0.8mg/kg/day; section 2.2.3.1) or 
vehicle in their drinking water for 5 weeks (Figure 5.1).  
5.3.3. Blood pressure measurements 
All mice had their systolic blood pressure monitored using tail cuff plethysmography 
(Pollock et al., 1993) (section 2.2.4) at days 14, 21 and 28 following commencement 
of treatment. 
5.3.4. Tissue collection 
At the end of the 5-week experimental period the mice were anaesthetised by 
isoflurane inhalation before their tail bleeding time was assessed as described 
(Schwer et al., 2001) (section 2.2.5). Blood was then collected from the vena cava 
into 3.8% sodium citrate and centrifuged (120 x g, 5 min, RT) to separate platelet 
rich plasma (PRP), for immediate flow cytometric analysis. The remaining PRP was 
centrifuged (10,000 x g, 1 min, RT) to gain platelet poor plasma (PPP), which was 
snap frozen and stored at -80ºC. After collection and weighing, a lobe of the liver, 
the left kidney, adrenal glands and femoral arteries were fixed in 10% neutral 
buffered formalin for 24 hours before being transferred to 70% ethanol. The 
remainder of the liver, the heart, aorta, lungs, right kidney, spleen and thymus were 
snap frozen and stored at -80°C. 
5.3.5. Assessment of platelet activation 
The activation status of the platelets was assessed using flow cytometry (section 
2.5.4). Briefly, the platelets were stained with a generic platelet marker (anti-CD41 




















































































































































































































































































































































considered. The platelets were also stained with a marker for p-selectin (anti-CD62P 
conjugated to FITC) (Braun et al., 2008). A positive control for platelet activation 
was also prepared using 10μM ADP to activate the platelets ex vivo (Cornelissen et 
al., 2010). During flow cytometry acquisition, platelets were gated by their forward 
scatter (FSC) and side scatter (SSC) characteristics and further identified by the 
expression of CD41. Activated platelets were identified by the expression of p-
selectin (CD62P) on their surface and quantified using the geometric mean 
fluorescence intensity (section 2.5.4).  
5.3.6. Assessment of mRNA levels 
Total RNA was extracted from the liver, lung and heart, and reverse transcribed to 
cDNA using reverse transcription polymerase chain reaction (RT-PCR). Total cDNA 
then underwent quantitative real-time PCR (qPCR) to assess mRNA abundance of 
specific clotting factor and fibrinolytic factor genes. Factor VIII (FVIII), von 
Willebrand factor (vWF), plasminogen, plasminogen activator inhibitor-1 (PAI-1) 
and tissue plasminogen activator (tPA) mRNA levels were assessed relative to 
reference genes (cyclophilin, β-actin, TATA-binding protein (TBP) and 18s) (section 
2.6.2). 
5.3.7. Measurement of plasma fibrinolytic factors 
Plasma concentrations of total PAI-1 protein, active PAI-1 protein, total tPA protein 
and active tPA protein were quantified using ELISA kits with defrosted PPP 
collected from the vena cava (section 2.5.3). 
5.3.8. Statistics 
All statistical analysis was performed by one-way ANOVA with Dunnett’s post-hoc 
test for comparison of treatment groups with the vehicle-treated group. Statistical 






There was no significant difference in body weights at the start of the study (Figure 
5.2A). Dex administration caused a dose-dependent reduction in body weight (low 
and high dose dex p<0.01; Figure 5.2B). The average dex intake was 
0.13±0.009mg/kg/day (low dose) and 0.82±0.02mg/kg/day (high dose). 
5.4.2. Organ weights 
Dex administration dose-dependently reduced both thymus weight (low dex: p<0.05, 
high dex: p<0.01; Figure 5.3A) and spleen weight (low and high dose dex: p<0.01; 
Figure 5.3B). High dex also increased liver weight compared with the vehicle-treated 
animals (p<0.05; Figure 5.3C). This effect was not seen at the low dose. There were 
no significant differences seen in the other organs collected (heart and kidneys; 
Figure 5.4). 
5.4.3. Systolic blood pressure 
The vehicle-treated animals showed no significant changes in systolic blood pressure 
between day 14 and day 28 of the experimental period, maintaining a pressure of 
around 125mmHg (Figure 5.5). Conversely, dex caused a dose-dependent increase in 
blood pressure with the high dose causing a significant increase (to 150mmHg) by 
day 14 (p<0.01). The low dose dex had no influence on blood pressure at day 14 but 
did cause a significant increase (to 140mmHg) by day 21 (p<0.05; Figure 5.5). 
5.4.4. Tail‐tip bleeding time 
Dex dose-dependently reduced tail-tip bleeding time with the high dose reaching 
significance (p<0.05; Figure 5.6).  
5.4.5. Platelet activation status 
Neither low nor high dose dex influenced p-selectin expression on platelets (Figure 
5.7). The p-selectin expression in the three test groups was 4-fold lower than the 








Figure 5.2: Weight changes induced by dexamethasone treatment.  
Mice were randomised to receive either vehicle or dexamethasone (dex; 0.1 or 0.8mg/kg/day) in 
their drinking water. Body weight was measured regularly throughout the 5-week experimental 
period. There were no differences in the weights of the animals at the start of the experiment (A). 
Dex treatment appeared to dose-dependently reduce body weight. Analysis of change in body 
weight from start to end of the experimental period confirmed that dex treatment caused a dose-
dependent reduction in body weight in comparison to the vehicle group (B). All data expressed as 
mean±SEM, n=6-7. Weight change was analysed by one way ANOVA with Dunnett’s post hoc 








Mice were randomised to receive either vehicle or dexamethasone (dex; 0.1 or 0.8mg/kg/day) in 
their drinking water. Organs were weighed upon sacrifice. Dex treatment caused a dose-
dependent reduction in both thymus (A) and spleen (B) weight. The high dose dex also increased 
liver weight (C).  All data expressed as mean±SEM, n=6-7. Data were analysed by one way 
ANOVA with Dunnett’s post hoc test vs vehicle. *p<0.05, **p<0.01. 








Figure 5.4: Organ weight changes induced by dexamethasone treatment. 
Mice were randomised to receive either vehicle or dexamethasone (dex; 0.1 or 0.8mg/kg/day) in 
their drinking water. Organs were weighed upon sacrifice. Dex had no influence on heart or 
kidney weight. All data expressed as mean±SEM, n=6-7. Data were analysed by one way 










































Figure 5.5: The impact of exogenous glucocorticoids on systolic blood pressure. 
Mice were randomised to receive either vehicle or dexamethasone (dex; 0.1 or 0.8mg/kg/day) in 
their drinking water. Systolic blood pressure was measured weekly from day 14 by tail cuff 
plethysmography. Dex dose-dependently increased systolic blood pressure with the high dose 
significantly increasing blood pressure above vehicle by day 14 and the low dose by day 21. Data 
expressed as mean±SEM, n=6-7. Data were analysed by two-way ANOVA with Bonferroni post 










Figure 5.6: The impact of exogenous glucocorticoids on tail-tip bleeding. 
Mice were randomised to receive either vehicle or dexamethasone (dex; 0.1 or 0.8mg/kg/day) in 
their drinking water. Tail-tip bleeding time was measured under anaesthesia at the end of the 5-
week experimental period. The low dose of dex had no significant effect, whereas the high dose 
significantly reduced the bleeding time of the mice. Data expressed as mean±SEM, n=6-7. Data 









Figure 5.7: The impact of dexamethasone treatment on platelet activation status. 
Mice were randomised to receive either vehicle or dexamethasone (dex; 0.1 or 0.8mg/kg/day) in 
their drinking water. Platelet activation status was assessed by flow cytometric analysis of p-
selectin expression. Platelets were gated by FSC/SSC characteristics and further identified by 
their expression of the platelet specific antigen CD41. Platelet activation was identified by their 
expression of p-selectin (CD62P; A) and quantification of the geometric mean fluorescence 
intensity (GMFI; B). Neither dose of dex influenced the p-selectin expression on platelets. 10μM 
ADP was used as a positive control for activated platelets. Data expressed as mean±SEM, n=5-6, 






Low dose dex reduced mRNA levels of FVIII in the lung (p<0.05) and heart 
(p<0.05), but not in the liver (Figure 5.8A). The high dose of dex had no significant 
effect in any tissue (Figure 5.8A). 
5.4.6.2 vWF 
Neither dose of dex affected mRNA levels of vWF in the liver and heart. It is worth 
noting that the abundace of vWF in the liver was particularly low in all three groups, 
thus making changes difficult to observe. There was, however, a dose-dependent 
reduction in vWF mRNA levels in the lung with the response to the high dose 
reaching significance (p<0.01; Figure 5.8B). 
5.4.7. Fibrinolytic factor gene expression 
5.4.7.1 Plasminogen 
Plasminogen gene expression was too low to be detected by qPCR in the heart or 
lung. In the liver, low dose dex significantly increased plasminogen mRNA levels 
(p<0.05; Figure 5.9A). This increase was not seen with the high dose. 
5.4.7.2 PAI‐1 
PAI-1 mRNA levels were too low to be detected in the liver. In the lung, neither dose 
of dex affected the mRNA levels, while in the heart the high dose only increased 
PAI-1 gene expression (p<0.05; Figure 5.9B). 
5.4.7.3 tPA 
tPA gene expression was too low to be detected in the liver. In the lung, dex 
treatment caused a dose-dependent increase in tPA mRNA levels with the high dose 
reaching significance (p<0.05; Figure 5.9C). Interestingly in the heart, dex treatment 
caused a dose-dependent decrease in tPA mRNA levels, with the high dose reaching 












































Figure 5.8: The impact of dexamethasone treatment on mRNA abundance of coagulation 
tor genes.  
ndomised to receive either vehicle or dexamethasone (dex; 0.1 or 0.8mg/kg/day) in 
their drinking water. Organs were collected and the mRNA levels of coagulation factor genes were 
assessed by qPCR relative to reference genes; β-actin (lung), TBP (TATA box-binding protein), 
cyclophilin and 18s (heart) and TBP, cyclophillin and β-actin (liver). Low dex treatment reduced 
mRNA levels of Factor VIII in the lung and heart but not in the liver, whereas, high dex had no 
significant effect on Factor VIII expression in any organ (A). Neither dose of dex affected mRNA 
levels of vWF in the liver or heart (B). However, there was a dose-dependent reduction in vWF 
mRNA levels in the lung, with the response to high dose dex reaching significance (B). Data 
expressed as mean±SEM, n=6-7. Data were analysed by one-way ANOVA with Dunnett’s post 












Figure 5.9: The impact of dexamethasone treatment on mRNA abundance of fibrinolysis 
factor genes.  
Mice were randomised to receive either vehicle or dexamethasone (dex; 0.1 or 0.8mg/kg/day) in 
their drinking water. Organs were collected and the mRNA levels of fibrinolysis factor genes 
were assessed by qPCR relative to reference genes; β-actin (lung), TBP (TATA box-binding 
protein), cyclophillin and 18s (heart) and TBP, cyclophillin and β-actin (liver). Low dex only 
increased mRNA levels of plasminogen in the liver (A). Neither dose of dex affected mRNA 
levels of PAI-1 in the lung while the high dose only increased levels in the heart (B). There was a 
dose-dependent increase in tPA mRNA levels in the lung and a dose-dependent decrease in levels 
in the heart (C). Data expressed as mean±SEM, n=6-7. Data were analysed by one-way ANOVA 
with Dunnett’s post hoc test vs vehicle. *p<0.05. PAI-1: plasminogen activator inhibitor-1, tPA: 





Plasma levels of total PAI-1 antigen and active PAI-1 antigen were both unaffected 
by low dose dex. However, the high dose dex increased the total PAI-1 antigen 3.5 
fold (p<0.001; Figure 5.10A) and the active PAI-1 antigen 3 fold (p<0.001; Figure 
5.10B). 
5.4.8.2 tPA 
Plasma levels of total tPA antigen and active tPA antigen were both unaffected by 
high dose dex. Interestingly, the low dose dex increased the active tPA antigen 
almost 2 fold (p<0.05; Figure 5.11B), while having no significant influence on the 










Figure 5.10: The impact of dexamethasone treatment on PAI-1 antigen levels in the plasma.  
Mice were randomised to receive either vehicle or dexamethasone (dex; 0.1 or 0.8mg/kg/day) in 
their drinking water. Total PAI-1 and active PAI-1 antigen levels were measured in the plasma by 
ELISA. Low dex had no influence on either total PAI-1 or active PAI-1 antigen levels. High dex 
greatly increased both total PAI-1 (A) and active PAI-1 (B) antigen levels in the plasma. Data 
expressed as mean±SEM, n=6-7. Data were analysed by one-way ANOVA with Dunnett’s post 













Figure 5.11: The impact of dexamethasone treatment on tPA antigen levels in the plasma.  
Mice were randomised to receive either vehicle or dexamethasone (dex; 0.1 or 0.8mg/kg/day) in 
their drinking water. Total tPA and active tPA antigen levels were measured in the plasma by 
ELISA. Neither dose of dex had any influence on the total tPA antigen levels (A). Low dose dex 
greatly increased both active tPA antigen levels (B) but this increase was not seen with the high 
dose. Data expressed as mean±SEM, n=6-7. Data were analysed by one-way ANOVA with 




The work described in this chapter addresses the hypothesis that high dose dex is 
pro-thrombotic. The results obtained suggest that high dose dex does indeed induce a 
systemic pro-thrombotic state, possibly as a result of increased PAI-1 activity. The 
low dose dex had no effect of thrombogenicity. 
 
Consistent with the previous investigation (Chapter 4), the dose-dependent weight 
loss and reduction in size of glucocorticoid-sensitive organs confirms that both doses 
of dex were pharmacologically active in the animals. The high dose dex also induced 
a small increase in liver weight. Hepatomegaly could be indicative of liver steatosis, 
the retention of lipid in the liver, which has been shown to be induced by 
glucocorticoid excess, both in humans (Farrell, 2002; Stravitz et al., 2003) and in 
rodents (Letteron et al., 1997; Pinheiro et al., 2009; Severino et al., 2002). 
 
It is well documented that glucocorticoids induce hypertension in rodents (Goodwin 
et al., 2008; Whitworth et al., 2001; Zhang et al., 2004). Blood pressure was not 
measured in the previous study (Chapter 4) to prevent any additional stress to the 
animals, which may have influenced neointimal proliferation. The study described in 
this chapter, therefore, provided an opportunity to confirm the effect of dex on blood 
pressure in a similar experimental protocol. The results confirm a dose-dependent 
increase in systolic blood pressure following dex administration. Traditionally, 
glucocorticoids have been believed to induce hypertension by MR activation in the 
kidney. However, along with the selectivity of dex for GR, there is growing evidence 
that this is not the primary mechanism underlying this form of hypertension 
(Goodwin et al., 2010). It has been suggested that disruption of the endothelial nitric 
oxide system is involved in glucocorticoid-induced hypertension (Whitworth et al., 
2001), but the precise mechanism remains incompletely understood. 
 
A crucial finding from this investigation is the dose-dependent reduction in tail-tip 
bleeding times in mice treated with dex. Tail-tip bleeding time is a well-established, 
albeit relatively crude, method of assessing platelet function and coagulation enzyme 
defects (Lavelle et al., 1998). For example, bleeding time is significantly increased in 
176 
 
mice administered aspirin (Yamamoto et al., 2009) and mice deficient in Factor VIII 
(Lauer et al., 2002). In the current investigation, reduced bleeding time indicates a 
systemic pro-thrombotic state in these mice, as a result of their high dose 
glucocorticoid treatment. This supports previous evidence that glucocorticoids 
increase the thrombogenicity of blood in patients and animals (Patrassi et al., 1992; 
van Giezen et al., 1994). A pro-thrombotic state could be produced via a number of 
mechanisms including those involving platelets, the endothelium and/or clotting 
factors. As tail-tip bleeding time cannot distinguish between these mechanisms, 
further explorations were carried out in order to clarify which are involved in 
glucocorticoid-mediated pro-thrombotic state. 
 
Glucocorticoids have mixed effects on platelet activation and aggregation. van 
Giezen et al showed that dex inhibits platelet aggregation in rats, thus suggesting an 
anti-coagulant outcome (van Giezen et al., 1994; van Giezen et al., 1992). 
Conversely, methylprednisolone has successfully been used clinically to reverse 
clopidogrel-related inhibition of platelet aggregation (Qureshi et al., 2008) and dex 
has been shown to block inhibition of platelet aggregation by activated macrophages 
in vitro (Pinto et al., 1993); both these studies indicate a pro-coagulant capability of 
glucocorticoids. Direct assessment of platelet aggregation (using aggregometry) was 
considered impractical due to the low volume of plasma obtained from individual 
mice. As an alternative, platelet involvement was assessed using flow cytometry to 
investigate the activation status of platelets isolated from these mice. Expression of 
the adhesion molecule p-selectin (which is stimulated following activation) on the 
surface of platelets was used as a marker of platelet activation (Griesshammer et al., 
1999). Using this assay, dex administration had no influence on the activation status 
of circulating platelets. When compared with the control platelets, which were fully 
activated with ADP ex vivo, the number of platelets expressing p-selectin was 4-fold 
lower in all three test groups. Also, this method investigated the effects of 
glucocorticoid administration on “resting” platelet activation and not did not explore 
changes that glucocorticoid treatment may have had on the potential for platelets to 
activate. It would, therefore, be very interesting to pre-treat platelets with 
glucocorticoids in vivo and then assess their activation with agonists in vitro.  
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Investigation into the influence of dex on coagulation and fibrinolysis factor gene 
transcription did not reveal any striking changes which could explain the pro-
thrombotic effect of the steroid. However, PAI-1 stood out due to the considerable 
increase in both the total and active circulating protein levels in response to high 
dose dex. Not only does this complement the dose-dependent increase in PAI-1 gene 
expression in the heart by dex, but it also complements many other in vitro, animal 
and clinical studies which have described a significant increase in total and active 
PAI-1 antigen levels with glucocorticoid treatment/excess (Ma et al., 2002; Patrassi 
et al., 1992; Sartori et al., 1999; van Giezen et al., 1994). An increase in PAI-1 
protein strongly implies there is decreased fibrinolytic potential, which would likely 
contribute towards the pro-thrombotic state that we see in the high dose dex-treated 
mice. It is important to note that there was no increase in total or active PAI-1 protein 
in the low-dose group.  
 
The influence of glucocorticoids on total tPA and active tPA protein levels are less 
clear. In vitro studies have concluded that dex administration increases tPA antigen 
in rat lymphocytes (Tsantarliotou et al., 1999) and HUVEC culture medium (Huang 
et al., 1995). However, clinical studies have reported inconsistent results, with 
Cushing’s patients and healthy subjects receiving glucocorticoids having either 
increased (de Kruif et al., 2007; Patrassi et al., 1992) or unchanged tPA levels 
(Ambrosi et al., 2000; Dover et al., 2007). Thus the results from this study, 
describing no influence on total tPA levels by dex, support the latter clinical studies. 
However, the low dose dex did increased active tPA protein in the blood. This effect 
was not seen at the high dose. Perhaps dex induces an increase in tPA activity which 
is appreciable at the low dose but is inhibited by elevated PAI-1 levels at the high 
dose. However, the functional relevance of this dex-induced increase in tPA is 
unclear, as the low dose of dex had no influence on bleeding time. 
 
In summary, the results from this investigation support the hypothesis that high dose 
dex is pro-thrombotic, while low dose dex had no influence on thrombogenicity, in 
this murine model.  These results may explain the thrombotic lesions observed 
following arterial injury in high-dose dex-treated mice. It is proposed that this effect 
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is in part accounted for by a decrease in the activity of the endogenous fibrinolytic 
pathway, attributable to an increase in PAI-1. This hypothesis can be addressed by 
investigating the effects of genetic deletion of PAI-1 on dex-induced changes in 






















The work described in the previous chapters suggests that elevated PAI-1 may be in 
part responsible for the effects of high dose dex on neointimal proliferation. Elevated 
PAI-1 levels would be expected to attenuate the endogenous fibrinolysis system, 
inhibiting the breakdown of thrombus by downstream plasmin and, therefore, may 
explain the increased presence of large semi-occlusive thrombi at the site of intra-
arterial wire injury in high dose dex-treated mice. Indeed, PAI-1 has been implicated 
in acute coronary thrombosis, with elevated PAI-1 levels in patients with coronary 
artery disease, angina pectoris and recurrent myocardial infarction (Carmeliet et al., 
1993b). 
 
However, a number of groups have reported evidence that PAI-1 itself is an 
important mediator of intimal hyperplasia in mice, albeit with discordant results. 
Some report that genetic deletion or pharmacological inhibition of PAI-1 decreases 
lesion development (Peng et al., 2002; Ploplis et al., 2001; Suzuki et al., 2008; Zhu 
et al., 2001), while others disagree, concluding that PAI-1-/- mice have increased 
lesion development (Carmeliet et al., 1997b; de Waard et al., 2002; Schafer et al., 
2006). Several different models of vascular injury were employed in these studies, 
including chemical injury, mechanical injury and electrical injury, which may be 
contributing to the variable results. Clearly, the exact role of the fibrinolytic system 
in vascular remodelling remains to be elucidated. Indeed, evidence from the clinic 
regarding the role of PAI-1 in restenosis is also conflicting: some studies found that 
elevated plasma PAI-1 levels were associated with increased risk of restenosis 
(Fornitz et al., 2001; Huber et al., 1992; Prisco et al., 2001; Sakata et al., 1996), 
while others reported a reduced risk of restenosis (Inoue et al., 2003; Shah et al., 
1992; Strauss et al., 1999). 
 
In order to further elucidate the role of PAI-1 in neointimal proliferation and to test 
the hypothesis that PAI-1 is responsible for dex-mediated thrombosis following 
arterial injury, PAI-1 must be manipulated. The most obvious approach would be to 
reduce PAI-1 activity, by either genetic deletion of the Serpine1 gene, resulting in 
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PAI-1-/- mice (Carmeliet et al., 1993a; Carmeliet et al., 1993b), or by use of the 
pharmacological inhibitor of PAI-1, tiplaxtinin (Elokdah et al., 2004). Both 
approaches have their advantages and disadvantages. Genetic deletion of PAI-1 
ensures an absence of circulating PAI-1 but may result in developmental 
abnormalities which could influence the outcome of the study. Pharmacological 
inhibition of PAI-1 by tiplaxtinin allows short-term manipulation of PAI-1 in parallel 
with dex treatment. However, it would require optimisation of dosage and 
administration regime, in addition to the risk of potential adverse side-effects. As the 
vast majority of studies investigating the role of PAI-1 in intimal hyperplasia use 
genetically-deficient mice, this was the approach chosen for this study. Reports on 
the characterisation of PAI-1-/- mice revealed that they develop normally, with a mild 








The work described in this chapter addresses the hypothesis that increased PAI-1 
activity is responsible for dex-mediated thrombosis following vascular injury. It is, 
therefore, proposed that genetic deletion of PAI-1 prevents the thrombotic side 
effects of dex, while maintaining the anti-restenotic effects of steroid treatment. In 
order to address this hypothesis, the specific aims of the work described in this 
chapter were to: 
 
• determine the role of PAI-1 in neointimal proliferation following intra-
luminal wire injury in mice. 
• determine whether genetic deletion of PAI-1 prevented dex-mediated 





Male C57Bl/6 mice (Harlan Olac, UK) and PAI-1-/- (C57Bl/6 background; The 
Jackson Laboratory, ME, USA) aged 19-21 weeks and weighing 26-34 grams were 
used in this study. It is important to note that these animals are not littermates. 
6.3.2. Administration of drugs 
All mice were randomised to receive either dexamethasone (dex; 0.8mg/kg/day) or 
vehicle (absolute ethanol) in their drinking water for 4 weeks (Figure 6.1).  
6.3.3. Femoral artery injury 
One week after commencement of drinking water treatments, the mice were 
subjected to unilateral femoral artery injury to induce neointimal hyperplasia (section 
2.2.2).  
6.3.4. Blood pressure measurements 
All mice had their systolic blood pressure monitored with measurements acquired 
using tail cuff plethysmography (section 2.2.4) at weekly intervals following 
commencement of drinking water treatment. 
6.3.5. Tissue collection 
At the end of the 4-week study the mice were anaesthetised by isoflurane inhalation 
before their tail bleeding time was assessed (section 2.2.5). Blood was immediately 
collected by cardiac puncture into 3.8% sodium citrate (1:9) and spun (8,000 x g, 10 
min, RT) and the plasma (supernatant) was snap frozen and stored at -80ºC. The 
mice were then perfusion fixed (section 2.2.6). Organs and femoral arteries were 
collected and stored as described previously (section 3.3.4). 
6.3.6. Measurement of plasma fibrinolytic factors 
Plasma concentrations of total PAI-1 protein, active PAI-1 protein, total tPA protein 

















































































































































































































































































































































































































Firstly, the femoral arteries were embedded in agarose for analysis by OPT (section 
2.3.2). Briefly, after being dehydrated in methanol for 24 hours and cleared in BABB 
for a further 24 hours, the arteries were scanned under UV light using a Bioptonics 
OPT tomograph. Computed tomography reconstructions were calculated by filtered 
back-projection of raw data using NRecon software. Volumetric measurements of the 
femoral artery were acquired by manual tracing of the estimated outline of the plaque 
and lumen using CTan software. 
6.3.7.2 Histology 
Following acquisition of OPT scans, the femoral arteries were processed, embedded 
in paraffin and cut into 4µm thick transverse sections. Sets of twenty serial sections 
(80μm) were collected every 160μm along the entire artery. One section every 
160μm along the artery were stained with United States trichrome stain (section 
2.4.2). Photomicrographs were taken using a light microscope coupled to a colour 
camera and image analysis system (section 2.4.4). The area (μm2) of lesion in each 
section was measured using Photoshop CS3 software (section 2.4.5). The section 
with the largest area of lesion was chosen to represent each arterial sample.  
6.3.7.3 Composition 
The cellular composition of the neointimal lesions was initially investigated using the 
United States trichrome-stained sections. Further immunohistochemical analysis was 
carried out on the section of the artery adjacent to the section identified as having the 
largest lesion. Smooth muscle cell content was assessed using an alkaline-
phosphatase conjugated monoclonal primary antibody against smooth muscle cell α-
actin (section 2.4.7.2).  
6.3.8. Statistics 
All statistical analysis was performed by two-way ANOVA with Bonferroni’s post-
hoc test to assess the effect of dex administration and the effect of PAI-1 deficiency, 
and any interaction between them. Statistical analysis of all data was performed 





There were no differences in the weights of the animals at the start of the experiment. 
Animals in all 4 groups showed a weight loss following wire injury surgery (Figure 
6.2A). Vehicle-treated PAI-1-/- mice appeared to recover fully by the end of the 
experimental period, while the C57Bl/6 mice maintained their post-surgery weight 
(p<0.01; Figure 6.2B), comparable with the previous study using C57Bl/6 mice 
(section 4.4.1). Dex administration caused a reduction in weight over the 4-week 
period in both C57Bl/6 mice (p<0.01) and PAI-1-/- mice (p<0.001; Figure 6.2B). The 
average doses of dex received were 0.84±0.02mg/kg/day (C57Bl/6 mice) and 
0.84±0.03mg/kg/day (PAI-1-/- mice). 
6.4.2. Organ weights 
Genetic deletion of PAI-1 had no effect on any organ weight in vehicle-treated mice. 
In both C57Bl/6 and PAI-1-/- mice, dex induced a significant reduction in spleen 
weight (p<0.001 and p<0.05, respectively; Figure 6.3A) and thymus weight (both 
p<0.001; Figure 6.3B). There were no significant changes in the other organs 
collected (liver, kidneys, adrenals and heart; data not shown). 
6.4.3. Systolic blood pressure  
Vehicle-treated C57Bl6 and PAI-1-/- mice maintained steady blood pressures of 
around 110-115mmHg throughout the study, with no significant differences between 
the genotypes (Figure 6.4). Dex administration increased blood pressure from week 1 
in both genotypes, reaching significance by week 2 (both p<0.001). By week 4 all 
dex-treated animals had a blood pressure of around 140mmHg (Figure 6.4). 
6.4.4. Tail‐tip bleeding time 
Genetic deletion of PAI-1 had no effect on bleeding time in vehicle-treated mice. As 
previously reported in Chapter 4 (section 4.4.5.2), dex administration significantly 
reduced tail-tip bleeding time in C57Bl/6 mice (p<0.01; Figure 6.5). However, this 
reduction by dex was lost in the PAI-1-/- mice (p>0.05), but there was no significant 










































Figure 6.2: Weight changes induced by genotype and dexamethasone treatment.  
C57Bl/6 and PAI-1-/- mice were randomised to receive either vehicle or dexamethasone (dex; 
0.8mg/kg/day) in their drinking water. Neointimal hyperplasia was induced by femoral artery 
wire-injury (FAI). (A) Body weight was measured periodically throughout the 4-week 
experimental period.  There were no differences in the weights of the animals at the start of the 
experiment. All animals showed a weight loss after the femoral artery injury surgery. (B) Change 
in body weight from start to end of the experimental period was also calculated. Vehicle-treated 
PAI-1-/- mice appeared to recover better from post-surgery weight loss than C57Bl/6 mice, whilst 
dex treatment caused a reduction in body weight in both genotypes. All data expressed as 
mean±SEM, n=6-8. Weight change analysed by two way ANOVA with Bonferroni post hoc test. 
** p<0.01, ***p<0.001. CV: C57Bl/6 on vehicle, CD: C57Bl/6 on dex, PV: PAI-1-/- on vehicle, 











































Figure 6.3: Organ weight changes induced by dexamethasone treatment. 
C57Bl/6 and PAI-1-/- mice were randomised to receive either vehicle or dexamethasone (dex; 
0.8mg/kg/day) in their drinking water. Neointimal hyperplasia was induced by femoral artery 
wire-injury. Organs were weighed upon sacrifice. Genotype had no influence on organ weight, 
whilst dex treatment caused a reduction in both spleen (A) and thymus (B) weight. All data 
ressed as mean±SEM, n=6-8. Data were analysed by two way ANOVA with Bonferroni post 

















Figure 6.4: Systolic blood pressure changes induced by dexamethasone treatment.  
C57Bl/6 and PAI-1-/- mice were randomised to receive either vehicle or dexamethasone (dex; 
0.8mg/kg/day) in their drinking water. Neointimal hyperplasia was induced by femoral artery 
wire-injury (FAI). Systolic blood pressure was measured weekly by tail cuff plethysmography. 
Dex treatment significantly increased systolic blood pressure by day 14, in both genotypes. Data 
expressed as mean±SEM, n=5-8. Data were analysed by two way ANOVA with Bonferroni post 
hoc test. ***p<0.001 vs CV, ººp<0.01 vs PV, ºººp<0.001 vs PV. CV: C57Bl/6 on vehicle, CD: 














Figure 6.5: The impact of PAI-1 and dexamethasone treatment on tail-tip bleeding. 
C57Bl/6 and PAI-1-/- mice were randomised to receive either vehicle or dexamethasone (dex; 
0.8mg/kg/day) in their drinking water. Neointimal hyperplasia was induced by femoral artery 
wire-injury. Tail-tip bleeding time was measured under anaesthesia at the end of the 4-week 
experimental period. Tail tip bleeding time was not affected by genetic deletion of PAI-1 in 
vehicle treated animals. However, dex treatment significantly reduced the bleeding time in the 
C57Bl/6 mice only. Data expressed as mean±SEM, n=5-8. Data were analysed by two way 






Dex administration significantly increased circulating total (p<0.001; Figure 6.6A) 
and active (p<0.001; Figure 6.6B) PAI-1 levels in C57Bl/6 mice. No PAI-1 antigen 
was detected in PAI-1-/- mice. 
6.4.5.2 tPA 
Neither genetic deletion of PAI-1 nor dex administration had any significant effect 
on circulating total tPA levels (Figure 6.7). Unfortunately, the active tPA assay did 
not produce conclusive results as the data was very noisy. This is thought to be due 
to too many freeze-thaw episodes. 
6.4.6. Neointimal lesion development 
6.4.6.1 Neointima quantification by OPT 
There were no differences, in any of the lesion or lumen parameters analysed, 
between the vehicle-treated C57Bl/6 and PAI-1-/- mice. Dex administration reduced 
absolute neointimal lesion volume, in both C57Bl/6 mice and PAI-1-/- mice (both 
p<0.05; Figure 6.8A). Interestingly, in the C57Bl/6 mice only, dex also reduced the 
total volume inside the internal elastic lamina (IEL; p<0.05; Figure 6.8B). 
Consequently, the volumetric stenotic ratio was unaffected by dex (Figure 6.8C). 
Conversely, dex had no effect on the total volume inside the IEL in PAI-1-/- mice 
(Figure 6.8B). Thus, lesion size was still reduced by dex when expressed as 
volumetric stenotic ratio (p<0.05; Figure 6.8C).  
 
Dex administration significantly reduced the maximum cross-sectional area of lesion 
in the C57Bl/6 mice (p<0.05; Figure 6.9A), but not in the PAI-1-/- mice. This effect 
was lost when the lesion size was calculated as stenotic ratio (Figure 6.9B), as a 
result of dex treatment also reducing the area inside the IEL in the C57Bl/6 mice 
(Table 6.1(b)). Analysis of the cross-sectional profiles of the lesions revealed that 
dex treatment reduced lesion development consistently along the length of the artery, 












































Figure 6.6: The impact of dexamethasone treatment on PAI-1 antigen levels in the plasma.  
C57Bl/6 and PAI-1-/- mice were randomised to receive either vehicle or dexamethasone (dex; 
0.8mg/kg/day) in their drinking water. Neointimal hyperplasia was induced by femoral artery 
njury. Total PAI-1 and active PAI-1 antigen levels were measured in the plasma by ELISA. 
Dex treatment greatly increased both total PAI-1 (A) and active PAI-1 (B) antigen levels in the 
plasma of C57Bl/6 mice. No PAI-1 antigen was detected in the plasma of PAI-1-/- mice. Data 
expressed as mean±SEM, n=6-8. Data were analysed by two way ANOVA with Bonferroni post 










levels in the plasma.  
C57Bl/6 and PAI-1-/- mice were randomised to receive either vehicle or dexamethasone (dex; 
0.8mg/kg/day) in their drinking water. Neointimal hyperplasia was induced by femoral artery 
wire-injury. Total tPA antigen levels were measured in the plasma by ELISA. Genetic deletion of 
PAI-1 had no effect on tPA levels. In addition, dex treatment had no significant effect on tPA 
antigen level in either genotype. Data expressed as mean±SEM, n=6-8. Data were analysed by 
two way ANOVA with Bonferroni post hoc test.  
 








































Figure 6.8: Impact of PAI-1 and dexamethasone treatment on neointimal lesion volume, as 
assessed by optical projection tomography (OPT). 
C57Bl/6 and PAI-1-/- mice were randomised to receive either vehicle or dexamethasone (dex; 
0.8mg/kg/day) in their drinking water. Neointimal hyperplasia was induced by femoral artery 
wire-injury, before isolation and OPT scanning. Lesion and lumen volumes were quantified from 
reconstructed tomograms and expressed as absolute volume (A and B, respectively) and as the 
volumetric stenotic ratio; plaque volume as proportion of volume inside internal elastic lamina 
(IEL; C). Dex treatment significantly reduced absolute lesion volume in both genotypes (A). Dex 
also increased the area inside the IEL in C57Bl/6 mice (B). Therefore, dex treatment reduced the 
volumetric stenotic ratio only in the PAI-1-/- mice (C). All data expressed as mean±SEM, n=6-8. 



















Figure 6.9: Impact of PAI-1 and dexamethasone treatment on neointimal cross-sectional 
area, as assessed by optical projection tomography (OPT). 
C57Bl/6 and PAI-1-/- mice were randomised to receive either vehicle or dexamethasone (dex; 
0.8mg/kg/day) in their drinking water. Neointimal hyperplasia was induced by femoral artery 
wire-injury, before isolation and OPT scanning. Lesion and lumen cross-sectional areas were 
quantified from reconstructed tomograms. Dex treatment reduced the absolute maximum cross-
sectional area of the lesion only in the C57Bl/6 mice (A). This effect was lost when lesion size 
was expressed as stenotic ratio (B). Analysis of the cross-sectional profiles revealed that dex 
treatment reduced lesion development consistently along the length of the artery, in both 
genotypes (C). All data are expressed as mean±SEM, n=6-8. A and B were analysed by two way 
ANOVA with Bonferroni post hoc test. *p<0.05. CV: C57Bl/6 on vehicle, CD: C57Bl/6 on dex, 
PV: PAI-1-/- on vehicle  PD: PAI-1-/- on dex.,
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n   8  7  6  6 
         
(a) 3D Morphometry (OPT)         
Lesion volume (x107μm3)   4.1 ± 0.8º 8.9 ± 1.5  4.5 ± 1.0*  8.8 ± 0.9 
Luminal volume (x107μm3)   14.7 ± 1.4  14.2 ± 0.8  11.4 ± 1.2  14.6 ± 1.7 
Volume inside IEL (x107μm3)  23.5 ± 1.7  18.8 ± 1.3*  20.3 ± 1.4  18.7 ± 1.7 
0.23 ± 0.05º Volumetric stenotic ratio   0.37 ± 0.05  0.24 ± 0.04  0.44 ± 0.05 
         
(b) 2D Morphometry (OPT)         
Lesion area (x104μm2)   5.3 ± 0.6   3.4 ± 0.6*  5.3 ± 0.3  4.7 ± 0.5 
Luminal area (x104μm2)   2.5 ± 0.7  1.6 ± 0.6  1.2 ± 0.8  1.1 ± 0.5 
Area inside IEL (x104μm2)   7.8 ± 0.8  5.1 ± 0.3**  6.5 ± 0.6  5.9 ± 0.3 
Stenotic ratio   0.70 ± 0.06  0.68 ± 0.11  0.85 ± 0.08  0.81 ± 0.08 
         
(c) 2D Morphometry (Histology)         
Neointimal area (x104μm2)   1.3 ± 0.5º 3.1 ± 0.5  1.5 ± 0.4*  3.3 ± 0.3 
Medial area (x104μm2)   1.2 ± 0.2  1.0 ± 0.1  1.5 ± 0.3  0.9 ± 0.2 
Intima/Media ratio   2.6 ± 0.7  1.8 ± 0.4  2.8 ± 0.2  3.2 ± 1.5 
Luminal area (x104μm2)   3.1 ± 0.6  3.4 ± 0.3  1.9 ± 0.7  4.2 ± 1.3 
Area inside IEL (x104μm2)   6.1 ± 0.3  4.9 ± 0.3  5.2 ± 0.5  5.4 ± 1.1 
0.37 ± 0.13º Stenotic ratio   0.50 ± 0.08  0.30 ± 0.06  0.72 ± 0.09 




1.9 ± 1.5ººº Smooth Muscle α‐actin (%)   51.9 ± 5.2  0.7 ± 0.3***  53.6 ± 7.2 
             
 
C57Bl/6 and PAI-1-/- mice were randomised to receive either vehicle or dexamethasone (dex; 
0.8mg/kg/day) in their drinking water. Neointimal hyperplasia was induced by femoral artery 
wire-injury, before isolation and examination of the left femoral artery by optical projection 
tomography (a and b), histology (c) and immunohistochemistry (d). Dex administration reduced 
absolute lesion size, as measured by OPT (a) and histology (c), and hugely reduced the smooth 
muscle cell content of lesions (d). PAI-1 deficiency had very little influence on neointimal lesion 
development (a, b, c) and composition (d). All data expressed as mean±SEM, n=6-8. Data were 
analysed by two way ANOVA with Bonferroni post hoc test. *p<0.05, **p<0.01, ***p<0.001 vs 





Dex administration reduced maximum cross-sectional area of lesion similarly in both 
C57Bl/6 and PAI-1-/- mice (both p<0.05; Figure 6.10). However, dex treatment only 
reduced the stenotic ratio in the PAI-1-/- mice (p<0.05; Table 6.1(c)). There was an 
indication that dex treatment also reduced the area inside the IEL in C57Bl/6 mice 
(ns; Table 6.1(c)), which may explain the loss of effect by dex when expressed as 
stenotic ratio. 
6.4.6.3 Neointima composition 
From evaluation of the UST stained sections it was clear that the lesions which 
developed in the vehicle-treated animals, of both genotypes, were elastin-rich and 
fibro-proliferative in nature (Figure 4.8a and e). Conversely, the lesions which 
developed in animals on dex treatment were acellular and elastin-deficient. This was 
observed both in C57Bl/6 (Figure 4.8c) and in PAI-1-/- (Figure 4.8g) mice. Further 
quantitative analysis of these sections confirmed that dex treatment vastly reduced 
the fibrous component of the lesion, in both genotypes (both p<0.001; Figure 6.10B). 
 
Smooth muscle α-actin immunostaining verified that vehicle-treated mice developed 
lesions rich in smooth muscle (Figure 4.8b and f), while dex administration almost 
completely eliminated smooth muscle content of lesions in both C57Bl/6 and PAI-1-/- 









Figure 6.10: Impact of PAI-1 and dexamethasone treatment on neointimal cross-sectional 
area, as assessed by histology. 
C57Bl/6 and PAI-1-/- mice were randomised to receive either vehicle or dexamethasone (dex; 
0.8mg/kg/day) in their drinking water. Neointimal hyperplasia was induced by femoral artery 
wire-injury, before isolation and OPT scanning. Lesion and lumen cross-sectional areas were 
quantified by histological analysis. Dex treatment reduced the total maximum cross-sectional area 
of the lesion in both C57Bl/6 and PAI-1-/- mice (A). Furthermore, dex treatment appeared to 
almost completely eliminate any fibrous component of the lesion, in both C57Bl/6 and PAI-1-/- 
mice (B). All data expressed as mean±SEM, n=6-8. Data were analysed by two way ANOVA 







Figure 6.11: Composition of lesions formed after femoral artery wire-injury. 
C57Bl/6 and PAI-1-/- mice were randomised to receive either vehicle or dexamethasone (dex; 
0.8mg/kg/day) in their drinking water. Neointimal hyperplasia was induced by femoral artery 
wire-injury, before isolation and OPT scanning. Composition was quantified at the point of 
largest lesion as determined by histological analysis with United States trichrome (UST) staining. 
Smooth muscle content was assessed using immunohistochemistry against smooth muscle α-actin 
(SMα-actin). Vehicle-treated animals, from both genotypes (CV and PV), developed typical 
lesions (a, e), staining strongly for smooth muscle (b, f). Whereas, dex-treated animals, from both 
genotypes (CD and PD), developed lesions that were acellular and elastin-deficient as assessed by 
UST staining (c, g), and did not stain for smooth muscle cells (d, h). Scale bar = 100μm. CV: 






Figure 6.12: Impact of PAI-1 deletion and dexamethasone treatment on neointimal smooth 
muscle cell content. 
C57Bl/6 and PAI-1-/- mice were randomised to receive either vehicle or dexamethasone (dex; 
0.8mg/kg/day) in their drinking water. Neointimal hyperplasia was induced by femoral artery 
wire-injury, before isolation and OPT scanning. Lesion cross-sectional areas were quantified by 
histological analysis. Smooth muscle cell content was quantified at the point of largest lesion 
using immunohistochemistry. Dex treatment significantly reduced smooth muscle cell content of 
lesion in both C57Bl/6 and PAI-1 -/- mice. All data expressed as percentage of total area of plaque; 





The work described in this chapter addresses the hypothesis that increased PAI-1 
activity is responsible for dex-mediated thrombosis following vascular injury. The 
results obtained suggest that PAI-1 plays a limited role in neointimal proliferation. 
Dex administration has been confirmed to increase local thrombus formation 
following vascular injury and increase circulating PAI-1. However, while increased 
PAI-1 does mediate the systemic pro-thrombotic effect of dex, it is not responsible 
for dex-mediated thrombotic response to injury.  
6.5.1. PAI‐1 and neointimal proliferation 
6.5.1.1 PAI‐1‐/‐ mice 
Plasminogen activator inhibitor-1 gene-deficient mice, purchased for use in this 
experiment, were confirmed to have no detectable PAI-1 antigen in their circulation.  
The knockout mice appeared to have no developmental abnormalities in comparison 
to C57Bl/6 control mice, with comparable starting body weights and organ weights. 
These results are consistent with the characterisation carried out by the group who 
first generated PAI-1-/- mice by homologous recombination (Carmeliet et al., 1993a). 
They reported that disruption of the PAI-1 gene did not significantly influence 
organogenesis or development, with no apparent functional or histological 
abnormalities. Further, systolic blood pressure measurements taken throughout the 
experimental period were equivalent with the C57Bl/6 mice, which is consistent with 
previous reports (Kaikita et al., 2001; Ma et al., 2006). 
 
PAI-1 is the endogenous inhibitor of the fibrinolytic pathway. Therefore, PAI-1 
deficiency would be expected to augment fibrinolysis and the subsequent breakdown 
of thrombi. However, genetic disruption of PAI-1 also did not appear to impair 
haemostasis in this investigation, as assessed by tail-tip bleeding time, a measure of 
coagulation and fibrinolysis factor activity, among other things (Lavelle et al., 1998). 
This result is supported by a previous report that tail-tip bleeding time and re-
bleeding does not differ between wild type and PAI-1-/- mice (Carmeliet et al., 
1993b). These results suggest that PAI-1, and perhaps the entire fibrinolysis 
pathway, plays a limited role in haemostasis in healthy individuals. Interestingly, 
202 
 
delayed re-bleeding after trauma or surgery has been reported in patients with absent 
or reduced PAI-1 levels (Dieval et al., 1991; Fay et al., 1992; Lee et al., 1993). A 
possible explanation of a milder hyperfibrinolytic state in mice may be the lower 
basal plasma levels of PAI-1+/+ mice (~2ng/mL; consistent with level reported here in 
C57Bl/6 mice) than in humans (~10ng/mL) (Carmeliet et al., 1993b). 
 
Of interest, PAI-1 deficiency did not influence total tPA antigen concentration in the 
plasma. This result is supported by reports that two patients with absent or reduced 
PAI-1 levels have normal circulating tPA protein levels, with increased tPA activity 
(Fay et al., 1992; Lee et al., 1993). As PAI-1 inhibits tPA’s activity at the protein 
level and not the gene level, changes in total tPA by PAI-1 deficiency would not be 
expected. Unfortunately, the tPA activity ELISA in the current investigation failed to 
produce conclusive results. Originally the assay did not work and on repeat the 
standard errors were such that the results were not reliable. This outcome may be a 
consequence of repeated freeze-thaw cycles leading to denaturation of the enzyme. 
Other studies using PAI-1-/- mice have, however, confirmed that tPA activity is 
increased using zymography analysis (Wang et al., 2005a; Wang et al., 2007b). 
 
In conclusion, the PAI-1-/- mice were viable, healthy and had no detectable 
circulating PAI-1 protein. In addition, PAI-1 appeared to have no influence on 
physiological parameters or on haemostasis. Ideally, wild-type (PAI-1+/+) littermates 
would have been used as controls in this investigation. However, due to cost and 
time constrains, this was not practical. Therefore, as the PAI-1-/- mice were generated 
on a C57Bl/6 background, C57Bl/6 mice were deemed the most appropriate 
alternative. 
6.5.1.2 Impact of PAI‐1 deficiency on neointimal proliferation 
Genetic disruption of PAI-1 had no apparent influence on neointimal hyperplasia, as 
measured by OPT and histology. This conclusion is supported by previous studies 
which have found PAI-1 to have no effect on neointimal lesion development in a 
carotid artery ligation model (Kawasaki et al., 2001) and an electrical model (Lijnen 
et al., 2004) of vascular injury. However, there are a number of groups who have 
reported evidence that PAI-1 is indeed an important mediator of intimal hyperplasia 
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in mice, albeit with discordant results. Some report that genetic deletion or 
pharmacological inhibition of PAI-1 decreases lesion development (Peng et al., 
2002; Ploplis et al., 2001; Suzuki et al., 2008; Zhu et al., 2001), while others directly 
disagree, concluding PAI-1-/- mice have increased lesion development (Carmeliet et 
al., 1997b; de Waard et al., 2002; Schafer et al., 2006). 
 
The conflicting conclusions on the influence of PAI-1 on lesion development may be 
explained by evidence that PAI-1 can potentially modulate neointimal proliferation 
by multiple mechanisms. PAI-1 may promote intimal hyperplasia by stabilising 
fibrin, which often forms following vascular injury, and which can then be invaded 
by VSMCs to form a neointima (Fay, 2004). This is supported by reports that 
hyperfibrinogenemic mice have increased neointimal lesion development (Kerlin et 
al., 2004) and depletion of circulating fibrinogen with the snake venom ancrod 
reduces lesion development (Kawasaki et al., 2001), following vascular injury. As 
well as by inhibiting tPA, PAI-1 may also stabilise fibrin and thrombin by inhibition 
of APC which would otherwise inhibit FVa and FVIIIa (Fay, 2004). In addition, 
PAI-1 increases proliferation of VSMCs as well as rendering them more resistant to 
apoptosis (Chen et al., 2006), which could contribute to an increase in neointimal 
proliferation.  
 
Conversely, PAI-1 may inhibit intimal hyperplasia by inhibiting urokinase uPA on 
the surface of VSMCs, and consequently, the formation of cell-associated plasmin, 
which is thought to be important in VSMC migration through extracellular matrices 
and across elastic laminae (Fay, 2004). This proposal is supported by reports that 
uPA deficiency and pharmacological inhibition of uPAR, but not tPA deficiency, 
inhibit neointimal proliferation in mice (Carmeliet et al., 1997a; Quax et al., 2001; 
Schafer et al., 2002). Complementary to this, binding of PAI-1 to its cofactor 
vitronectin (VN), within the extracellular matrix, can competitively inhibit VSMC 
binding to VN (Czekay et al., 2003; Deng et al., 2001; Deng et al., 1996) and, 
consequently, the migration of VSMCs through extracellular matrices (Stefansson et 
al., 1996). Consistent with these results, one study has shown that VN deficiency 
attenuates neointimal proliferation after carotid artery ligation and chemical injury in 
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mice (Peng et al., 2002). However, a similar study concluded that both VN 
deficiency and PAI-1 deficiency augment intimal hyperplasia in a carotid artery 
ligation model (de Waard et al., 2002). The authors proposed that the inhibition is 
mediated by the capacity of PAI-1/VN complexes to inhibit thrombin (Naski et al., 
1993), a VSMC mitogen. 
 
Clearly, PAI-1 has multiple functions in the vascular wall and on fibrin homeostasis, 
which makes predicting the outcome, and explaining the result, of manipulation of 
PAI-1 on neointima development very difficult. It has been proposed that the model 
of vascular injury, and more specifically the extent of thrombus initially formed, 
determines the outcome of the action of PAI-1 on the subsequent intimal hyperplasia 
(Fay, 2004). This may explain some of the different effects of manipulating PAI-1 
reported with use of different models of vascular injury (Carmeliet et al., 1997c; 
Kawasaki et al., 2001; Lijnen et al., 2004; Peng et al., 2002; Ploplis et al., 2001; Zhu 
et al., 2001). Interestingly, all of these models employ perivascular injury, as 
opposed to the intra-luminal wire-injury model described in this study. 
 
Perhaps, in the current investigation, the pro-fibrinolytic effects of PAI-1 deficiency 
were inhibiting neointimal proliferation, while the accelerating effect of PAI-1 
deficiency on VSMC migration was augmenting neointimal proliferation, resulting in 
no net effect on lesion development, as reported, despite PAI-1 actively affecting 
intimal hyperplasia. Further mechanistic analysis would be required to confirm this 
proposal. Firstly, the significance of PAI-1’s fibrin-stabilising ability could be tested 
by administration of recombinant α2-antiplasmin to PAI-1-/- mice to restore the 
inhibition of plasmin activity, in a model of wire injury. Secondly, in the current 
investigation, lesions that developed in the PAI-1-/- mice contained an equivalent 
proportion of smooth muscle cells as the control mice, implying net smooth muscle 
cell migration and proliferation are unaffected by PAI-1. However, as described 
above, PAI-1 may have the potential to inhibit migration but increase proliferation of 
VSMCs. Repeating the current experiment in PAI-1/VN DKO mice elucidate the 
influence of VN on neointimal proliferation in the absence of the inhibitory role of 
PAI-1 on VN-mediated VSMC migration. In addition, as uPA has been implicated in 
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VSMC proliferation, it may be of interest to assay its activity. Despite PAI-1 being 
the endogenous inhibitor of uPA, there have been some reports that PAI-1 deficiency 
has no influence on uPA activity (Oda et al., 2001; Wang et al., 2005a) and another 
which confirms it increases uPA activity (Hertig et al., 2003). Unfortunately, there 
were insufficient blood samples remaining to carry out this assay here. 
 
In addition, using PAI-1-/- mice only allows insight into the impact of physiological 
levels of PAI-1 on neointimal proliferation. Basal circulating PAI-1 levels are 
relatively low, especially in mice (Carmeliet et al., 1993b), and so perhaps removing 
PAI-1 from circulation is not a significant enough change to influence the complex 
process of vascular lesion development. 
 
Because PAI-1 interacts with several molecules and cells types, global genetic 
deletion is perhaps not the most effective method of determining the role of PAI-1 on 
neointimal proliferation. An alternative approach is to inactivate specific functional 
domains of PAI-1, rather than the whole gene and corresponding protein (Fay, 2004). 
PAI-1 mutants lacking anti-proteolytic activity, while maintaining normal VN 
binding (and vice versa) have been generated (Stefansson et al., 1996). In addition, 
targeted modulation of PAI-1 expression in specific cell types, for example VSMCs 
and macrophages, may provide useful clarification, as the source of PAI-1 that 
modulates neointimal proliferation is not precisely defined (Schafer et al., 2006). 
6.5.2. Dexamethasone and neointimal proliferation 
6.5.2.1 Dexamethasone administration 
Dex was administered to the mice at the same dose and by the same method as 
described and discussed in the previous chapter (section 4.5.2.1). Weight loss and 
reduction in size of glucocorticoid-sensitive organs again confirms the efficacy of 
dex in this investigation. Similarly, dex administration significantly increased 
systolic blood pressure, as we (section 4.5.2.1) and others (Goodwin et al., 2008; 
Whitworth et al., 2001; Zhang et al., 2004) have previously described. Therefore, 
confidence can be drawn from the results of this investigation that dex is having a 
reproducible influence on the mice compared to the previous study. 
206 
 
In addition, it was confirmed that dex does indeed significantly increase total and 
active PAI-1 protein levels in the plasma of C57Bl/6 mice, with an associated 
reduction in tail-tip bleeding time. A key finding of this investigation was that tail-tip 
bleeding time was not influenced by dex administration in PAI-1-/- mice, implicating 
PAI-1 as the mediator of dex-induced effects on haemostasis. As discussed above 
(section 6.5.1.1), PAI-1 deficiency alone does not affect tail-tip bleeding time. This 
suggests that under normal physiological conditions, fibrinolysis plays a limited role 
in haemostasis. However, the results from this investigation indicate that inhibition 
of the pathway, by elevated PAI-1, does influence haemostasis. These results 
strongly support the hypothesis that dex administration is increasing the 
thrombogenicity of the mice through an increase in PAI-1. 
6.5.2.2 Impact of dexamethasone administration on neointimal 
proliferation 
The results from this investigation indicate that dex administration reduces 
neointimal lesion development following intra-luminal wire injury. This result 
confirms the many studies which have reported that glucocorticoid treatment reduces 
neointimal proliferation in animal models of vascular injury (Guzman et al., 1996; 
Nagasaki et al., 2004; Petrik et al., 1998; Valero et al., 1998; Van Put et al., 1995; 
Villa et al., 1994) and complements the work described in the previous chapter 
(section 4.5.2.2). In addition, the use of OPT to allow 3D quantification of lesion size 
has permitted, for the first time, verification that glucocorticoid administration 
reduces lesion volume.  
 
The influence of dex appears to be more pronounced in the investigation described 
here compared with the investigation described in Chapter 4 (section 4.5.2.2). The 
most obvious difference between these two studies is that the animals in the previous 
study were adrenalectomised, while in this study the mice had intact adrenal glands. 
The negligible influence of bilateral adrenalectomy on neointimal proliferation is 
discussed in the previous chapter (section 4.5.1.2); however, it has not been 
determined whether removal of the adrenal glands influences dex-mediated effects 
on neointimal proliferation. A study involving the direct comparison between dex 
administration in adrenalectomised and intact mice would have to be carried out 
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before conclusions can be drawn. It is more likely that the more pronounced effect of 
dex in the current investigation is due to differences in practices between the two 
studies. Firstly, my surgical and histological skills have no doubt improved with the 
experiences of this PhD. Secondly, the animals in the current investigation were 
perfusion fixed, whereas in the previous study, the femoral arteries were dissected 
prior to fixation. Maintenance of vascular integrity by perfusion fixation is likely to 
have a significant effect on subsequent histological analysis. Therefore, due to a 
number of differences between the two studies, direct comparisons of the effect of 
dex administration on neointimal proliferation must be made with caution. 
 
Glucocorticoids are thought to primarily inhibit neointimal proliferation through their 
anti-inflammatory properties (Liu et al., 1999; Yamada et al., 1993) and their 
potential to inhibit smooth muscle cell migration and proliferation (Goncharova et 
al., 2003; Voisard et al., 1994). The inflammatory status of the lesions was not 
evaluated in this study as this was not the primary focus. Although, there was an 
indication from the previous study (Figure 4.11) that this dose of dex reduces the 
macrophage content of lesions that develop following intra-luminal wire injury. 
Potential methods for more detailed analysis of the inflammatory status of the mice 
and specifically their neointimal lesions are described in Chapter 4 (section 4.5.2.2). 
Conversely, smooth muscle cell content was assessed in the lesions of this study as it 
is an important indicator of the nature of the lesions. Dex administration almost 
completely eliminated the smooth muscle cell content of the lesions, a similar, 
although perhaps more pronounced, result to that found in the previous investigation 
described in Chapter 4 (Figure 4.9). The anti-migratory (Cronstein et al., 1992; 
Goncharova et al., 2003; Pross et al., 2002) and anti-proliferative (Bitzer et al., 2004; 
Voisard et al., 1994) effects of dex on VSMCs are relatively well established and are 
likely to play a crucial role in dex-mediated effects on neointimal proliferation. In 
addition, it has been suggested that inflammatory cells differentiate into smooth 
muscle cells in vascular lesions (Sahara et al., 2007; Tanaka et al., 2003), 
contributing to neointimal development. Therefore, the anti-inflammatory properties 




The dramatic reduction in smooth muscle cell content, by dex administration, was 
associated with the development of an acellular lesion, appearing thrombotic in 
nature. This finding was consistent with the effects of dex reported in the previous 
investigation (section 4.5.2.2). As discussed in detail in Chapter 4, this thrombotic 
product may be attributable to a number of well-established glucocorticoid-mediated 
pathways, including stabilisation of the injury-induce thrombus, inhibition of 
inflammation-driven clearance of the clot and inhibition of smooth muscle cell 
recruitment, migration and proliferation. It was decided to focus this investigation on 
the influence of dex on the potential stabilisation of the thrombotic stage, 
specifically, the role of PAI-1, considering the dramatic increase in circulating levels 
of this protein with dex administration. 
6.5.3. Role of PAI‐1 in dexamethasone‐induced thrombotic response 
to injury. 
It was proposed that PAI-1 mediates the dex-induced thrombotic response to intra-
vascular injury. Therefore, it was hypothesised that PAI-1 deficiency would prevent 
the thrombotic effect, but maintain the anti-restenotic effect of dex administration, in 
the wire-injury model of neointimal proliferation. However, PAI-1 deficiency 
appeared to have no influence on dex-mediated thrombus formation. The lesions that 
developed in the PAI-1-/- mice on dex treatment were indistinguishable from those 
that developed in the C57Bl/6 mice on dex treatment; acellular, smooth muscle-
deficient and appearing thrombotic in nature. 
 
One possible explanation as to why PAI-1 deficiency did not prevent the thrombotic 
effect of dex administration, following vascular injury, is that dex may also drive the 
up-regulation or activation of α2-antiplasmin, thereby compensating for the lack of 
PAI-1-mediated inhibition of the fibrinolysis pathway. One study has suggested that 
dex administration increases plasma α2-antiplasmin in a rat model of acute 
pancreatitis (Muller et al., 2008). However, the dex-induced reduction in tail-tip 
bleeding time was abolished in the PAI-1-/- mice, implying there is no compensatory 
inhibition of the fibrinolytic pathway. The more likely explanation for the result is 
simply that PAI-1 is not the principle mediator of the local pro-thrombotic effect of 
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dex that results following vascular injury. As PAI-1 does appear to mediate the 
systemic pro-thrombotic effect of dex, the circulatory pathways involved 
(coagulation, fibrinolysis and platelet activation/aggregation) cannot significantly 
contribute to dex-induced thrombotic lesion development. This suggests that 
stabilisation of the thrombotic stage 1 of lesion development is not the principle 
mechanism by which dex causes thrombotic lesion development as was 
hypothesised. Rather, it implicates local pathways in the vessel wall as the mediators 
of the thrombotic side effect of dex administration following vascular injury. 
 
As described in Chapter 4 (section 4.5.2.2) there are a number of cells that are 
thought to act within the vessel wall during neointimal proliferation that are sensitive 
to glucocorticoids and may contribute to a delayed healing process and a thrombotic 
product. One likely candidate is the macrophage. Monocytes/macrophages are likely 
to play important roles in the progression of the response to vascular injury, 
including lysis and phagocytosis of the thrombus (Shantsila et al., 2009; Simon et al., 
1993) and mediating cellular recruitment (Clinton et al., 1992). The potent anti-
inflammatory properties of glucocorticoids can inhibit infiltration (Poon et al., 2001) 
and proliferation (Asai et al., 1993) of monocyte/macrophages at the site of injury, 
and reduce further recruitment of circulating monocytes and macrophages into the 
vessel wall (Prescott et al., 1989; Yamada et al., 1993), through inhibition of MCP-1 
secretion (Dhawan et al., 2007; Fasshauer et al., 2004). Another potential 
glucocorticoid-sensitive candidate is the VSMC. It is well-established that 
glucocorticoid can directly inhibit VSMC migration (Goncharova et al., 2003; 
Ribichini et al., 2005) and proliferation (Berk et al., 1988; Voisard et al., 1994), 
which are both key processes in the pathogenesis of neointimal formation. 
Furthermore, glucocorticoids can inhibit PDGF release from VSMCs (Nakano et al., 
1993), a growth factor which has been implicated in both the induction of migration 
and the expression of inflammatory chemoattractant molecules by VSMCs following 





In summary, physiological levels of PAI-1 appear to play a limited role in neointimal 
lesion development following intra-luminal wire injury. While PAI-1 does appear to 
mediate the systemic pro-thrombotic effect of dex, PAI-1 is not responsible for dex-
mediated local thrombosis following vascular injury. Instead, it is proposed that the 
thrombotic effect of dex on neointimal proliferation may be mediated by alternative 

















CVD is the single biggest cause of death in developed countries. Central to its 
pathogenesis is the development of atherosclerotic lesions. In addition, the major 
advancement in CVD treatment with PCI has been limited by the complication of 
restenosis. It is therefore critical to study the processes involved in vascular lesion 
development, to allow further advancement in the prevention and treatment of CVD. 
Both atherogenesis and restenosis are reactions to vascular injury, involving 
inflammation and cellular proliferation. Glucocorticoid hormones have 
widely-recognised anti-inflammatory and anti-proliferative properties which appear 
to make them ideal candidates for inhibition of vascular lesion development. Indeed, 
administration of glucocorticoids to experimental animals does inhibit the growth of 
vascular lesions in some models. However, chronic glucocorticoid excess in patients, 
either as a result of Cushing’s syndrome or chronic treatment, is associated with 
enhanced CVD risk (e.g. central obesity, insulin resistance, dyslipidemia and 
hypertension). Therefore, the overall effects of glucocorticoids on vascular lesion 
development remain imperfectly understood. Elucidating these effects will improve 
our understanding of the role of glucocorticoid activity in regulating atherogenesis 
and restenosis and the therapeutic potential of glucocorticoids as a treatment for, or 
as a target in, CVD.  
 
Therefore, the overall objective of these studies was to determine the influence of 
endogenous and exogenous glucocorticoids on vascular lesion development using 
murine models of atherosclerosis and neointimal hyperplasia. The work described in 
this thesis addressed the hypothesis that glucocorticoids are pro-atherogenic, yet anti-
restenotic, based on clinical evidence.  
7.1 Animal models of vascular lesion development 
An important pre-requisite for any such investigation is to select appropriate models 
of atherosclerosis and neointimal hyperplasia, which will allow quantification of the 
extent of lesion development and the opportunity to further investigate the 




Until 1992, the majority of in vivo atherosclerosis research used rabbits as their 
primary animal model.  However, a major limitation of the rabbit model is that the 
lesions that develop tend to be fatty streaks rather than complex advanced lesions 
that are seen in humans. The use of mice became more popular following the 
development of the ApoE-/- mouse (Plump et al., 1992; Zhang et al., 1992). These 
genetically modified mice have diminished hepatic uptake of circulating cholesterol 
and so are hypercholesterolaemic and consistently develop advanced plaques at 
vascular branch points. Currently, the most commonly used murine model of 
atherosclerosis combines the ApoE-/- mouse with high cholesterol, “Western” diet to 
further accelerate plaque development. An alternative mouse model of 
atherosclerosis is the LDLR-/- mouse. No fundamental differences in pathogenesis 
have been reported between the two models, but the LDLR-/- mouse does have a 
milder phenotype than the ApoE-/- mice (Bentzon et al., 2010a), and requires a high 
cholesterol diet to promote lesion development, whereas the ApoE-/- mice will 
develop lesions on a standard chow diet (Zhang et al., 1992). 
 
Although the ApoE-/- mouse is the most commonly used model of atherosclerosis, 
and has certain advantages over the rabbit model, there are a number of shortcomings 
of this murine atherosclerosis model (reviewed in (Bentzon et al., 2010a)). The major 
limitations are the rarity of plaque rupture and thrombosis and the small size of the 
animals that prohibits interventional cardiology and diagnostic imaging. Several 
porcine models of advanced coronary atherosclerosis do exist which have the 
potential to overcome these limitations (Granada et al., 2009). However, for the 
purpose of this investigation into the influence of glucocorticoids on atherogenesis, 
the “Western” diet-fed ApoE-/- mice remains the most appropriate model. 
7.1.2. Neointimal proliferation 
There are a number of commonly-used animal models of neointimal proliferation, 
including balloon angioplasty in rabbits and rats, stent implantation in the pig and 
dog, and various arterial injury models in the mouse. A mouse model was chosen for 
this investigation as use of this species allows study of the mechanisms of neointimal 
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proliferation at a molecular level, through the use of genetically-modified animals. 
The two most commonly used murine models of neointimal proliferation are intra-
luminal wire injury (Lindner et al., 1993; Sata et al., 2000) and carotid artery ligation 
(Kumar et al., 1997b). Both of these procedures produce large fibro-proliferative 
neointimal lesions after 2-3 weeks. While the ligation model has a less challenging 
operational procedure, the advantage of the wire injury model is it resembles the 
endothelial denudation seen with angioplasty and it maintains continuous blood flow. 
For this reason, a murine femoral artery wire-injury model, adapted from the method 
described by Sata et al (2000), was optimised in this department (Macdonald, 2007). 
The procedure involves the insertion of an angioplasty guidewire into the femoral 
artery via a small muscular side-branch. The wire stretches the vessel, causing 
endothelial denudation and extensive medial damage and results in the time-
dependent development of a smooth muscle-rich neointimal lesion. Characteristics of 
the model, including thrombus formation, medial cell loss, and the vascular and 
inflammatory cell types involved in lesion development, were consistent with those 
described with the original method (Sata et al., 2000). As this method affords 
reproducible, large neointimal lesions with relatively minimal detriment to the 
animals, it is now the preferred model of neointimal hyperplasia used in this 
department. Indeed, all previous and subsequent investigations into the role of 
glucocorticoids in neointimal proliferation in this department have used this model. 
 
However, it must be acknowledged that using mice to model neointimal proliferation 
has the disadvantage of their small size, limiting interventional procedures such 
balloon angioplasty and stent implantation. Ideally, after using mice to elucidate the 
mechanisms involved in glucocorticoid-mediated effects on intimal hyperplasia, the 
investigation will be taken into larger animals (such as the porcine or canine 
coronary artery), which may provide more clinically-relevant models of restenosis. 
7.2 Quantifying vascular lesion development 
The most common methods for assessing atherosclerotic lesion development in mice 
are en face analysis and histological examination. For neointimal lesion 
development, only the latter is available due to limited, if any, lipid content of these 
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lesions. Although these techniques are the gold standard for vascular lesion 
quantification, they have a major, recognised limitation that they provide only a 2-
dimensional (2D) measurement of a 3-dimensional lesion. In this investigation OPT 
has, for the first time, successfully been utilised to allow reproducible 3-dimensional 
quantification of atherosclerotic plaque and lumen volumes, as well as corresponding 
2-dimensional cross-sectional areas. OPT has also been successfully applied to the 
visualisation and quantification of neointimal hyperplasia in the femoral artery of 
mice (induced by both intra-luminal wire injury and ligation injury), in this 
department (Kirkby et al., 2011). The importance of lesion composition cannot be 
overlooked and although, at present, OPT cannot provide compositional description 
of lesions, it is non-destructive and so standard histological and 
immunohistochemical analysis of the arteries can be carried out to allow a valuable 
complement to OPT with the generation of further information regarding lesion 
composition.  
 
Another potential development of the OPT technique in vascular analysis is the use 
of whole-mount immunofluorescence to allow visualisation and quantification of the 
distribution of particular cell types or proteins. This has already been successfully 
demonstrated in embryos and isolated organs (Alanentalo et al., 2007; Sharpe et al., 
2002). However, preliminary investigations into staining injured arteries with a 
fluorescent macrophage marker yielded little success due to poor antibody 
penetration throughout the tissue and non-specific antibody binding as a result of the 
necessarily long incubation times. Further investigation will require careful 
optimisation of incubation and washing times, blocking solution compositions and 
perhaps trials with alternative primary antibodies. 
7.3 Glucocorticoids and atherosclerosis 
The influence of glucocorticoids on atherosclerosis is imperfectly understood and 
unpredictable. Clinically, glucocorticoid excess, whether as a result of chronic 
glucocorticoid treatment or in patients with Cushing’s syndrome, is associated with 
enhanced cardiovascular disease. However, the majority of animal (rabbit) studies 
have suggested that systemic glucocorticoid treatment protects against 
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atherosclerosis. Interestingly, studies using mouse models have described a pro-
atherosclerotic effect of glucocorticoids (Hermanowski-Vosatka et al., 2005; Nuotio-
Antar et al., 2007; Tous et al., 2006). Therefore, this investigation aimed to confirm 
whether these steroids are indeed pro-atherosclerotic and elucidate any difference 
between the influence of endogenous and exogenous glucocorticoids, using ApoE-/- 
mice on a high cholesterol “Western” diet.  
 
The effects of endogenous and exogenous glucocorticoids on atherosclerosis were in 
fact quite different. Adrenalectomy had no effect on atherosclerotic plaque 
development, suggesting that physiological levels of endogenous glucocorticoids 
play a limited role in the regulation of atherogenesis in the mouse. The most likely 
explanation for the discrepancy between this result and the majority of the literature 
is that removal of the adrenal glands is too crude a method for manipulating the 
complicated and delicate homeostasis of endogenous glucocorticoid action. An 
important limitation of this study is that adrenalectomy did not completely abolish 
circulating corticosterone. Although this anomaly is widely-reported, there may have 
been insufficient corticosterone ablation to modulate atherogenesis. In addition, in 
order to explain the results, the influence of removing glucocorticoids would have to 
be isolated from the influence of removing mineralocorticoids and catecholamines. 
Perhaps a more selective approach to manipulating endogenous glucocorticoids 
would be more appropriate. Inhibition of 11βHSD1 (Hermanowski-Vosatka et al., 
2005; Nuotio-Antar et al., 2007) and genetic deletion of 11βHSD2 (Deuchar et al., 
2011) have been shown to attenuate and augment atherosclerotic lesion development 
in mice, respectively. Alternative approaches could include ACTH administration, to 
mimic endogenous glucocorticoid excess, or pharmacological inhibition of GR.  
 
In contrast, exogenous glucocorticoid treatment significantly augmented 
atherosclerotic plaque development. The mechanism behind this effect remains to be 
elucidated but appears to be independent of circulating lipid levels and macrophage 
numbers. This study supports the conclusion of Tous et al., who described an 
increase in aortic atherosclerosis in dex-treated ApoE-/- mice on a normal chow diet 
(Tous et al., 2006), using the “Western” diet-fed ApoE-/- mouse model. In addition, 
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the results from this investigation support the proposal that the ApoE-/- mouse model 
is a more clinically-relevant model of atherosclerosis than the cholesterol-fed rabbit. 
Therefore, it would be of great interest to use this model to expand our understanding 
of the mechanism behind the pro-atherosclerotic effects of glucocorticoid treatment. 
7.4 Glucocorticoids and neointimal proliferation 
Previous animal studies have consistently shown that glucocorticoid administration 
inhibits neointimal proliferation, attributable to the potent anti-inflammatory and 
anti-proliferative properties of glucocorticoids. However, a previous study in this 
department observed that the anti-“restenotic” effect of glucocorticoids was 
associated with the formation of organised acellular lesions of a thrombotic nature, at 
the site of injury (Macdonald, 2007). Therefore, this investigation aimed to confirm 
the thrombotic effect of systemic glucocorticoid treatment and elucidate the 
mechanism behind the result. In addition, the influence of endogenous 
glucocorticoids was investigated as there do not appear to be any reports detailing the 
effects of these glucocorticoids on neointimal proliferation. 
 
As with their effects on atherosclerotic lesions, the influences of endogenous and 
exogenous glucocorticoids were not comparable. Adrenalectomy had no influence on 
neointimal lesion development. This result supports a previous investigation in this 
department (Macdonald, 2007), which concluded that both genetic deletion and 
pharmacological inhibition of 11βHSD1 and pharmacological GR antagonism had no 
influence on neointimal proliferation in the same wire-injury model. Therefore, 
confidence can be drawn in the conclusion that physiological levels of endogenous 
glucocorticoids play a limited role in neointimal proliferation. However, as so little 
research has been done on this topic, further investigation into the more clinically-
relevant issue of endogenous glucocorticoid excess on neointimal proliferation needs 
to be conducted before endogenous glucocorticoids are neglected as a potential 
therapeutic target in restenosis. A previous study in this department has concluded 
that genetic deletion of 11βHSD2 has no influence on neointimal proliferation 
following intra-luminal wire injury (Iqbal, 2010). An alternative approach could be 
to administer ACTH to wire-injured mice and assess neointima size. 
218 
 
In contrast to endogenous glucocorticoids, exogenous glucocorticoids had a striking 
inhibitory effect on neointimal proliferation, supplementing the widely-accepted anti-
restenotic reports of glucocorticoid administration. However, this positive effect of 
glucocorticoids was accompanied by thrombotic lesion development at the site of 
injury. These results directly mimic the results of the previous study carried out in 
our department, which administered dex by a potentially more stressful method; 
daily intra-peritoneal injection (Macdonald, 2007). It is proposed that this thrombotic 
outcome results from glucocorticoid treatment impeding the progression of 
neointimal development past the initial thrombotic stage induced by vascular injury. 
As dex was found to significantly increase PAI-1, it was hypothesised that the 
glucocorticoid was preventing neointimal development by stabilising the initial 
thrombus. However, while elevated PAI-1 was found to mediate the systemic pro-
thrombotic effect of dex, it was not responsible for the local thrombus formation 
following vascular injury. There are a number of alternative potential mechanisms, 
involving glucocorticoid-mediated pathways, which could be contributing to 
inhibition of lesion progression. For example, glucocorticoids have potent anti-
inflammatory and anti-proliferative properties that may prevent key mechanisms 
involved in the progression of lesion formation beyond the thrombotic stage. 
7.5 Endogenous vs exogenous glucocorticoids 
Given the demonstrable ability of exogenous glucocorticoids to augment 
atherosclerosis and inhibit neointimal proliferation, it is surprising that manipulating 
endogenous glucocorticoids has no effect in these models. It is possible that, while 
high pharmacological concentrations of glucocorticoids exert potent anti-restenotic 
effects, changes in physiological levels of glucocorticoids are not sufficient to alter 
neointimal lesion development. Indeed, adrenalectomy did not influence 
glucocorticoid-sensitive systemic parameters, including body weight and spleen 
weight, or local effects, such as smooth muscle and inflammatory content of the 
lesion. In addition, a lower pharmacological dose of dex, which did influence the 




An additional explanation may be in the type of glucocorticoid investigated. 
Adrenalectomy examines the influence of corticosterone, whereas the glucocorticoid 
administered was synthetic dex. The main difference in the action of these steroids is 
that dex is selective for GR (Cole et al., 2007) whereas corticosterone activates both 
MR and GR (Kim et al., 1998). The role of MR activation in atherosclerosis and 
intimal hyperplasia has been addressed previously (section 3.5.2.2 and 4.5.1.2, 
respectively), with evidence that it likely affects the influence of adrenalectomy on 
lesion development. For example, genetic deletion of 11βHSD2, thereby allowing 
activation of MR by glucocorticoids, exacerbates atherosclerosis in ApoE-/- mice 
(Deuchar et al., 2011). In addition, elevated angiotensin II (due to low circulating 
aldosterone) may also confound the influence of adrenalectomy on vascular lesion 
development given the plethora of effects angiotensin II has on the cardiovascular 
system. Although saline replacement will prevent the pressor-mediated effects, there 
are a number of direct actions of angiotensin II on the vasculature, including 
vasoconstriction, VSMC proliferation and ECM production (Strawn et al., 2002).  
 
Consideration must also be given to the diurnal rhythm of endogenous glucocorticoid 
synthesis and, consequently, plasma levels (Oster et al., 2006), which is not attained 
with the method of glucocorticoid administration used in this investigation. 
Therefore, there are important differences between the manipulation of endogenous 
and exogenous glucocorticoids, which may contribute to the differences described in 
their influences on vascular lesion development. However, it must be stressed that 
while removal of approx. 75% of endogenous glucocorticoids appears to have little 
effect on restenosis, endogenous glucocorticoid excess must also be considered. 
7.6 Potential clinical significance of results 
7.6.1. Endogenous glucocorticoids 
Investigations into the influence of endogenous glucocorticoids on atherosclerosis 
and neointimal proliferation have important clinical implications for patients with 
Cushing’s disease and the metabolic syndrome. Associated with increased circulating 
cortisol, these patients have a well-established, but incompletely understood 
increased risk of CVD and consequently are more likely to require PCI.  
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The finding that physiological levels of endogenous glucocorticoids appear to play a 
limited role in atherogenesis and neointimal proliferation questions the future clinical 
use of 11βHSD1 inhibitors for the prevention of cardiovascular lesion development. 
It is proposed that increased tissue 11βHSD1 activity, and so intracellular 
glucocorticoid levels, may contribute to the aetiology of metabolic syndrome and its 
underlying cardiovascular risk factors (which include central obesity, hypertension, 
insulin resistance, dyslipidemia and atherosclerosis). Therefore, inhibitors of 
11βHSD1 have become an important novel therapeutic target for the treatment of the 
metabolic syndrome. There have been a number of more direct investigations into the 
impact of 11βHSD1 inhibition on atherosclerosis and restenosis, which suggest that 
it may have beneficial effects on atherosclerotic lesion development (Hermanowski-
Vosatka et al., 2005; Nuotio-Antar et al., 2007), but a limited influence on restenosis 
(Macdonald, 2007). Further investigations into the potential clinical application of 
11βHSD1 inhibitors are currently being carried out and should take into 
consideration the findings reported here on the effect of global removal of 
glucocorticoids on vascular lesion development. 
7.6.2. Exogenous glucocorticoids 
Investigations into the influence of exogenous glucocorticoids on atherosclerotic and 
neointimal lesion development have important clinical implications for patients on 
chronic steroid therapy for management of an inflammatory condition. These patients 
also have a well-established increased risk of CVD. In addition, glucocorticoids are 
currently being investigated for their anti-restenotic potential, but have been limited 
by their detrimental systemic effects and disappointing efficacy with local 
application. Alongside furthering our understanding of the impact of glucocorticoids 
on restenosis, it is imperative that the influence this treatment may have on the 
underlying atherosclerotic disease in patients undergoing PCI is understood. 
 
Use of animal models to help understand the glucocorticoid-mediated mechanisms 
involved in atherosclerotic has been limited, so far, by their failure to mimic the pro-
atherosclerotic effect of glucocorticoids seen in the clinic. However, the results from 
this study provide evidence that the Western diet-fed ApoE-/- mouse does mimic the 




also suggested that glucocorticoid-mediated augmentation of atherosclerosis is 
independent of circulating lipid levels and the macrophage content of the plaque. 
More detailed investigations are required to confirm these findings, but this model of 
atherosclerosis provides the opportunity to do so. 
 
The finding that systemic pharmacological doses of glucocorticoid attenuate 
neointimal proliferation but induce thrombotic lesion development is important 
considering that: firstly, patients on chronic glucocorticoid treatment for 
inflammatory conditions an have increased risk of CVD and are more likely to 
require PCI; and secondly, glucocorticoids are currently being trialled clinically as 
anti-restenotic agents (Ribichini et al., 2009). However, changes in composition such 
as this are unlikely to be visible by angiographic analysis of restenotic lesions, as 
used in the clinical trials. Instead, compositional analysis of restenotic lesions is 
limited to arterectomy or post-mortem samples. It would be of great benefit to 
confirm whether systemic steroid treatment has a similar thrombotic effect following 
PCI in humans. However, continued investigation using animal models of neointimal 
proliferation may provide crucial insight into the mechanism behind the thrombotic 
effect of exogenous glucocorticoids on neointimal proliferation, which later may be 
applied in the clinic. The results from this study have already allowed PAI-1 to be 
discounted as the primary mediator of this pro-thrombotic effect.  
7.7 Future studies 
The work described in this thesis has described the influence of exogenous 
glucocorticoids on atherosclerosis and neointimal proliferation. However, the 
mechanisms driving the contradictory effects on the different types of vascular lesion 
development remain to be clarified. In addition, the influence of endogenous 
glucocorticoids on atherosclerosis and neointimal proliferation was not fully 
elucidated. Therefore, there are several prospective studies that could extend the 





Adrenalectomy allowed a broad insight into the role of endogenous glucocorticoids 
on atherosclerosis and neointimal proliferation. However, removal of the adrenal 
glands appeared to be too blunt a method for manipulating the complicated and 
delicate homeostasis of endogenous glucocorticoid action. Additionally, 
adrenalectomy does not completely remove circulating corticosterone. Perhaps a 
more appropriate, and clinically-relevant, method would be to investigate the 
influence of endogenous glucocorticoid excess, mimicking Cushing’s syndrome, on 
vascular lesion development. There are a number of approaches which could be used 
to carry out such an investigation, the simplest of which would be administration of 
ACTH (Bailey et al., 2009; Dunbar et al., 2010) to Western diet-fed ApoE-/- mice or 
wire-injured C57Bl/6 mice. High levels of ACTH would stimulate excess 
corticosterone release from the adrenal glands. An alternative method would be to 
use GR over-expressing mice (Nguyen Dinh Cat et al., 2009). However, potential 
compensational depression of the HPA axis would have to be considered. Taking the 
clinical observation of increased CVD risk in Cushing’s patients into account, it is 
hypothesised that the aforementioned approaches would augment atherosclerosis and 
neointimal proliferation. If so, these “Cushing’s” models would be an important 
platform to investigate the pro-atherosclerotic mechanisms of endogenous 
glucocorticoids excess and to trial potential agents against glucocorticoid-
exacerbated vascular lesion development. 
7.7.2. Mechanism of pro‐atherosclerotic effects of glucocorticoids 
The results from this investigation mimic the clinical observation that exogenous 
glucocorticoids exacerbate atherosclerosis, which was not observed in rabbit models 
(Asai et al., 1993; Makheja et al., 1989; Naito et al., 1992). Therefore the Western 
diet-fed ApoE-/- provides model to investigate the mechanisms driving the pro-
atherosclerotic effect of exogenous glucocorticoids. There are a number of 
glucocorticoid-mediated processes that are involved in atherogenesis which require 
exploration. Importantly, the local effects of glucocorticoids must be distinguished 
from the systemic influences. Previous in vitro studies suggest that the anti-
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inflammatory and anti-proliferative effects glucocorticoids have locally on the vessel 
wall would in fact reduce atherosclerotic lesion development. This could be 
confirmed by the use of dex or cortisol pellets, implanted alongside the femoral 
artery branch point, an easily accessible predisposed area to lesion development. 
Morphometric analysis of the resulting lesions would allow a general conclusion of 
the role of local glucocorticoid-mediated effects on atherogenesis, while IHC and 
laser microdissection (Taatjes et al., 2008) would allow influences at the cellular and 
genetic level, respectively, to be elucidated. The systemic glucocorticoid-sensitive 
parameters could be further investigated by again administering dex in the animals’ 
drinking water. Detailed blood pressure measurements could be acquired with the 
use of implanted telemetry devices and a full lipid profile could be determined by 
fast protein liquid chromatography (FPLC). In addition, it would be important to 
identify any metabolic disturbances; insulin resistance could be monitored with a 
glucose-tolerance test, unfavourable fat distribution could be assessed with dual 
energy X-ray absorptiometry (DEXA) scanning (Leung et al., 2008) and histological 
analysis of the liver would identify any liver steatosis. Elucidation of the influence of 
exogenous glucocorticoids on these parameters will likely indicate the primary 
mechanisms behind the pro-atherosclerotic effect of glucocorticoid excess, and 
further advance the quest to find a treatment for CVD. 
7.7.3. Mechanism of glucocorticoid‐induced thrombotic lesion 
development following intra‐luminal injury 
As described above (section 7.6.2), it is important that the mechanisms driving 
glucocorticoid-induced thrombotic lesion development are elucidated. It is proposed 
that administration of glucocorticoids impedes the progression of arterial healing past 
the initial thrombotic stage, instigated by denudation of the vessel. It has been shown 
that this effect is not mediated by stabilisation of the thrombus by elevated PAI-1. 
Alternatively, the inhibitory properties of glucocorticoids on macrophage function 
and smooth muscle cell migration and proliferation, may be responsible for 
preventing progression to a fibro-proliferative neointimal lesion. There are a number 
of methods by which the role of macrophages in glucocorticoid-mediated thrombotic 
lesion development could be further elucidated, by again using dex-treated,         
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wire-injured mice. Firstly, the adhesion of monocytes to the injured vessel wall at 
very early time points (immediately and 2 days following injury) could be 
investigated by assessing the expression of adhesion molecules using IHC or 
quantitative PCR. Complementary to that, macrophage accumulation and activation 
status could be assessed at the peak of macrophage infiltration (7 days following 
injury) with the use of IHC and flow cytometry. In addition, the impact of 
glucocorticoids on the release of inflammatory cytokines and chemokines could be 
assessed by measuring the level of these factors in an in vitro model of arterial 
injury.  
 
The first step in determining the role of smooth muscle cells in glucocorticoid-
mediated thrombotic lesion development is to verify the source of the intimal smooth 
muscle cells that accumulate during neointimal proliferation. There is evidence that 
these cells are derived from circulating bone-marrow-derived progenitors (Sahara et 
al., 2007; Sata et al., 2002; Tanaka et al., 2003). This suggestion can be confirmed 
by carrying out wire-injury surgery in mice whose bone marrow has been replaced 
with that of ROSA26 mice, which express β-galactosidase (LacZ) ubiquitously 
(Zambrowicz et al., 1997). Immunofluorescence double staining for LacZ and 
smooth muscle α-actin will reveal both whether any bone-marrow-derived cells are 
assuming a smooth muscle cell-like expression pattern, and the localisation of these 
cells. Administration of dex to this model would allow elucidation of the impact of 
glucocorticoids on the accumulation of these cells.  Secondly, the influence of dex on 
the proliferation of smooth muscle cells could be assessed by injection of the 
thymidine analogue BrdU prior to sacrifice in vehicle-treated and dex-treated wire-
injured mice. This would provide a nuclear marker for proliferating cells in 
subsequent histological analysis of the lesions. Ideally these would be assessed at 14 
days post-injury, as most cellular proliferation occurs before this time-point 
(Macdonald, 2007). Determination of the role of macrophages and smooth muscle 
cells in dex-mediated thrombotic lesion development following arterial injury will 
provide invaluable information for optimising the use of glucocorticoids in 




While OPT has provided an important advancement in the ex vivo analysis of 
vascular lesions, representative in vivo quantification of lesion progression and of 
cellular and molecular changes is the ultimate goal. There are already a number of 
potential non-invasive imaging techniques which have been used for such 
quantification. Ultrasound biomicroscopy has previously been applied to assess 
plaque morphologies and flow velocities in the carotid artery of mice (Gan et al., 
2007; Ni et al., 2008). Use of this technique could provide valuable information on 
the influence of glucocorticoids on neointimal and atherosclerotic lesion 
development, complementary to data derived from OPT and histology. In addition, 
use of this imaging modality can be further supplemented with use of microbubbles 
as tracers of specific cells types. For example, fluorescein-labelled lipid 
microbubbles, once phagocytosed, can be used to track monocytes/macrophages 
during atherogenesis (Lindner et al., 2000). Similarly, microbubbles targeted for p-
selectin, may allow in vivo visualisation of the development of the thrombotic lesions 
induced by dex administration following intra-vascular injury. 
 
MRI has also previously been utilised for non-invasive imaging of atherosclerotic 
plaque progression in mice (reviewed in (Weinreb et al., 2007)). In addition to 
plaque morphology, MRI has been described to allow determination of murine 
plaque composition, differentiating between lipid and fibrous material (Trogan et al., 
2004). This imaging technique could clearly be used to complement the findings of 
the investigations described in this thesis, with the added benefit of allowing lesion 
progression to be monitored with serial MRI scanning. Similar to ultrasound, 
contrast-enhanced MRI is permissible: superparamagnetic iron oxides can be used to 
track monocytes/macrophages, while other magnetofluorescent nanoparticles can be 
utilised to visualise specific proteins, for example VCAM-1 (Kelly et al., 2005).  
 
Employment of either/both of these imaging techniques would provide a valuable 
opportunity to improve both our understanding of the development of vascular 




In conclusion, these studies have provided valuable insights into the complex 
influence of glucocorticoids on vascular lesion development, facilitated by the novel 
use of optical projection tomography. Not only do glucocorticoids influence 
atherogenesis and neointimal proliferation differently, but crucially, endogenous and 
exogenous glucocorticoids appear to have distinct impacts on vascular lesion 
development. Physiological levels of endogenous glucocorticoids appear to play a 
limited role in atherogenesis and neointimal proliferation; however further 
exploration into the impact of endogenous glucocorticoid excess may be worthwhile, 
perhaps using a more clinically-relevant approach. Conversely, exogenous 
glucocorticoids augmented the development of atherosclerosis in ApoE-/- mice, 
mimicking the clinical influence of glucocorticoids on atherosclerosis. This model, 
therefore, provides an important tool for distinguishing the influence of the local and 
systemic mechanisms that may be responsible for the pro-atherosclerotic effect of 
glucocorticoid treatment. In contrast, exogenous glucocorticoids were found to 
induce thrombotic lesion development, negating their beneficial inhibition of fibro-
proliferative lesion development. The primary mechanism behind this pro-thrombotic 
effect of glucocorticoid treatment is yet to be elucidated, but is known to not be 
mediated by reduced fibrinolysis. Further research is therefore required to improve 
the cardiovascular outcome of patients requiring glucocorticoids therapy and for the 
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Abstract
Objective: Traditional methods for the analysis of vascular lesion formation are labour intensive to perform - restricting
study to ‘snapshots’ within each vessel. This study was undertaken to determine the suitability of optical projection
tomographic (OPT) imaging for the 3-dimensional representation and quantification of intimal lesions in mouse arteries.
Methods and Results: Vascular injury was induced by wire-insertion or ligation of the mouse femoral artery or
administration of an atherogenic diet to apoE-deficient mice. Lesion formation was examined by OPT imaging of
autofluorescent emission. Lesions could be clearly identified and distinguished from the underlying vascular wall.
Planimetric measurements of lesion area correlated well with those made from histological sections subsequently produced
from the same vessels (wire-injury: R2 = 0.92; ligation-injury: R2 = 0.89; atherosclerosis: R2 = 0.85), confirming both the
accuracy of this methodology and its non-destructive nature. It was also possible to record volumetric measurements of
lesion and lumen and these were highly reproducible between scans (coefficient of variation = 5.36%, 11.39% and 4.79% for
wire- and ligation-injury and atherosclerosis, respectively).
Conclusions: These data demonstrate the eminent suitability of OPT for imaging of atherosclerotic and neointimal lesion
formation, providing a much needed means for the routine 3-dimensional analysis of vascular morphology in studies of this
type.
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Introduction
The formation of vascular lesions in response to acute or
chronic injury to the arterial wall defines atherosclerosis and post-
interventional restenosis, conditions that contribute greatly to
cardiovascular morbidity and mortality[1]. Understanding of the
processes that lead to such lesion formation has been advanced
considerably by exploiting murine models of acute vascular injury
and atherosclerosis that are amenable to genetic manipulation[2].
Despite these advances, ex vivo identification and quantification of
vascular lesions typically relies on 2-dimensional histological
analysis. This is time consuming and provides only limited
information on lesion volume. In particular, lesion burden in an
artery is commonly assessed by measurement of cross-sectional
lesion area, either at randomly selected sites along its profile or at
the site of maximum occlusion, providing an imperfect analysis of
overall lesion burden.
Whole-mount 3-dimensional imaging technology should pro-
vide a solution to this problem, yet surprisingly few suitable
approaches have been described. This reflects the scale of the
murine vasculature – too large for microscopic techniques such as
single-photon confocal microscopy but too small for techniques
derived from the clinic, including magnetic resonance imaging
(MRI)[3] and computed tomography (CT)[4]. Indeed, whilst both
ex vivo MRI and micro CT have been applied to the study of
murine atherosclerosis, they offer limited resolution, even in
relatively large arteries and require long acquisition times limiting
throughput [3,5]. Several newer optical imaging modalities have
been described in attempt to span this region of scale poorly served
by traditional systems. For example, optical coherence tomogra-
phy [6] and photo-acoustic tomography [7] offer tissue penetra-
tion depths of 1–3 mm and imaging of optical scattering and
absorbance, and do so at relatively high resolution.
Another such technique is optical projection tomography
(OPT). Originally conceived for the study of mouse embryos,
OPT is able to image biological specimens approximately ,0.3 to
10 mm in diameter, using two image modes [8]. Transmission
imaging records the opacity of a semi-translucent sample to
polychromatic visible light and therefore primarily describes its
pattern of absorbance. This may reflect the presence of pigments
such as hemoglobin or of particles resistant to optical clearing, and
can often be used to distinguish anatomical structures. Emission
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imaging records the ability of endogenous (e.g. collagen, elastin,
NADPH, certain amino acids) and exogenous fluorophores
contained within that sample to emit light upon excitation at
specific wavelengths. This imaging mode may also describe
anatomical structure because the individual tissue components
making up a sample can differ in the type and density of
autofluorescent species present. Further, through the use of
fluorescent reporters the distribution of immunoreactivity or gene
expression may be determined [9]. For both imaging modes, light
(transmitted or emitted) is focused to a charge coupled device by
conventional microscope optics, and images captured at multiple
increments of rotation (typically 400 images at 0.9u increments).
From these, the 3-dimensional volume can be calculated by
standard tomographic reconstruction methods such as filtered
back-projection or iterative reconstruction. A full description of the
method can be found elsewhere [8,9].
Since its introduction, the application of OPT has been
broadened considerably, for example, having being adapted to
the study of b-cells in the diabetic mouse pancreas, and the
development of neuronal structures in human tissue samples[10].
Surprisingly given the need for such methodology, the suitability of
OPT imaging for the 3-dimensional assessment of morphology in
vascular tissues from adult animals has not been determined.
We addressed the proposal that OPT could be used as a rapid
and cost-effective method to produce quantifiable 3-dimensional
images of intimal lesions within murine arteries. The suitability of
this technique was assessed using three commonly used models of
murine vascular injury: femoral artery wire-injury and ligation
models of neointimal hyperplasia and the apolipoprotein E-
deficient (apoE-/-) mouse model of atherosclerosis.
Methods
Induction of neointima formation
All animal experiments were performed in accordance with the
Animals (Scientific Procedures) Act (UK), 1986 and approved by
the University of Edinburgh ethical review committee (PPL 60/
3867). Surgical procedures were carried out under isoflurane
anaesthesia and with buprenorphine post-operative analgesia.
Acute vascular injury was performed in male, 12 week old
C57Bl6/J mice (Harlan, UK). Wire-injury to the femoral artery
was performed by insertion of a 0.014’’ diameter wire into the left
femoral artery, previously described[11]. Ligation-injury was
performed by occlusion of the right femoral artery of the same
mice with a 5-0 silk ligature across the femoropopliteal bifurcation,
analogous to the carotid artery ligation-injury model[12]. Animals
were allowed to recover for 28 days before sacrifice by
transcardiac perfusion fixation.
Induction of atherosclerosis
Atherosclerotic lesion formation was induced in male, 6 week
old ApoE-null mice (bred in house) by feeding a Western diet
(0.2% cholesterol; Research Diets, USA) for 12 weeks. At the end
of this period, animals were killed by perfusion fixation.
OPT scanning and quantification
For OPT imaging, isolated vessels were embedded in 1.5% low
melting point agarose (Invitrogen, UK), dehydrated in methanol
(100%; 24 hours) and optically cleared in benzyl alcohol:benzyl
benzoate (1:2 v/v; 24 hours). Vessels were imaged using a
Bioptonics 3001 OPT tomograph. All studies on injured arteries
were performed using emission imaging, after UV illumination
(425 nm excitation filter with 40 nm band pass; 475 nm long pass
emission filter; 1.048Mpixel scanning resolution). For each vessel
type, a magnification was chosen to provide the smallest voxel size
whilst allowing the entire region of interest to be covered. This
resulted in voxel sizes of 216, 64 and 166 mm3 respectively for
wire- and ligation-injured femoral arteries and atherosclerotic
aortic arches. For each vessel, exposure time was adjusted to
maximise the dynamic range of the resulting image and was
approximately 400, 800 and 1000ms per projection for wire- and
ligation-injured femoral arteries and atherosclerotic aortic arches,
respectively. Raw data (400 projections per scan at 0.9u
increments) was subject to Hamming-filtered back-projection
using NRecon software (Skyscan, Belgium). Quantification was
performed using CTan software (Skyscan, Belgium). Briefly, lesion
and lumen volumes were segmented by semi-automated tracing of
the internal elastic lamina and subsequent grey-level thresholding
to distinguish neointima from lumen. (See Methods S1 for a step-
by-step protocol).
Histology
After tomographic scanning, vessels were immersed in methanol
for 24 hours, trimmed of excess agarose and processed to paraffin
wax. Histological sections (3–4 mm thick) underwent ‘United
States Trichrome’ (UST) staining to highlight morphology[13] or
picro-sirius red to highlight collagen. Measurements of lesion area
(defined as the area between the luminal border and internal
elastic lamina) were recorded from photomicrographs of UST-
stained sections using Photoshop CS4 Extended software (Adobe
Inc, USA).
Immunohistochemistry
Immunohistochemistry was performed for a-smooth muscle
actin (aSMA) and Mac2. Briefly, rehydrated sections were
incubated with mouse anti-aSMA (Sigma, UK; 1/400 dilution;
30 mins) or rat anti-Mac2 primary antibodies (Cederlane Inc,
USA; 1/6000 dilution; overnight) before treatment with goat anti-
mouse IgG (Vector Labs, UK; 1/400 dilution; 30 mins) or goat
anti-rat IgG secondary antibodies (Vector Labs, UK; 1/200
dilution; 30 mins), respectively. Sections were then treated with
streptavidin-conjugated peroxidase (Extravidin-Peroxidase; Sigma,
UK; 1/400 dilution; 30 mins) and the stain developed by
application of 3,3-diaminobenzidine.
Statistics and data analysis
OPT slices corresponding to histological sections were identified
based on the distance of each from a fixed reference point within
the sample (the femoropopliteal bifurcation, the ligation and the
root of the brachiocephalic artery, respectively, for wire- and
ligation-injured femoral arteries and atherosclerotic aortic arches).
As z-axis distances can only be approximated from serial sections,
visual cues, such as the position of arterial branches and vessel
conformation were, in some cases, used to aid selection of
appropriate image pairs. Measurements of lesion areas from OPT
and histological sections were then compared by linear regression.
The deviation of the slope from 1.0 was determined by F-test.
Precision was assessed by calculation of the coefficient of variation
between lesion volume measurements made from four indepen-
dent scans/reconstructions of the same vessels.
Additional methodological detail is provided in Methods S2.
Results
Transmission and emission imaging of isolated arteries
To determine the suitability of OPT for the study of isolated
murine blood vessels, healthy femoral arteries (n = 5) were each
scanned twice - for visible light transmittance, and for fluorescent
Optical Tomographic Imaging of Vascular Lesions
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emission. In the transmission channel, the opacity of these tissues
was so low as to preclude the capture and reconstruction of useful
data. In emission channels, however, femoral arteries were seen to
autofluoresce strongly, with the greatest signal following excitation
at 405–445 nm, corresponding to a 410 nm excitation peak for
elastin[14]. In reconstructed 2-dimensional slices of arteries
imaged in this way, the medial layer was clearly distinguished
from the adventitia and lumen by its greater fluorescent signal (not
shown). Fluorescent emission imaging was thus adopted for all
further investigations.
Imaging Intimal Lesions
To establish whether OPT imaging could characterise neoin-
timal lesion formation, mouse femoral arteries were subject to
wire- (n = 6) or ligation- (n = 5) injury. Following either insult,
neointimal thickening could be seen clearly in non-tomographic
emission projections (Figure 1a). In reconstructed 2-dimensional
slices, concentric neointimal lesions were obvious and could be
distinguished from the media by their weaker emission
(Figure 1b, Figure S1).
To extend the possible application of this technique to
atherosclerotic lesions in large conduit arteries, the aortic arch
from apoE-/- mice was also examined (n = 8). In OPT emission
images of atherosclerotic aortic arches, lesion formation was again
clearly evident with the expected anatomical distribution com-
prising lesions in the lesser curvature of the arch, in the
brachiocephalic artery and at the origins of the left carotid and
left subclavian arteries (Figure 2a). In cross-section, these lesions
typically possessed an eccentric morphology and could be
distinguished from media and lumen (Figure 2b,c, Figure S2).
2-dimensional validation and quantification
To validate the interpretation of OPT reconstructions following
tomographic imaging, the same arteries were processed for
histological examination. For both neointimal (Figure 1c) and
atherosclerotic lesions (Figure 2c), histological sections and
corresponding OPT reconstructions were strikingly similar. We
compared planimetric measurements of lesion area obtained by each
method. For wire- and ligation-induced neointimal lesions and
atherosclerotic plaques, these correlated strongly by linear regression
Figure 1. Identification of neointimal lesions in the ligation-injured mouse femoral artery. In non-tomographic fluorescent emission
images of a ligation-injured femoral artery (a) neointimal thickening is clearly visible (red arrowheads). Image has been inverted for clarity (darker
regions reflect stronger emission). In tomographic reconstructions (b), all layers of the vessel wall can be identified. Reconstructions strongly
resemble US trichrome-stained histological sections of the same vessels (c). Scale bars in (a–c) are 200 mm.
doi:10.1371/journal.pone.0016906.g001
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(R2 = 0.92, R2 = 0.89 and R2 = 0.85, respectively) and the slope of
these relationships did not differ from 1 (p = 0.49, p = 0.58 and
p = 0.88, respectively). Bland-Altman analysis indicated no obvious
bias in measurements of neointimal lesions induced by either injury
(Figure 3a,b) but a small positive bias in OPT-derived measure-
ments of lesion size in the brachiocephalic artery (Figure 3c),
possibly reflecting shrinkage of these larger vessels during histological
processing. Importantly, however, this bias was independent of lesion
size indicating that measurements made in this way are comparable
within and between vessels. We also confirmed that the OPT imaging
procedure did not compromise subsequent analysis of lesion
composition. In vessels previously subjected to OPT scanning,
(immuno)staining for markers of smooth muscle (a-smooth muscle
actin), macrophages (Mac2) and collagen (picro-sirius red) all
occurred with the expected intensity and distribution (Figures 2c).
3-dimensional quantification and reproducibility
Whilst 2-dimensional comparisons of OPT and histology provide
crucial validation, the greater potential of OPT is in the
consideration of 3-dimensional parameters. We established proto-
cols for the volumetric quantification of lesions by OPT. Using these
methods, we were able to record lesion volumes in wire-
(0.110060.0091 mm3; n = 6) and ligation-injured femoral arteries
(0.020060.0089 mm3; n = 5) and in atherosclerotic brachiocephalic
arteries (0.1860.018 mm3; n = 8). As would be expected from the
degree of injury, lesions in wire-injured vessels were significantly
greater (p,0.0001 by unpaired t-test) than those in ligation-injured
vessels. Coefficients of variation (5.36%, 11.39% and 4.79%,
respectively, n = 4) indicated that for all lesion types, measurements
were highly reproducible. These data were also expressed as profiles
of lesion burden along the length of the vessel (Figure 4) and
Figure 2. Identification of atherosclerotic lesion formation in the aortic arch of apoE-/- mice. In non-tomographic fluorescent emission
images of the aortic arch of atherosclerotic mice (a), lesion formation (red arrowheads) is apparent with the expected distribution. Image has been
inverted for clarity (darker regions reflect stronger emission). In cross-sectional reconstructions, lesions are visible with the same distribution (b) and
possess strong resemblance to histological sections of the same vessels (c). Successful analysis of the brachiocephalic artery by standard (immuno)-
histochemical procedures further emphasises the non-destructive nature of this technique (c). Scale bars in (a–b) are 1 mm. RSA, right subclavian
artery; RCA, right carotid artery; LCA, left carotid artery; LSA, left subclavian artery; BCA, brachiocephalic artery; AAo, ascending aorta; DAo,
descending aorta.
doi:10.1371/journal.pone.0016906.g002
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rendered for dynamic, qualitative evaluation (see Figures S1–S3),
in both cases, highlighting the uneven distribution of lesion
formation occurring in injured vessels.
Discussion
We have demonstrated, for the first time, the eminent suitability
of OPT for the assessment of vascular structure in isolated arteries.
Using this technique, 3-dimensional images describing the
autofluorescent emission of the specimen were used to provide
anatomical information on lesion size and distribution, as well as
reproducible quantification of both the lesion and the residual
lumen. This was achieved in vessels spanning the commonly
studied size range in mice, and should be equally suitable for
analysis of vascular lesions from other species, including small-to-
medium sized human vessels. This methodology represents a
Figure 4. Longitudinal profiles of lesion and lumen cross-sectional area in un-injured, ligation- and wire-injured femoral arteries.
When cross-sectional area of lesion (red) and lumen (grey) are plotted against distance along the axial length of the femoral artery, the difference in
extent of lesion formation between ligation- (b) and wire-injury models (c) is apparent. In both cases, the variability in lesion size that occurs along
the length of each vessel is also highlighted.
doi:10.1371/journal.pone.0016906.g004
Figure 3. Comparison of planimetric measurements of lesion size between OPT reconstructions and histological sections. Planimetric
measurements of lesion size recorded from OPT and histology image sets correlate strongly for all lesion types; Bland-Altman analysis indicates that
this is unbiased for wire- (a) and ligation-injured femoral arteries (b) and that OPT measurements have a consistent positive bias in atherosclerotic
brachiocephalic arteries (c).
doi:10.1371/journal.pone.0016906.g003
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considerable advance over traditional histological and, alternative
3-dimensional imaging techniques for the analysis of intimal lesion
formation in small arteries.
Application of OPT to three widely-used models of arterial
lesion development in the mouse, was designed to assess its
potential for imaging atherosclerotic and proliferative lesions in
large (aorta) and small (femoral) arteries. Importantly, these vessels
define the required resolution for studies of this type - the aorta
being the largest artery, and the femoral artery, which has a lumen
diameter of ,200–250 mm[15], being amongst the smallest vessels
in which studies of vascular lesion formation are commonly
performed. The striking similarities of OPT-generated images and
those obtained from subsequent histological analysis of the same
samples confirmed the suitability of the technique in both vessels.
Moreover, we were able to quantitatively validate this similarity.
The consistency of cross-sectional area measurements obtained
from OPT with those obtained by planimetric analysis of the
corresponding histologically-stained sections (the current gold
standard) confirmed the accuracy of the former. Further, because
each OPT data set is composed of many hundreds of cross-
sectional scan lines, using OPT it was simple to generate profiles of
lesion area along the injured vessel. The advantage of this was
exemplified by the comparison of lesions induced by wire-
injury[11] with those caused by arterial ligation[12]. This
demonstrated that whilst cross-sectional narrowing caused by
wire-injury and ligation were broadly similar close to the origin of
the injury, the lesions resulting from insertion of a wire extended a
far greater distance along the arterial wall. Generating comparable
data from histological sections would have been expensive and
extremely labour intensive.
Whilst these advantages alone might be sufficient to warrant
adoption of OPT as the analytical method of choice; the real
strength of the technique is conferred by the ability to quantify
lesion volume. Measurements of lesion volume provide a more
representative of the total lesion burden in an artery[3], and are
therefore not subject to the bias and error introduced by selection
of particular portions of the vessel for analysis. This is again
emphasised in the current investigation by longitudinal profiles of
lesion formation produced from OPT images, which indicate just
how much lesion size can vary over short lengths of injured vessel.
Whilst these advantages may be shared with other 3D imaging
modalities, in comparison to previously reported MRI and micro-
CT ex vivo examinations of small arteries, OPT appears to produce
images of comparable or superior quality, yet with much shorter
imaging times and less expense. Indeed, despite preparation of
samples for OPT imaging taking several days, little labour is
required on each occasion. As such, many vessels can be prepared
in parallel and data acquired in one session, thereby providing a
relatively high throughput method of imaging arterial lesions and
not requiring prolonged use of the imaging device.
In addition to direct 2- and 3-dimensional quantification of
vessel morphology from OPT images, because this technique is
non-destructive, it can be considered complementary to traditional
analysis. Rather than laboriously sectioning, staining and analys-
ing long lengths of lesions to find sites of interest for
immunohistochemical examination, OPT images can be used to
quickly identify such regions for selective sectioning and
subsequent, in-depth analysis using standard histology and
immunohistochemistry. Thus, OPT imaging of vascular lesions
can be easily adopted into existing workflows to accelerate
traditional methods of analysis and provide volumetric informa-
tion from the same tissues.
There are inevitably limitations of OPT-based analysis of
arterial lesions that must be considered. First, although image
quality is comparable or superior to that of other tomographic
imaging systems, it is noticeably inferior to microscopic imaging
techniques (which can, of course, only be performed on smaller
segments). Several refinements to the back-projection algo-
rithms used to reconstruct OPT data sets have been proposed
which may in future, further improve the quality of images
produced by this method[16,17]. Second, the reagents used to
prepare samples for OPT imaging might potentially alter
certain aspects of the specimen. Perhaps the biggest potential
source of artefacts resulting from the OPT procedure described
here is the choice of a lipophilic agent (benzyl alcohol/benzyl
benzoate) for optical clearing, which is likely to, for example,
remove lipid pools from atherosclerotic plaques, and requires
prior dehydration, which may cause shrinkage of tissue. In
contrast to hydrophilic clearing agents such as glycerol,
however, benzyl alcohol/benzyl benzoate is reported to cause
minimal deformation of tissue morphology [18]. It is also
important to consider that similar dehydration and lipid
removal steps are otherwise required in the preparation of
paraffin-embedded tissue sections. Further, although we have
not directly compared tissues subject to both OPT imaging and
histological analysis, with those only subject to the latter, we
feel that the appearance and immunoreactivity of lesions in
these models are subjectively similar to those we have
previously observed in directly prepared histological sections.
Beyond these rather general limitations, those more specific to
the methodology presented here appear relatively minor.
Ironically, perhaps the most obvious of these derives from the
strong autofluorescence of arterial tissue, which enables such
clear anatomical imaging. We have found this to be resistant to
bleaching by previously set out methods[19], and as such, it
may restrict the use of fluorescent probes to assess RNA and
protein distribution patterns.
Much potential for further development of this technique exists,
particularly with regard to tracking the 3-dimensional arrange-
ment of key cells and signalling factors involved in arterial
remodelling. Despite the above-described limitations, this may be
achievable by several means. For example, the low opacity of
optically-cleared arteries might suggest that colorimetric reporters,
such as b-galactosidase, that can be visualised by transmission
imaging, might be more suitable than fluorescent probes for this
purpose. Alternatively, we have generated preliminary data
(Bezuidenhout et al., unpublished) to suggest that OPT can be
used to identify nanoparticulate within arterial lesions, perhaps
providing the means to track phagocytic cells. Finally, whilst the
data presented here describe only studies of the mouse vasculature,
preliminary studies suggest that is also suitable for imaging
morphology and atherosclerotic lesion formation in larger vessels
including rat and rabbit aortas (Bezuidenhout et al., unpublished).
OPT, should, therefore, be equally suited to the study of
comparably sized human vessels.
In summary, OPT imaging is a valuable tool for the 3-
dimensional evaluation of neointimal and atherosclerotic lesion
burden and distribution in mouse arteries; a considerable advance
because traditional 2-dimensional methods for the analysis of these
lesions are labour intensive and do not effectively represent total
lesion volume. Imaging by OPT is relatively fast and high
throughput, convenient and non-destructive. Further, in contrast
to previously published studies of OPT in adult mouse tissues[19],
these methods are achievable using commercially-available
equipment and software. This technique should provide the
much-needed means to allow 3-dimensional evaluation of
morphology to become a routine component of vascular
remodelling studies.
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Supporting Information
Figure S1 Tomographic cross-sections of an OPT-
imaged, ligation-injured mouse femoral artery. After
tomographic reconstruction, cross-sectional OPT images (excita-
tion 425 nm with 40 nm band-pass; emission 475 nm long pass)
can be animated for qualitative evaluation of vascular structure (in
addition to quantitative measurement). In ligation-injured femoral
arteries, presented in this way, morphologically-normal vessel can
be seen proximal to the site of ligation and the media and lumen
can be distinguished. Closer to the ligation, neointima formation is
apparent, and this can also be distinguished from the media and
lumen. The size of this lesion increases with proximity to the
ligation, and eventually completely occludes the vessel. The
position of each cross-section within the artery is indicated on the
non-tomographic image inset left.
(MOV)
Figure S2 Tomographic cross-sections of an OPT-
imaged, atherosclerotic aortic arch. After tomographic
reconstruction, cross-sectional OPT images (excitation 425 nm
with 40 nm band-pass; emission 475 nm long pass) can be
animated for qualitative evaluation of vascular structure (in
addition to quantitative measurement). In atherosclerotic aortic
arches, presented in this way, the media and lumen of the
ascending and descending aorta can be seen clearly and some
lesion formation is apparent on the lesser curvature of the arch.
This can be clearly distinguished from the vessel media and lumen.
More severe lesion formation is present at the roots of right carotid
and subclavian arteries, and throughout the length of the
brachiocephalic artery. The position of each cross-section within
the artery is indicated on the non-tomographic image inset left.
(MOV)
Figure S3 Volume rendering of a tomographically
reconstructed, OPT-imaged, atherosclerotic aortic arch.
After tomographic reconstruction, cross-sectional OPT images
(excitation 425 nm with 40 nm band-pass; emission 475 nm long
pass) can be volume rendered to visualise vascular structure and
lesion formation in 3-dimensions. In atherosclerotic aortic arches,
presented in this way (a), lesion formation can be observed with the
predicated anatomical distribution (brachiocephalic artery, roots
of the right carotid and subclavian arteries and lesser curvature of
the arch). Regions within cross-sections corresponding to lesion
can be segmented, separately rendered, and superimposed on
original data to further highlight distribution and extent of lesion
formation (b; lesion displayed in red). This process is analogous to
that required to quantify lesion volume.
(MOV)
Methods S1 Protocol for OPT imaging and quantifica-
tion of murine intimal and atherosclerotic lesions. Step-
by-step protocol detailing procedures for OPT-based examination
of intimal and atherosclerotic lesions in mouse arteries.
(DOC)
Methods S2 Additional methodological detail. Compre-
hensive description of the methodology used for all the techniques
utilised in these studies.
(DOC)
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methods for three-dimensional reconstructions from confocal images: I. tissue
shrinking and axial scaling. Journal of Neuroscience Methods 100: 135–143.
19. Alanentalo T, Asayesh A, Morrison H, Loren CE, Holmberg D, et al. (2007)
Tomographic molecular imaging and 3D quantification within adult mouse
organs. Nat Methods 4: 31–33.
Optical Tomographic Imaging of Vascular Lesions
PLoS ONE | www.plosone.org 8 February 2011 | Volume 6 | Issue 2 | e16906
